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Parasitic infections are the major causes of illness and death in tropical 
regions especially in Africa. The main parasitic diseases include 
leishmaniasis, filariasis, malaria, river blindness, Chagas disease and 
schistosomiasis. With the absence of vaccines, treatment relies mainly on 
chemotherapy hence the need for efficacious and safe medicines. Many of 
the medicines currently used have low efficacy and cause side effects. Some 
are also being lost to drug resistance. To address the inadequacy of 
treatment options for infectious diseases, a number of initiatives have been 
started to promote drug discovery and development in Africa. In parallel they 
have been collaboration between African institutions and leading 
pharmaceutical companies as well as other relevant R & D organizations. 
This has led to the need to modernize African approaches to drug discovery 
and development with respect to the integration of medicinal chemistry, 
pharmacology and pharmacokinetics as reflected in the processes of 
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET). 
However, scientific and technological expertise in pharmacokinetics for drug 
discovery is under developed in Africa. 
 
Objectives 
The first objective of this work was to set up in silico and in vitro methods for 
the evaluation of the major determinants of pharmacokinetic properties of 
drugs. The processes that determine a compound’s pharmacokinetics are 
solubility and permeability (which determine compound absorption), protein 
binding (which determine volume of distribution), and metabolism (which 
determine compound clearance). Absorption and metabolism, in turn 
determine a compound’s bioavailability. The second objective was to apply 
these in silico and in vitro assays set up in the characterization of chemical 
entities in different scenarios of drug discovery, development and optimal 
clinical use of medicines in Africa against parasitic infections. ADMET assays 
were applied in the characterization of synthetic hybrid molecules with anti-
malarial activity to guide the choice and molecular design of lead compounds 
with good pharmacokinetic and pharmacodynamic (PK/PD) properties. In the 
herbal medicine/ natural products driven drug discovery setting, which is one 
of the most common approaches in Africa, the aim was to apply the ADMET 
assays in the characterization of Frutinone A, a natural product from a herbal 
extract with broad spectrum anti-microbial activity. The third aim was to apply 
the ADMET tools in the rationalization of pharmacokinetic liabilities of 
thiabendazole, an anti-helminthic drug in clinical use with a view to improve 
its safe clinical use.   Successful demonstration of the utility of these ADME 
assays in these commonly used models of drug discovery and development 
in Africa would add value to the increasing effort to find safe and effective 







Setting up of in silico and in vitro ADME assays was bench marked against 
leading pharmaceutical industry standards. Physicochemical properties were 
determined using in silico predictions and in vitro assays. For solubility, the 
turbidimetric method was used. Lipophilicity and purity determination were 
conducted using the reverse phase HPLC method. Screening for inhibition 
was performed using recombinant enzymes and known diagnostic inhibitors 
as controls. Mechanism and mode of inhibition studies were determined 
using the same system. Metabolism and clearance of the compounds were 
determined in human liver microsomes and cryopreserved hepatocytes. 
Metabolites, possible routes of metabolism and the enzymes involved in 
metabolism were also determined. In silico, the interaction of the various 
enzymes with the enzyme active site were simulated using docking software 
including GOLD, GLUE, FlexX and AutoDock. 
 
Results 
In silico and in vitro ADME platforms for the determination of compound 
purity, solubility, lipophilicity (logP and LogD), ionisability (pKa), permeability, 
protein binding, metabolic stability, metabolite identification, reaction 
phenotyping, and enzyme inhibition based drug-drug interactions were 
successfully setup in this study. These methods were then applied various 
scenarios of drug discovery.  
 
In the medicinal chemistry driven drug discovery approach, ADMET 
characterization was conducted on two new chemical series from our 
laboratory with demonstrated anti-malarial activity. The artemisinin-
chloroquine hybrid chemical series demonstrated good metabolic stability 
predictive of good bioavailability.  The compounds where, however, potent 
inhibitors of CYP3A4 and CYP2D6, and were predicted to pose the risk drug-
drug interactions if given together with other drugs, which rely on the 
enzymes for elimination. Most of the compounds inhibited via the non-
competitive mode, which is difficult to simulate using docking methods.  For 
the 3,4-HPO-4-amino-7-chloroquinolinyl hybrid chemical series, metabolic 
clearance was predicted to be moderate in hepatocytes and human liver 
microsomes. 
 
In the herbal products/natural products driven drug discovery approach, 
Frutinone A, which is a component of abroad-spectrum herbal extract 
demonstrated potent CYP1A2 inhibition and moderately inhibited CYPs 3A4, 
2D6, 2C9 and 2C19. CYP1A2 inhibition was characterized by an IC50 of 
0.56µM. Inhibition was differential showing mixed (Ki = 0.48µM) and 
competitive (Ki = 0.31µM) inhibition with CEC and ER respectively. Two 
binding sites, one for inhibitors and the other for substrates were identified in 
silico. Hepatic clearance was predicted to be low (7.17ml/min/kg), with 
reaction phenotyping studies indicating no clearance by the enzymes tested. 
 
In the rational use of medicines approach, the ADMET assays were applied 
to thiabendazole, an anthelminthic drug, which was shown to be a potent 
inhibitor against CYP1A2. The compound was a potent reversible and 




and a KI of 1.4μM. Drug-drug interaction (DDI) simulation studies using 
SimCyp showed good predictions for competitive inhibition. However, 
predictions for mechanism-based inhibition (MBI)-based DDI were not in 
agreement with clinical observations.  
 
Conclusion 
This work has led to the successful setting up of an ADMET platform capable 
of supporting drug discovery projects in Africa. The work demonstrated the 
application ADMET in various scenarios of drug discovery, development and 
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ABSTRACT 
Thiabendazole (TBZ) and its major metabolite 5-hydroxythiabendazole (5OH-
TBZ) were screened for potential time-dependent inhibition (TDI) against 
CYP1A2. Screen assays were carried out in the absence and presence of 
NADPH. TDI was observed with both compounds, with kinact and KI values of 
0.08 and 0.02min-1 and 1.4 and 63.3μM for TBZ and 5OH-TBZ, respectively. 
Enzyme inactivation was time-, concentration-, and NADPH-dependent. 
Inactivation by TBZ was irreversible by dialysis and oxidation by potassium 
ferricyanide, and there was no protection by glutathione. 5OH-TBZ was a 
weak TDI of CYP1A2, and enzyme activity was recovered by dialysis. IC50 
determination of TBZ and 5OH-TBZ showed both compounds to be potent 
inhibitors, with IC50 values of 0.83 and13.05μM, respectively. IC50 shift studies 
also demonstrated that TBZ was a TDI of CYP1A2. In silico methods 
identified the thiazole group as a TDI fragment and predicted it as the site of 
metabolism. The observation pointed to epoxidation of the thiazole and the 
benzyl rings of TBZ as possible routes of metabolism and mechanisms of TDI. 
Drug-drug interaction (DDI) simulation studies using SimCyp showed good 
predictions for competitive inhibition. However, predictions for mechanism-
based inhibition (MBI)-based DDI were not in agreement with clinical 
observations. There was no TBZ accumulation upon chronic administration of 
the drug. The in vitro MBI findings might therefore not be capturing the in vivo 
situation in which the proposed bioactivation route is minor. This might be the 
case for TBZ in which, in vivo, UDP glucuronosyltransferases and 





Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the 
broad spectrum antimicrobial herbal extract from P. fruticosa 
 
Roslyn S. Thelingwani, Kariema Dhansay, Peter Smith, Kelly Chibale, and 
Collen M. Masimirembwa 
 
Xenobiotica. 2012 Apr 25. [Epub ahead of print]. PMID: 22533317 
 
ABSTRACT 
Frutinone is an active ingredient extracted from the lipophilic fraction of the 
Polygala Fruticosa demonstrating various antibacterial and fungal properties. 
The aim of this study was to characterize its metabolism in an effort to 
understand metabolism based drug-herb interactions. In vitro metabolic 
clearance and metabolite identification studies were done using 
cryopreserved hepatocytes. Reaction phenotyping and inhibition studies were 
done using human liver microsomes and recombinant cytochrome P450s 
(CYPs). Frutinone A-CYP1A2 interactions were rationalized using docking 
simulations. Hepatic clearance was predicted to be low (7.17 ml/min/kg), with 
reaction phenotyping studies indicating no clearance by the enzymes tested. 
Frutinone was identified as a potent inhibitor of CYP1A2 with moderate effects 
on CYP2C19, 2C9, 2D6 and 3A4. CYP1A2 inhibition was reversible and 
characterized by an IC50 of 0.56µM. Inhibition was differential showing mixed 
(Ki= 0.48 µM) and competitive (Ki= 0.31 µM) inhibition with 3-cyano-7-
ethoxycoumarin and ethoxyresorufin, respectively. Two binding sites, one for 
inhibitors and the other for substrates were identified in silico. The potent 
CYP1A2 inhibition by Frutinone A could be predictive of the potential drug-
herb interaction risk in the use of herbal extracts from P. fruticosa. The data 
suggest future pharmacological research on this chromocoumarin should take 





Application of in silico, in vitro and in vivo ADMET/PK platforms in drug 
discovery. 
 
Collen Masimirembwa and Roslyn Thelingwani 
 
In Drug Discovery Africa: Impacts of Genomics, Natural Products, Traditional 
Medicines, Insights into Medicinal Chemistry, and Technology Platforms in 
Pursuit of New Drugs. Springer 2012. Edited by Kelly Chibale, Mike Davies-
Coleman and Collen Masimirembwa 
 
ABSTRACT 
Drug discovery is a risky and expensive business fraught with high attrition 
rates. The healthcare benefits and financial rewards that can be realized if 
successful have, however, ensured the relevance and continued growth of the 
pharmaceutical industry. The major reasons for high attrition rates during drug 
discovery include lack of efficacy, toxicity, inadequate pharmacokinetics (PK), 
and market forces; factors which can be complexly interrelated. PK has been 
shown to affect the efficacy and safety of new chemical entities (NCEs). The 
pharmaceutical industry responded by frontloading the characterization of the 
processes that determine the PK of compounds, that is, absorption, 
distribution, metabolism and excretion (ADME). The ADME data is being used 
to guide medicinal chemists in the design of molecules with favourable 
disease specific PK properties. In late stages of drug discovery, the preclinical 
ADME data is being used to predict human PK and safety of NCEs. As 
African research scientists initiate drug discovery activities, integration of PK, 
in the traditionally medicinal chemistry and disease pharmacology driven 
efforts, is important towards ensuring increased chances of discovering good 
candidate drugs (CD). We have therefore setup in silico, in vitro and in vivo 
ADMET platforms, which various African drug discovery scientists can 
access. Drugs for non-communicable disease fail more from lack of efficacy 
than poor PK whereas drugs for infectious disease fail more from poor PK 
than from lack of efficacy. Drug discovery efforts in Africa are also mainly 
based on natural products for which little is known or can be inferred from the 
PK of conventional synthetic drugs. These factors point to the need of 
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Modern pharmaceutical industry aims to integrate pharmacology, medicinal 
chemistry and ADME/PK in the drug discovery and development value chain. 
This is an approach applied by major R&D-based pharmaceutical companies 
in developed countries. In Africa the picture is different with drug discovery 
still in its infancy and still conducted in non-integrated approaches by small 
academic research groups, which are either pharmacology or medicinal 
chemistry driven. A few groups have begun working on establishing 
ADME/PK platforms to support the increasing drug discovery initiatives on the 
continent.  
 
Drug discovery in Africa has traditionally been driven by herbal and/or 
traditional medicines as well as natural products chemistry with limited 
expertise in synthetic medicinal chemistry and ADME/PK. In pharmacology, 
discovery efforts in Africa largely involve the use of cell cultures and animal 
disease models. There is comparatively limited work on molecular-target 
based drug discovery. With challenges such as drug resistance, drug-drug 
interactions and suboptimal PK properties resulting in treatment failures being 
faced in the treatment of many parasitic infections, there is any urgent need 
to come up with new medicines.  
 
This thesis therefore explores the integration of ADME/PK in herbal/natural 
products and in synthetic medicinal chemistry-driven drug discovery as well 
as the optimal clinical use of drugs already on the market for the treatment of 




will be setup and employed towards the identification of ADME/PK liabilities, 
molecular and kinetic data, which will be used in the future design and 
synthesis of safer analogues or guide the design of safer dosing regimens. 
 
1.1. Parasitic infections 
Infections with parasites are important causes of morbidity worldwide, ranking 
among the top killers according to the WHO reports (World Health 
Organisation, 2004). It is estimated that over half of the world’s population 
suffers from parasitic diseases which include malaria, leishmaniasis, African 
trypanosomiasis, Chagas disease, protozoal diarrhea, schistosomiasis, river 
blindness and lymphatic filariasis (Watkins, 2003). Low-income countries are 
the hardest hit especially in Africa where they are the major causes of death. 
Of the parasitic infections malaria is the deadliest with the WHO reporting 216 
million cases in 2010 (World Health Organisation, 2011). The main parasitic 
diseases, causal agents and epidemiology are shown in Table 1.1. 
 
1.1.1 Challenges with drugs available for treatment 
Many of the drugs used to treat parasitic infections are decades old, with 
many of them having been discovered using empirical methods or initially 
targeted for other diseases or veterinary use. Therefore many of the drugs on 
the market have many challenges including low efficacy, severe side effects 
and drug resistance. If many of them were to be evaluated for efficacy and 
safety using current regulatory standards, they would not pass the drug 





Table 1.1: Main parasitic diseases 
(Table adapted from Renslo et.al (Renslo and McKerrow, 2006)). 
 
Disease  Organism  Burden  
Therapy 
needs 
Malaria  Plasmodium spp 
Estimated 216 million 
reported cases with 655 
000 deaths in 2010 (World 
Health Organisation, 2011) 
Drugs 
circumventing 
drug resistance  
 
Leishmaniasis  Leishmania spp 
Estimated 1.6 million new 
cases annually (World 




for the visceral 
form of the 
disease 
Trypanosomiasis  
T. Brucei (African 
Trypanosomiasis) 
 
T. Cruzi (Chagas 
Disease) 
 
50-70000 estimated cases 
in 2006 (World Health 
Organisation, 2006) 
 
20 million estimated to be 




Safe and orally 
bioavailable 
drugs especially 
for the chronic 
disease phase  
Schistosomiasis  Schistosoma spp 
> 200 million existing 
infections (Renslo and 
McKerrow, 2006) 
Backup drugs in 




The choice of effective medicines for treating parasitic infections is very 
limited due to reasons indicated above. For example, praziquantel is the only 
drug available for treatment of schistosomiasis which is effective against all 
three species affecting humans (Fenwick et al., 2003). The two other drugs, 
oxamniquine and metrifonate are effective against S. mansoni and S. 
haematobium respectively (Caffrey, 2007). However the drugs are not in use 
anymore. The structure of the drugs is shown in Fig 1.1. 
 
























Drug resistance to many of the many of the traditional drugs has also been 
one of the major challenges associated with antiparasitics (Fig 1.2). 
 
 
Adapted from Hyde (Hyde, 2005) 
Figure 1.2: Dates of introduction of antimalarials and observations of 
treatment failure: Q - quinine, Pyr – pyrimethamine, SDX – sulfadoxine, CQ- 
chloroquine, Mef –mefloquine, ato – atovaquone, PG - proguanil combination, Art – 
artemisinin and derivatives, Hal – halofantrine, LD – LapDap (chlorproguanil–
dapsone). 
 
This has seen the loss of clinical usefulness of most drugs. Resistance to 
melarsoprol, diminazene and isometamidium (Fig 1.3) by trypanosomes has 
been reported (Delespaux and de Koning, 2007). P. falciparum resistance 
has been recorded in all the current antimalarials including the recommended 
artemisinins (Dondorp et al., 2011; Dondorp et al., 2009; Noedl et al., 2008). 
 































Some treatments are associated with severe side effects. For example in the 
treatment of malaria and HAT several drugs have been associated with side 
effects. In malaria the use of amodiaquine, quinine and halofantrine is limited 
because of toxicity. Amodiaquine is effective against drug resistant malaria 
but its use is limited because long-term exposure is associated with 
agranulocytosis (Rouveix et al., 1989) and hepatitis (Larrey et al., 1986). 
Examples are of drugs associated with side effects are shown in Fig 1.4. 
 
Figure 1.4: Examples of drugs associated with side effects in the 
treatment of malaria and HAT. Drugs associated with side effects in malaria 
treatment are amodiaquine, quinine and halofantrine with melarsoprol, 
pentamidine, suramin and eflornithine associated with side effects in HAT 
treatment 
 
Long term exposure to halofantrine is associated with cardiac dysrhythmias 
(Sowunmi et al., 1998)and quinine with predisposition to blackwater 
fever(Bruce-Chwatt, 1987). The treatment of HAT with melasoprolol, suramin, 
pentamidine and eflornithine is associated with severe side effects which 
















































































ones such as kidney damage to reactive encephalopathy(Fairlamb, 2003). 
 
In general, the current antiparasitic drugs are characterized by large and 
complex dose regimens, prolonged administration for successful treatment, 
and possess various modes of toxicity (Table 1.2). Many of the drugs are 
used in combination to increase efficacy and reduce emergence of drug 
resistance. No PK/PD rationalization and optimization was done in the choice 
of combination drugs hence the sometimes complex empirical dosing 
regimens. 
 
1.1.2 Burden of parasitic diseases in relation to drug discovery 
Many parasitic diseases are found mainly in the tropics, which lie in some of 
the poorest regions of the World. In Africa the burden mainly comes from 
diseases such as malaria, trypanosomiasis, leishmaniasis and protozoal 
diarrhoea. For most of the diseases, there are no vaccines, leaving 
chemotherapy to be the only effective way of treating and controlling the 
diseases. The development and discovery of drugs for curing parasitic 
diseases is not market driven because the bulk of the people living in endemic 
areas cannot afford to pay for their treatments. With the cost of producing one 
drug being estimated at $1.8 billion (Paul et al., 2010), coming up with new 
medicines is extremely challenging. Some drugs are also not able to recover 
their production cost due to tough competition on the market (Lombardino and 
Lowe, 2004). This makes this area unappealing to pharmaceutical companies, 





Table1.2: Dosing regimen and safety issues associated with selected antiparasitic drugs. 
Disease Drug Dosing Regimen Toxicity  References 
     
Malaria 
Amodiaquine 10mg/kg/day once a day for 3 
days (fixed dose with 
artesunate)  
Linked to agranulocytosis and 
hepatotoxicity. Unsafe for prophylaxis  
(World Health 
Organisation, 2010a) 
Quinine 20mg/kg salt intravenously 
over 4hrs in cases of severe 
malaria  
 
10mg/kg orally every 8hrs  
Hyperinsulinaemic hypoglycaemia, 
predisposition to blackwater fever, 
ototoxicity.  
(Taylor and White, 2004; 
Krishna and White, 1996) 
HAT Eflornithine 100-400mg/kg bodyweight at 
6hr intervals for 14 days  
Vomiting, nausea, diarrhea, nausea, 
thrombocytopenia, convulsions and 
leucopenia. Severity increases with 
treatment duration 
(Burri and Brun, 2003; Na-
Bangchang et al., 2004) 
Pentamidine 4mg/kg bodyweight at 24h 
intervals for 7 days 
Hypoglycaemia, injection site pain, 
diarrhoea, nausea, vomiting 
(Delespaux and de 
Koning, 2007; Nok, 2003) 
Leishmaniasis  Amphotericin B  1 mg/kg on alternate days × 
15 doses in 30 days 
intravenously  
 
Nephrotoxicity and acute reactions after 
IV infusion including high fever, chills, 
vomiting and drowsiness  
(Berman, 2005; Croft et 
al., 2005) 
Onchocerciasis Diethylcarbamazine  2-3mg/kg of body weight 3 
times a day  
Visual impairment, cellular cytotoxicity 
as a result of immune factors, 
inflammatory reactions, itching and 
swelling of the face  





1.1.3 Efforts in promotion of drug discovery for parasitic infections 
1.1.3.1 Public-private partnerships  
The formation of public-private partnerships (PPP), which operate on a non-
profit basis, has been one of the approaches used to promote the discovery of 
drugs for parasitic and infectious diseases in resource poor nations. The aim 
is to spread the cost and risk for drug development among international 
networks, pharmaceutical companies, academic institutions and non-
governmental organizations. Drugs developed in the networks are distributed 
at cost price. Examples of successes so far include the registration of the 
artesunate-amodiaquine combination therapy for malaria by the Drugs for 
Neglected Diseases initiative (DNDi) (http://dndi.org/portfolio/asaq.html). 
Other examples include Coartem® a fixed dose combination of artesunate and 
lumefantrine by the Medicines for Malaria Venture (MMV) 
(http://www.mmv.org/). 
 
1.1.3.2 Drug repositioning  
In this approach new uses for existing approved drugs are examined. Since 
the drugs will have been approved, they will have undergone the various 
required evaluations for safety. This results in big reductions in costs and 
research and development time. An example where this approach has been 
widely used is in antimalarials and some examples are shown in Fig 1.5. 
Antibiotics including clindamycin, doxycycline, tetracycline and sulfonamides 
(Nzila et al., 2011) have been found to be effective. Withdrawn drugs can also 
be reoptimised for use. An example is piperaquine, which was withdrawn in 




found to be a suitable drug for use in artemisinin based combination therapies 
(Davis et al., 2005). Combined with dihydroartemisinin, it has become one of 
the WHO recommended artemisinin based combination therapies for malaria 
treatment (World Health Organisation, 2010a). 
 
Figure 1.5: Repositioned drugs in the treatment of malaria. The 
compounds include the antibacterial sulphonamides sulfadoxine, dapsone 
and sulfamexazole, the long acting antibacterials doxycycline, clindamycin 
and tetracycline, the 4-aminoquinoline piperaquine and the anticancer drug 
methotrexate 
 
1.1.3.3 Novel approaches with existing drugs  
Drugs may be reintroduced after a period of non-use. This approach is used 
in cases where a drug has been stopped because of resistance. The hope will 
be that re-expansion of drug non-resistant parasites will have occurred. This 
approach was successfully applied in Malawi where chloroquine was 
reintroduced after 10 years of non-use and showed effectiveness (Laufer et 
al., 2010). To delay the reoccurrence of resistance, the drug is used as part of 
a combination. Other drugs may also be combined with newer ones to offer 






































































can also be made with older drugs. However current recommended 
combinations in malaria chemotherapy are the ACTs. 
 
1.2. Overview of the drug discovery process 
The drug discovery process is a long, multidisciplinary (Fig 1.6), costly and 
risky business that requires careful planning and good communication 
between researchers. The process begins with the identification of the 
medical need, a process that requires formation of a research team. A 
working hypothesis is formulated and novel compounds are synthesized and 
tested against a validated molecular target, whole organism or cell culture.  
 
Further preclinical studies conducted either in vitro, in silico and/or in vivo. 
Data from the studies then determines whether a compound will pass as a 
preclinical candidate and go though the whole process up to clinical trials and 
final approval. Considering the lengthy, risky and costly nature of the process 
many considerations have to be made early in the discovery stages to ensure 
candidates proceeding to the next stages carry minimum risk in terms of 
liabilities either physicochemical or pharmacokinetic. 
 
 
Figure 1.6: Overview of the drug discovery process. Adapted from Kerns 




1.2.1. Integrated approaches to drug discovery 
Although the drug discovery process is often depicted as a linear process, 
(Fig 1.6) a lot of the screening and assays are carried out in parallel. This 
enables decisions to be made based on assessment of activity and liabilities 
each series carry. The integrated approach is exemplified in Fig 1.7, which 
depict the workflow for a series of new chemical entities with antimalarial 
activity in the discovery stage.  
 
Figure 1.7: The parallel and integrated approach to lead identification for 
compounds with anti-malarial activities. 
 
The aim for pharmacology is to quickly identify compounds with efficacy 
especially in resistant strains of the disease, determine cytotoxicity and 
elucidate the likely mechanism of action. The aim of medicinal chemistry is to 
determine cheap no-complicated routes of synthesis. From pharmacological 
and chemical data, structure activity relationships (SAR) can be quickly 
determined. Liabilities such as toxicity, non-optimal physicochemical and 




from all the screens is ultimately be used to improve on analogues of newly 
synthesized series of compounds. 
 
The integrated approach has also been used in silico where various methods 
broadly categorized into ligand based, protein based and ligand-protein 
interactions are used. The methods are used to investigate the interaction of 
compounds with the enzyme active site, and can be used in combination, 
hence the integrated approach. Data from the different methods is combined 
in an effort to probe various questions under investigation. The interlinking of 
the various methods is depicted in Fig 1.8. 
 
 
Figure 1.8: An integrated approach to molecular modeling. Relationships 
between the major groups and within each category are indicated by the 
arrows (De Graaf  et al., 2005) 
 
Various software packages are available for in silico predictions with many 




made. The in silico methods are being used to understand drug-receptor 
interactions in pharmacology and drug-enzyme/transporter interaction in 
pharmacokinetics towards the design of efficacious and safer analogues. 
 
1.3. Target screening 
Target screening involves the identification of a potential drug and the 
understanding of its role in the disease process. It also involves the studies of 
the mechanism of action. Various approaches have been used to identify drug 
targets including whole parasite screening and molecular target screening. 
 
1.3.1. Whole parasite screening 
In this approach, diverse compounds are screened on whole parasites. This 
has been successfully done for parasites such as P. falciparum, T. brucei and 
T. cruzi, which are easy to maintain in culture. For parasites that are difficult to 
maintain in continuous culture for example leishmania, transgenic cell lines 
are used. The lines incorporate reporter constructs such as β-lactamase, 
luciferase and green fluorescent protein which identify bioactive compounds in 
either axenic or intra-cellular cultures (Sereno et al., 2007). The gene 
transcripts have also been used on parasites that grow well in culture for easy 
detection of antiparasitic activity.  
 
To enable fast detection of antiparasitic activity some of the assays are now 
high throughput making it easy to screen chemical libraries of thousands of 
compounds. This is performed with standardized assays, and detection is by 




An example is the use of the fluorescent active cell sorting in combination with 
YOYO-1 which is a nuclear dye in high throughput screening (HTS) for P. 
falciparum (Weisman et al., 2006). 
 
The use of HTS assays is limited to centers, which are well funded. Many 
research groups still use traditional methods such as lactate dehydrogenase 
(LDH) assay for antiplasmodial activity which are less sensitive for activity 
screening (Makler and Hinrichs, 1993; Makler et al., 1993). The method 
generates optical density values at various concentrations of the drug as raw 
data after addition of Malstat reagent and the nitrotetrazolium salt in 
phenazine ethosulfate (NBT/PES). Other methods include the 3H-
hypoxanthine incorporation assay, staining with giemsa and counting under 
the microscope and flow cytometry (Fidock et al., 2004). 
 
1.3.2. Molecular target screening 
Molecular targets screening is conducted using parasite genomes in an effort 
to identify gene products unique to parasites. This has been made possible by 
the availability sequences of whole parasite genomes combined with good 
bioinformatic and genome mining tools. Resistant parasites can also be 
generated in silico creating a drug that targets many variants of the molecular 
target. This is an approach that was used in the synthesis of spiroindolone 
NITD609 (Fig 1.9) (Rottmann et al., 2010), a compound which represents a 
new class of antimalarials which act by inhibiting protein synthesis. Parasite 
drug targets once identified are validated using chemical or genetic methods 





Figure 1.9: Structure of spiroindolone NITD609 
 
1.3.3. In vivo screening 
In vivo screens are also performed in model animals infected with parasites 
and various new chemical entities (NCEs) are screened by dosing the animal. 
Antiplasmodial activity screening is done mostly in rodent parasite models, 
which include P.berghei, P. yoelii, P. chabaudi and P. vinckei. This is because 
plasmodium species, which affect humans, are unable to infect non-primates 
except for one rodent model which can be infected by P. falciparum (Angulo-
Barturen et al., 2008). The models have been shown to predict outcomes in 
humans sufficiently provided the closest model is used (Langhorne et al., 
2011). 
 
1.4. Medicinal chemistry strategies in antiparasitic drug discovery 
Many strategies have been employed in the design and discovery of new 
chemical entities (NCEs) with antiparasitic activity. The aim is to obtain 
molecules with better profiles compared to existing ones. Due to drug 
resistance to many of the traditionally used antiparasitic drugs, there is an 
urgent need for new medicines. Some of the approaches currently being used 
in medicinal chemistry include use of known pharmacophores to create better 














1.4.1. Improvements to known drugs and compounds classes 
Improvements to drugs and known classes of compounds are made to 
address liabilities inherent in the parent drugs such as toxicity. Amodiaquine is 
a good example where analogues with better toxicity profiles are being 
synthesized. Amodiaquine is used to cure acute malaria. The 
biotransformation of amodiaquine however, leads to the formation of a 
quinoneimine intermediate, which is conjugated, with protein thiols resulting 
hepatotoxicity and agranulocytosis (Larrey et al., 1986; Rouveix et al., 1989).  
 
It has been shown that isoquine an isomer of amodiaquine does not form the 
quinoneimine metabolite (O'Neill et al., 2003). This approach circumvented 
the toxicity while at the same time retaining activity. An analogue with fluoro 
group replacing the 4-hydroxyl group of 4-hydroxyanilino nucleus was 
synthesized (Fig 1.10). The addition of the fluorine increases the oxidation 
potential reducing the in vivo oxidation of the molecule to the quinoneimine 
hence a good toxicity profile (O’Neill et al., 2009).Unfortunately isoquine still 
failed in clinical trials due to toxicity (O'Neill et al., 2009) indicating the 
possible existence of other bioactivation pathways resulting in drug toxicity. 
 
 





















Chloroquine had been an ideal drug of choice in treatment for malaria 
because of its good safety profile, oral bioavailability and low cost. Efforts 
have been made to synthesize analogues of chloroquine, which have better 
activity and can be used to treat resistant plasmodium strains. One approach 
has been to vary the length of the alkyl side chain. Structure activity 
relationships have shown analogues, which have shorter and longer side 
chains than chloroquine to have activity against resistant strains of P. 
falciparum(De et al., 1996). Other analogues have been synthesized in- 
cooperating transition metals(Biot et al., 1997; Ajibade and Kolawole, 
2008)and have been shown to be stable and to have a good safety profile 
making them suitable for use in combination with other drugs (Sa´nchez-
Delgado et al., 1996; Navarro et al., 1997; Biot et al., 1997) 
 
1.4.2. Resistance reversers 
Resistance by parasites to drugs is a major challenge in treatment where it 
has rendered many drugs ineffective. Some drugs such as chloroquine have 
been the mainstay of treatment and have been drugs of choice for many 
years because they are cheap, safe and generally have a good safety profile. 
However many of the drugs are being lost globally. The global distribution of 
resistance to chloroquine and sulfadoxine–pyrimethamine is shown (Fig 1.11). 
 
In malaria treatment, chloroquine is thought to work by inhibiting the formation 
of hemozoin from heme. Accumulation of heme in the cell will therefore cause 
heme-induced cell death since heme is toxic to the plasmodium parasite. 




the parasite’s digestive membrane protein called Plasmodium falciparum 
chloroquine resistance transporter (PfCRT)(Fidock et al., 2000). The 
mutations result in the change of a charged amino acid to an uncharged one, 
which allows efflux of charged chloroquine. An example is the change from 
positively charged lysine (K) or arginine (R) to neutral isoleucine (I) which 
results in the K76T and R371I mutations. This efflux reduces the 
concentrations of chloroquine in the food vacuole resulting decreased drug 
access to the heme target. However the drug target is not altered in the 
process (Fitch, 1969) and still remains vulnerable if the right concentrations 
are reached again. 
 
 
Figure 1.11: The global distribution of drug resistant malaria 
Areas where Plasmodium falciparum resistance to the most commonly used 
antimalarial drugs, chloroquine and sulfadoxine-pyrimethamine are circled 
(Fidock et al., 2004) 
 
To prevent the pumping out of the drug, chemosensitizers have been used. 




from being effluxed out. Verapamil and imipramine are examples of such 
drugs (van Schalkwyk and Egan, 2006).The clinical use of these agents 
however has been very difficult as concentrations required to achieve the 
reversal are high, causing toxicity. Attempts have therefore been made to 
incorporate moieties, which promote resistance reversal to known 
pharmacophores, which are known to have activity against parasite strains. 
An example is substituted acridone chemosensitizers (Kelly et al., 2007), 
which were made from tricyclic xanthones (Fig 1.12) which had been 
demonstrated to have antimalarial activity (Kelly et al., 2007). 
 
Figure 1.12: Design pathway of acridone chemosensitizers 
The acridone chemosensitizers were designed with an alkyl side chain with 
tertiary amines at the terminal position. The acridone chemosensitizers were 
shown to enhance the activity of other antimalarials such as chloroquine 
(Kelly et al., 2007) 
 
1.4.3. Molecular hybridization 
Molecular hybridization is a method where single entities containing two 
drugs/pharmacophoric units derived from bioactive molecules are linked 
together by a covalent linker (Walsh and Bell, 2009). The approach takes 
advantage of good properties of one drug e.g. the transport mechanism of 






The advantages of the molecular hybridization approach include potentially 
reduced costs and improved patient compliance. The reduced cost is in terms 
of quality control, production and logistics as the drug will now just be 
considered as one active pharmaceutical ingredient (API) instead of two. The 
disadvantage of the method is that it requires a fixed ratio of the two 
pharmacophores; hence they have to have the same magnitude of activity. 
Also the covalent linkage can lead to undesirable changes to the parent 
activity, safety and pharmacokinetic profile. 
 
Many hybrid drugs have been explored to date. The first hybrids to be 
successfully synthesized were the trioxaquines, which comprised of 
chloroquine and synthetic endoperoxide cores (Fig 1.13). The hybrids (a and 
b) were shown to have good antimalarial activity and this was attributed to the 
secondary amines in the linker which led to accumulation of compounds in the 
parasite food vacuole (Dechy-Cabaret et al., 2004). Compound b was 
selected as an antimalarial drug candidate (Coslédan et al., 2008).  
 
Figure 1.13: Representative structures of trioxaquine hybrids 
 
Further studies into the trioxaquine hybrids led to the synthesis of analogues 

















a1, n = 2
a2, n = 3 





Although the trioxaferrocene analogue had comparable activity to a (Fig 1.13) 
it was still inferior compared to b. 
 
 
Figure 1.14: Trioxaferrocene hybrid incorporating the ferrocene moiety 
 
Other hybrids have been synthesized from trioxolanes (Vennerstrom et al., 
2004), tetraoxaquines (Opsenica et al., 2008) and dioxane scaffold, based on 
ascaridole (Opsenica et al., 2007). The approach has also been further used 
to make hybrid prodrugs which release an active group once inside the 
parasite in the presence of iron (O'Neill et al., 2004). Other groups have 
hybridized artemisinin and 1,4-naphthoquinone derivatives with good 
antimalarial activity (Feng et al., 2011). Although the hybrids are cytotoxic 
against mammalian cell lines they have potential to be optimized and 
represent a new class of effective antimalarials. 
 
1.4.4. Exploration of natural products 
This strategy benefits from knowledge of medicinal plants among natives of 
parasite disease endemic regions. Natural products represent a source of 
potential new pharmacophore because of the diverse array of chemicals they 
present. The chemical diversity is high among plants, which use them as 
defense against parasitic infections.  This has inspired medicinal chemists to 
identify and synthesize some of these compounds and/or their analogues. 





Figure 1.15: Hybrid antimalarials. The compounds include (a) 
trioxalaquines, (b)combination of 4-aminoquinoline with a dioxane scaffold, 
based in ascaridole, (c)trioxolanes, (d)artemisinin-chloroquinoline hybrids and 
(e) tetraoxalaquines. 
 
The challenge with this approach is the chemical qualitative and quantitative 
variations associated with seasonal changes and geographical location, 
making it sometimes challenging to standardize herbal medicines. Activity has 
also been shown to be lower in some natural products when the active 
ingredient is isolated as compared to the crude extract, which is believed to 
be a cocktail of many interacting substances (Rasoanaivo et al., 2011). 
 
The established natural product antimalarial drugs include quinine, an alkaloid 
isolated from the bark of the cinchona tree, artemisinin, an endoperoxide 
sesquiterpene lactone from Artemisia annua sp and lapachol, a prenylated 
naphthoquinone from tabebua sp (Fig 1.16). Lapachol provided the main 
pharmacophore that was used in the development of atovaquone. Natural 




and Efferth, 2008) and HAT(Hoet et al., 2004) where drugs in current use are 
either toxic or are being lost to resistance. 
 
Figure 1.16: Isolated natural products with pharmacophores that have 
been used in the synthesis of antimalarial drugs 
 
1.5. Property and Physicochemical screening 
Structural properties of compounds offer a fast way of evaluating the drug 
likeliness of new chemical entities. Physicochemical properties on the other 
hand are affected by the various structural properties. This makes the 
structural properties very useful for predicting physicochemical properties 
without even measuring them. 
 
1.5.1. Structural properties 
Structural properties that are widely used include molecular weight (MW), 
polar surface area (PSA), hydrogen bonding (HB), lipophilicity (logP), shape 
and ionisability (pKa). It is from these properties that rules and guidelines have 
emerged and are widely used as guidelines for design and synthesis of new 























1.5.1.1. MW  
High molecular weight has been shown to cause a decline in bioavailability as 
it affects the fraction absorbed (Fa)(Varma et al., 2010). On the other hand 
high molecular weight has been linked to increase in lipophilicity hence better 
interaction with target site such as enzyme active sites. This has been 
associated with increased activity in general but some studies have indicated 
that high molecular weight does not necessarily result in high activity (Oprea, 
2002a). This is demonstrated in Fig 1.17, which shows the relationship 
between the MW and activity. Other disease target classes have also been 
shown to favour low molecular weight compounds, for example CNS drugs 
(Pajouhesh and Lenz, 2005). 
 
Figure 1.17: The relationship between molecular weight (MW) and 





1.5.1.2. Hydrogen bonding and the polar surface area  
Hydrogen bonding is a major determinant of permeability as the shedding of 
hydrogen bonded water molecules facilitates the diffusion through the 
membrane. Therefore, the higher the hydrogen bonding, the more 
unfavorable the permeability process becomes. This has been demonstrated 
with peptides, which are compounds with high hydrogen bond forming 
potential, and they have been shown to have minimal distribution through the 
BBB (Pardridge, 1998) and low intestinal absorption (Chan and Stewart, 
1996). 
 
Hydrogen bonding is a major determinant of permeability as the shedding of 
hydrogen bonded water molecules facilitates the diffusion through the 
membrane. Therefore, the higher the hydrogen bonding, the more 
unfavorable the permeability process becomes. This has been demonstrated 
with peptides, which are compounds with high hydrogen forming potential, 
and they have been shown to have minimal distribution through the BBB 
(Pardridge, 1998) and low intestinal absorption (Chan and Stewart, 1996).  
 
The hydrogen bonding potential of a drug is measured by the polar surface 
area (PSA), which is defined as a sum of surfaces of polar atoms (usually 
oxygens, nitrogens) and their attached hydrogens. PSA is a useful parameter 
in predicting drug transport properties and has been widely used to 
investigate blood-brain barrier penetration (BBB) (Feng, 2002) and to predict 
absorption of drugs (Clark, 1999; Palm et al., 1997). PSA has been shown to 




absorption (Fig 1.18a). Intestinal absorption decreases with an increase in the 
number of hydrogen bonds (Fig 1.18b). 
a) (b)  
Figure 1.18: The correlation between the polar surface area and 
intestinal absorption: The amount of compounds absorbed has been 
demonstrated to decrease with an increase in the polar surface area (a) 
(Clark, 1999; Palm et al., 1997). This has been further shown in a study done 
with renin inhibitors (b) (Chan and Stewart, 1996) 
 
1.5.1.3. Lipophilicity  
Lipophilicity is the tendency of a compound to partition into a nonpolar lipid 
matrix versus an aqueous matrix (Kerns and Di, 2008b). It is a very important 
parameter affecting ADME, toxicity, protein binding and permeability and has 
been used as a predictor in many in silico models.  The partition between the 
aqueous phase and the organic phase when all the compounds are in neutral 
form is expressed using the relationship 
 
         
                 
                 
  
 
When the partition is measured at known pH lipophilicity is expressed as the 




            
                 
                 
  
 
Many methods have been used to measure lipophilicity, but the main ones are 
the shake-flask, reverse-phase HPLC and capillary electrophoresis. In the 
shake flask method, compounds are dissolved in dimethylsulfoxide (DMSO) 
and added to a plate containing a mixture of octanol and buffer. The mixture is 
agitated and the amount of compound in each phase determined. The reverse 
phase HPLC method utilizes the partitioning between the aqueous mobile 
phase and the stationery phase. The lipophilicity of standards, which have 
known lipophilicity and retention times, is used to calculate the lipophilicity of 
the unknowns. 
 
The capillary electrophoresis method utilizes microemulsion electrokinetic 
chromatography, where the affinity for the microemulsion phase is used to 
estimate LogD (Poole et al., 2000). The greater the affinity the compound has 
to the stationary phase, the longer time it will take to elute. The LogD is 
estimated in the same manner as the reverse HPLC methods where a series 
of standards are used. Various software have also been used to estimated 
lipophilicity with many chemical drawing software (e.g. CHEMDRAW, ACD 
and Marvin Beans) incorporating software to calculate lipophilicity. 
 
1.5.1.4. pKa 
The pKa is an indication of a compound’s ionisability. It is therefore an 




various pHs. The pKa is defined as the negative log of the ionization constant 
Ka where, for the ionization of an acid; 
HA  H+ + A- 
         
         
    
  
From this equation the Henderson-Hasselbach equation, which shows the 
relationship between pKa and pH, can be derived. 
           
    
    
  
 The Henderson-Hasselbach equation is useful in calculating the 
concentration of ionic and neutral species if the pKa is known.  
 
Ionized compounds are more soluble in aqueous media than neutral ones as 
they are more polar. The reverse is true for permeability where ionized 
compounds are less permeable than neutral ones. Since the pKa determines 
the degree of ionization it is a major determinant of solubility and permeability. 
In turn the balance between permeability and solubility is therefore essential 
for orally absorbed compounds and should be noted when modifications on 
synthetic compounds are to be made.  
 
Many methods have been utilized in the determination of pKa both 
experimentally and in silico. There has been a variety of software for the 
prediction of pKa which include MOKA (www.moldiscovery.com), advanced 
chemistry development (ACD) pKa database (www.acdlabs.com) and some of 
the software has been added to structure drawing software such as Marvin 




some being high throughput methods suitable for screening large compound 
libraries. 
 
The method that is termed the ‘gold standard’ is the pH-metric method 
(Avdeef, 1993) where the compound is dissolved in water and titrated with an 
acid or base mixture of a known molarity. A pH electrode measures the 
change in molarity. The pKa is measured at the inflection point of the curve. 
The method has been incorporated in instruments and commercialized for 
example the Sirius GLpKa instrument (www.sirius-analytical.com). Variations 
have also been made where UV has been used to monitor the changes in pH, 
for example in the Sirius spectral gradient analysis method (www.sirius-
analytical.com). The spectral gradient method utilizes an HPLC pump and the 
absorption changes with pH are measured using a diode array detector 
(DAD). Another method is capillary electrophoresis, which is based on the 
electrophoretic mobility of a compound in neutral and ionized form in different 
buffers (Cleveland Jr et al., 1993). The mobility increases with ionization 
therefore the pKa is obtained by plotting pH against mobility. 
 
1.5.2. Rules based on structural properties 
Many rules have been formulated around structural properties with some 
being used as a standard for rapid property profiling. The most common rule 
is the Lipinski rule of 5 which is used as a quick predictor of oral absorption 
and permeability (Lipinski et al., 2001). The rule states that poor absorption is 
likely when the molecular weight is greater than 500, logP is greater than 5 




respectively. Additions to these rules were proposed by Veber, who added 
≤10 rotatable bonds and ≤ 140 Å2 PSA as essential for good absorption 
(Veber et al., 2002). 
 
Uptake of drugs in the brain has also been shown to be affected by 
physicochemical properties with a set of rules being defined for a drug to be 
active in the central nervous system (CNS) like(Pardridge, 1995). The rules 
states that the MW should be less than 500, LogD should be between 1 and 
4, and the PSA should be between 60 and 90 Å2. These guidelines have been 
generally accepted, and further studies have been done to verify the 
usefulness of the rules in estimating the BBB crossing of compounds (van de 
Waterbeemd et al., 1998). The CNS compounds clustered around the MW, 
LogD and PSA cutoff (Fig 1.19). Although a significant number of non-CNS 
drugs clustered in the same space, the rules are still very useful for guiding 
the synthesis of CNS like drugs and also for avoiding them. 
 
Figure 1.19: Effect of structural properties on blood-brain barrier 
crossing ability: The influence of size (MW), lipophilicity (LogD7.4) and polar 
surface area on the ability of compounds to cross the blood-brain barrier (van 
de Waterbeemd et al., 1998). 
 
Rules have also been defined to guide in the identification of lead like 




and 450, the calculated LogP between 3.5 and 4.5, and the LogD to be 
between -1 and 4 was formulated for lead-like compounds (Oprea, 2002a; 
Oprea, 2002b). Further computational studies led to a set of further properties 
being added as guide to identifying lead like compounds (Hann and Oprea, 
2004). In these revised rules the Mw ≤ 460, hydrogen bond donors ≤ 5, 
hydrogen acceptors ≤ 9, rings ≤ 4, rotatable bonds ≤ 10, log of water solubility 
(LogSw) ≤ -5 and the log P to be -4 ≤ Log P ≤ 4.2. 
 
1.5.3. Physicochemical properties 
The most commonly used physicochemical properties are integrity/stability, 
permeability, solubility, protein binding and volume of distribution. Screening 
for physicochemical properties is an important aspect of drug discovery as it 
provides information that is used to design, select and optimize leads with the 
highest chances of success. The screens are a valuable tool to medicinal 
chemists because they can be correlated to structure and are the main 
determinants of ADME. Poor physicochemical properties have also been 
linked to long development time line and high resource demands mainly due 
to difficult formulation development, stability and dissolution studies (Kerns 
and Di, 2008b). 
 
1.5.3.1. Integrity  
Integrity screens seek to verify the identity and purity of the compound. Many 
APIs are produced by organic chemical synthesis, a process that leaves 
behind various components including residual solvents and various organic 




as many of the experiments that are performed on the compound will assume 
the correct identity and purity of the compound. It also provides confidence in 
SAR data. Purity checks can be done using high performance liquid 
chromatography (HPLC). However for the verification of the compound 
structure more sensitive methods such as liquid chromatography-mass 
spectrometry (LC-MS) and nuclear magnetic reasonance (NMR) are used.  
 
1.5.3.2. Permeability  
Permeability is the velocity of a molecule as it passes through a membrane 
barrier. Permeability experiments are important in drug discovery as 
compounds often meet membrane barriers in living systems. The major 
barriers are the gastrointestinal epithelial cells and the blood-brain barrier 
(BBB). Various methods by which molecules cross the barrier have been 
described as illustrated in Fig 1.20. Methods to estimate permeability have 
been described with the parallel artificial membrane assay and the monolayer 
transport assays being the most commonly used. 
 
Figure 1.20: Mechanism of transport across cell membrane 
Simple (passive) diffusion is the most important mechanism for drugs and it involves 
movement by Brownian motion across the bilayer. Transport also occurs by active 
uptake where compounds bind to transmembrane proteins using ATP as a source of 
energy. Molecules may also enter cells via paracellular transport where they pass 




1.5.3.2.1. Parallel artificial membrane assay  
The parallel artificial membrane assay (PAMPA) (Kansy et al., 1998) 
effectively measures permeability assuming the mode of transport across the 
cell membrane is passive diffusion. The system utilizes lipids such as lecithin 
diluted in organic solvent such as dodecane to mimic lipids in the bilayer of 
the cell membrane.  The assay is performed as illustrated in Fig 1.21. 
 
Figure 1.21: Representation of the parallel artificial membrane assay. 
 
The method offers a rapid way of screening compounds and is suitable for 
high throughput screening. Concentration of compound is then measured 
from both the acceptor and donor well after an incubation period (5hrs – 
overnight) and the permeability calculated. Permeability is then calculated 
using the relationship below: 
 
 
Where CD = final drug concentration in donor well (µM); CA =final drug 
concentration in acceptor well (µM); VD = volume of drug solution added into 
the donor well (ml); VA = volume of buffer added into the acceptor well (ml); 
Cequilibrium = (CD * VD + CA* VA) / (VD + VA); S = membrane area (cm2) and t = 





1.5.3.2.2. Cell monolayer transport  
This method utilizes cell lines and takes into account the effects of other 
mechanisms such as active transport and the effect of transporters. Common 
cell lines used in this assay include the CaCO-2 (Artursson et al., 2001) and 
the MDCK (Irvine et al., 1999) cells. The experimental setup is illustrated in 
Fig 1.22. 
 
Figure 1.22: Setup for the cell monolayer transport assay. Transport of 
test compounds can be measured in the A-B as well as the B-A direction. 
Effect of test compounds on transporters expressed by the cells as they grow 
can also be investigated. 
 
CaCo-2 cells express efflux transporters such as P-glycoprotein and uptake 
transporters on the apical side. Permeability experiments are then done by 
measuring the apical to basolateral transport and basolateral to apical 
transport. Inhibitors can be incorporated to evaluate their effect on 
transporters. Permeability and inhibition of transporters by antiparasitic drugs 
have been investigated (Hayeshi et al., 2006), with a number of the 






1.5.3.3. Solubility  
Solubility affects absorption hence an important parameter for orally 
administered drugs. Parameters affecting solubility include pKa, lipophilicity, 
molecular weight, hydrogen bond formation and size. Poor solubility may 
necessitate novel formulations, which lead to increases in costs and delays 
during drug development. Besides being important for the achievement of 
good oral bioavailability, solubility experiments give a guide for the 
concentrations that can be used for in vitro assays. Poor solubility may lead to 
misleading data where, for example, a compound may be determined as non-
inhibiting where in actual fact the compound will have precipitated and was 
not available to the enzyme.  
 
The choice of solubility determination experiments is usually governed by the 
amount of compound available and the experimental factors that need to be 
controlled. The type of assay needed for the discovery stage may differ to the 
requirements for the development or clinical stage, and the decisions are 
governed by a number of factors as illustrates in Fig 1.23. 
 
Thermodynamic and kinetic solubility assays are used to measure solubility. 
Kinetic solubility assays measure the fastest precipitating species of the 
compound. The compounds are dissolved in organic solvent, usually DMSO, 
and then a small volume is added to aqueous buffer. The onset of 
precipitation is measured by the change in absorbance (Avdeef, 2007) or 
nephelometry (Bevan and Lloyd, 2000). The solubility assays can be adapted 




Kinetic assays are suitable for the discovery phase as there are many 
compounds to evaluate. The method also requires small amounts of 
compound. The assay however has low sensitivity making it difficult to rank 
compounds below 20μM (Teng-Man Chen et al., 2002). 
 
Figure 1.23: Considerations for the setup of solubility assays in drug 
development: The number of compounds that need to be screened and the 
quantity of drug available governs the choice of assay. Solubility range and 
number of experimental factors to be controlled increase as the drug 
candidate moves along the drug discovery pipeline. The number of solvents 
used increases in the preclinical stage to provide the necessary data to 
facilitate formulation. Adapted from Alsenz and Kansy (Alsenz and Kansy, 
2007) 
 
Thermodynamic assays measure the saturation of a compound in equilibrium 
with excess undissolved solid at the end of the dissolution process (Bard et 




solubility, namely the shake flask and the pH-metric method. In the shake 
flask method the solubility is measured by adding solid crystalline solid 
compound in a vial and adding solvent. The vial is shaken for 24-75 hours 
under controlled temperature. The undissolved material is then removed by 
filtration and concentration of compound measured by LS-MS. 
 
The pH-metric method utilizes the pKa of the compound to determine the 
intrinsic solubility. Known volumes of acid or base are added to a solution of 
test compound. The pH change produces a titration curve and the pKa shift is 
used to calculate solubility using the relationship below:  
            
 
 
      
         
Where S0 is the intrinsic solubility, C is the concentration of compound,    
    
is the shifted pKa and pKa is the actual measures pKa of compound (Avdeef, 
2007) 
 
Thermodynamic solubility measurements are used mainly in development 
where large amounts of the compound will have been synthesized. It is also 
an expensive method but it provides better quality data, which can be used to 
make models for solubility prediction. Apart from the in vitro methods, various 
software have also been used to measure solubility including Volsurf (Cruciani 
et al., 2000), AlogPs (www.vcclab.org) and QikProp (www.schrondinger.org).   
 
1.6. Pharmacokinetic screening 
Pharmacokinetics is the study of the time course of a drug and metabolite 




mathematical relationships required to develop models to interpret such data 
(Gibaldi and Perrier, 1975). It is a process that describes the fate of a drug 
from the time it is taken to the time of elimination as illustrated in Fig 1.24. The 
process involves absorption, distribution, metabolism and excretion ADME. 
Toxicity can also be added to the process hence ADMET. 
 
Figure 1.24: The fate of a drug. The drug is absorbed from the site of 
administration into the blood stream where it is carried to site of action. Many 
drugs are carried to the liver where metabolism occurs. The drug is changed 
to more soluble products, which are excreted in urine. 
 
Knowledge of the ADME process will determine how much and how often a 
certain drug will need to be given to obtain the right therapeutic effect.  
Concentrations above the therapeutic window may lead to toxic effects and 
those below may lead to under treatment. The time course for a drug given 
either orally (p.o.) or intravenousely (i.v.) is illustrated in Fig 1.25. The effect of 







Figure 1.25: Pharmacokinetic profile following p.o and i.v dose. 
 
ADME/PK is one of the main causes of drug failure in the late phases of drug 
discovery. It was the leading cause of drug failure in the 1990s before PK and 
ADME screens were developed accounting for up to 40% of drug attrition. The 
introduction of screening platforms saw a drop in the attrition rate to less than 
10% (Fig 1.26) 
 
 
Figure 1.26: Major causes of drug attrition 1991-2000 (Kola and Landis, 
2004): With the development of ADME/PK screens poor efficacy, toxicity, and 






Absorption is the major determinant of bioavailability in orally administered 
compounds. It is a fundamental property for orally administered drugs as they 
rely on the absorption in the GI tract and also need to overcome other barriers 
to get to their sites of action. Many of the drugs are absorbed via the passive 
diffusion route and the major parameters that affect this are the acid/base 
character, lipophilicity, solubility and permeability.  
 
The solubility and the lipophilicity are two opposing properties. Highly 
lipophilic compounds will have low solubility but good permeability across lipid 
membranes. However for compounds to cross the membrane they have to be 
in solution requiring lipophilicity to be low. Therefore compounds possessing a 
good balance of the two have higher chances of achieving high oral 
bioavailability.  
 
The acid base character as determined by the pKa determines the charge 
state of the molecule in solution at a particular pH and the site at which most 
the drug is absorbed. Many drug products are absorbed in their unionized 
forms. The GI has various pHs depending on the site and the state i.e. 
whether it is the fasted or fed state as illustrated in Fig 1.26. The ileum and 
the jejunum offer the greatest area for absorption and it is at these two sites 
that many drug products are absorbed (Avdeef, 2001) within a pH range of 
4.5 -8.0. Also many weak acids are absorbed in the stomach and weak bases 






Figure 1.27: Physical properties of the GI tract (Avdeef, 2001). 
 
In vitro, absorption is measured using cell lines such as the CaCO-2 and 
MDCK. These are models that take into account the role of transporters. 
Many drugs have been shown to be substrates or inhibitors of P-glycoprotein 
(P-gp). The role of P-gp has been well studied and it has been shown to 
inhibit the transport of some compounds across membranes (Burton et al., 
2002). Metabolism has also been shown to have a role in the absorption of 
drugs (Burton et al., 2002). 
 
1.6.2. Metabolism 
Metabolism involves the enzymatic conversion from one chemical entity to 




insults and is therefore regarded as a detoxification mechanism. It facilitates 
the excretion of drugs by converting them from lipid soluble non-polar 
compounds to more polar compounds. Metabolism mainly occurs in the liver 
with the cytochrome P450 (CYP) being the most important enzymes in the 
biotransformation of most drugs. 
 
1.6.2.1. Major classes of drug metabolizing enzymes  
The drug metabolizing enzymes are a diverse group of proteins responsible 
for metabolizing xenobiotic compounds. Xenobiotics include drugs, 
environmental pollutants and endogenous compounds such as steroids and 
prostaglandins (Guengerich, 1995).  The enzymes are grouped as Phase I 
and Phase II enzymes. The CYP3A family is the largest contributor to drug 
metabolism in the Phase I enzymes accounting for up to 50% of metabolism 
of current drugs on the market and UGTs are the most important phase II in 
terms of metabolism (Fig 1.28). The other enzymes in each class are also 
shown with their contribution depicted by the size of each section in the chart. 
 
Phase I reactions are mainly performed in the liver and they often make 
xenobiotics more accessible to phase II reactions. Some phase II reactions 
can occur directly without first undergoing phase I reactions. The endoplasmic 
reticulum (ER) and the cytosol are the most important subcellular organelles 
containing the drug metabolizing enzymes in the hepatocytes. The phase I 
oxidative enzymes are almost exclusively localized in the ER together with the 
phase II enzyme, glucuronosyl transferase. Other phase II enzymes including 





Figure 1.28: The major classes of drug metabolizing enzymes and their 
relative contribution to drug metabolism (Evans and Relling, 1999).(ADH, 
alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome 
P450; DPD, dihydropyrimidine dehydrogenase; NQO1, NADPH: quinone 
oxidoreductase or DT diaphorase; COMT, catechol O-methyltransferase; 
GST, glutathione S-transferase; HMT, histamine methyltransferase; NAT, N-
acetyl-transferase; STs, sulfotransferases; TPMT, thiopurine 
methyltransferase; UGTs, Uridine 5'-diphospho-glucuronosyltransferase ). 
 
1.6.2.2. Sources of drug metabolizing enzymes for metabolism studies 
1.6.2.2.1. Subcellular fractions 
The liver is the richest source of drug metabolizing enzymes. Other sources 
include the skin, blood and gut wall. Homogenizing the liver and subjecting it 
to different centrifugation speeds results in different enzymes sources 
illustrated in Fig 1.29. The main advantage of the enzyme subfractions is in 
the ease of preparation for most of them, reproducible nature, capacity for 
long term storage at -800C and ample characterization of incubation 





Microsomes are the most used source of enzymes and contain the major 
membrane bound enzymes including CYPs, FMOs and UGTs. They are 
particularly useful when comparing results before and after the addition of 
specific CYP inhibitors, enhancers and antibodies. Microsomes can also be 
made from pooled liver samples. This takes into account interindividual 
variability making them a useful in vitro study model (Venkatakrishnan  et al., 
2003). 
 
Figure 1.29: Preparation of drug metabolizing enzyme containing 
subcellular fractions 
 
Hepatocytes and liver slices are prepared from fresh tissue. Their main 
advantage is that they mimic the in vivo enzyme environment as compared to 
all the other cell fractions. They represent a complete system taking into 
account the role of transporters. However they are expensive and long-term 
storage is problematic. The other cell fractions include the cytosol, which 




1.6.2.2.2. Recombinant enzymes  
A variety of systems have been used to express drug-metabolizing enzymes 
including E. coli, insect cells, yeast and human embryonic cells. Much of the 
effort has gone into the CYPs because of their predominant role in drug 
metabolism. The first expression systems to be used were the yeast and the 
human lymphoblastoid cells (Crespi et al., 1991), but the commercially 
competent enzymes are the E. coli and baculovirus infected insect cells 
expressed because of the high expression in these systems (Waterman, 
1994). Some of the common expression systems for drug metabolizing 
enzymes are summarized in Table 1.3. 
Table 1.3: Expression systems for recombinant drug metabolizing 
enzymes 
Enzyme  Enzyme source  Comment  
CYP Human lymphoblastoid cells Low expression levels 
 Yeast CYP alone or CYP/reductase 
 
Baculovirus infected insect 
cells CYP alone or CYP/reductase 
 E.Coli 
CYP alone or CYP/reductase; N-terminal 
modifications 
   
UGT COS cells Low expression levels 
 
Human Embryonic Kidney 




Expression of active protein at a level less 
than 1mg/liter 
 
E. coli  
 
Expression of aglycone or UDPGA binding 
domains as fusion proteins 
   
ST Baculovirus-infected Insect Cells 
Very high activity levels, purification 
unnecessary 
 E. coli High level expression of soluble, active proteins 
   
NAT E. coli High level expression of soluble, active proteins 
   




1.6.2.3. Scope of drug metabolism  
Drug metabolism can lead to a variety of outcomes depending on the type of 
chemical exposure, route of metabolism and the enzyme that is involved. 
Drugs can be given as prodrugs, which are inactive but are changed to the 
active form of the drug after biotransformation. An example is the antimalarial 
proguanil which is relatively inactive but is metabolized to the active 
cycloguanil by CYP3A family and CYP2C19 (Fig 1.30) (Lu et al., 2000; Birkett 
et al., 1994).  
 
Figure 1.30: CYP3A and CYP2C19 biotransformation of proguanil to 
cycloguanil 
 
An active drug can also be metabolized to an inactive metabolite. For 
example, the broad-spectrum anthelmintic drug praziquantel, which is 
metabolized by CYP3A4 to 4-hydroxypraziquantel (Fig 1.31) (Meier and 
Blaschke, 2001; Masimirembwa and Hasler, 1994). 
 



































Metabolism may also result in the formation of toxic metabolism from 
otherwise safe compounds. An example is the metabolism of paracetamol 
and amodiaquine. The two compounds are both metabolized to quinoneimine 
metabolites (Fig 1.32), which have toxic effects. At high concentrations, 
paracetamol is metabolized by several CYP isoforms including CYPs 2E1, 
1A2, 2A6, 3A4 and CYP2D6 (Dong et al., 2000; Laine et al., 2009) to the 
reactive paracetamol quinoneimine which is associated with hepatic injury.  
 
Figure 1.32: Bioactivation of paracetamol and amodiaquine to reactive 
quinoneimine intermediates associated with toxicity 
 
CYPs have also been associated with bioactivation of xenobiotics such as 
aflatoxin B1 to carcinogenic aflatoxin B1-8-9-epoxide (Fig 1.33). 
 










































1.6.2.4. Assays for evaluating drug metabolism  
The most commonly used assays to evaluate drug metabolism are hepatic-
based systems. The common assays that are performed are metabolic 
stability, reaction phenotyping and metabolite profiling which are discussed in 
detail in the following sections. 
 
1.6.2.4.1. Metabolic stability  
Screening for metabolic stability gives an estimation of the susceptibility of a 
compound to biotransformation. The disappearance of a compound from 
reaction media containing drug metabolizing enzymes is expressed as the 
half life (t1/2) and intrinsic clearance (CLint). These parameters are then used 
to calculate secondary pharmacokinetic values such as the hepatic clearance 
(CLH), bioavailability and in vivo t1/2. Hepatocytes and microsomes are the 
commonly used systems for doing metabolic stability assays as they have a 
good representation of drug metabolizing enzymes with hepatocytes taking 
into account phase II enzymes and the role of transporters. Measurements of 
drug concentrations are conducted using the mass spectrometer. 
 
Several models have been used to extrapolate in vitro data to in vivo including 
the well stirred, parallel tube and dispersion models (Houston and Carlile, 
1997). Various scaling factors have also been used and they differ depending 
on the animal model that is being used. Commonly used scaling factors for 
humans take into account the body weight for an average man (70kg), liver 
weight (1680g) and number of hepatocytes (117.5 million cells) or 




The assay and calculations are performed assuming that the liver is the main 
organ of clearance, the major elimination pathway is oxidative metabolism, 
there is no inactivation of the enzyme or non specific binding, and the 
concentration of the test compound is below the Michaelis-Menten constant 
(Km). It is also assumed the rate of metabolism and the activity of the 
metabolizing enzymes in vitro is the same as the in vivo situation.  
 
Various in silico methods have been used to estimate metabolic stability. 
Metasite® (Cruciani et al., 2005) predicts sites of metabolic instability and can 
be useful in structure design where it can be used to determine if planned 
substructure modifications  will be liable to metabolism. VolSurf has been 
used to predict CYP3A4 stability (Crivori et al., 2004). Other software 
packages that have been used include KnowItAll (www.biorad.com), 
ADMENSA (www.inpharmatica.com) and Meteor (www.ihasalimited.org). 
 
1.6.2.4.2. Metabolite profiling  
Metabolite profiling involves the incubation of drug candidate with hepatic 
enzymes followed by identification of major metabolites on mass 
spectrometer. This allows the identification of major routes of metabolism 
providing information as to whether modifications need to be made or not. It 
also allows the selection of animal models to use. Ideal models will be the 
ones that form metabolites similar to those generated with human in vitro 
systems. Identification of major metabolites of a lead can allow their synthesis 
and testing for activity. There are compounds that are active together with 




active metabolites including artesunate and dihydroartemisinin both of which 
have been registered as effective antimalarials. In silico software such as 
Metasite® are useful in predicting the likely metabolites that can be formed 
from a compound by various CYPs.  
 
1.6.3. Metabolism based toxicity 
Toxicity is responsible for the failure of many drugs and withdrawal of drugs 
after approval (Fig 1.26). The main causes of drug toxicity include drug-drug 
interactions and bioactivation into reactive metabolites which bind to proteins 
and form adducts which are recognized as foreign by the body. Many of the 
causes of toxicity are metabolism based. Common drug-drug interactions that 
result in toxicity include induction, inhibition and formation of toxic metabolites.  
 
1.6.3.1. Inhibitory drug-drug interactions  
 Inhibitory drug-drug interactions have been recognized as one important 
cause of pharmacokinetic toxicity. The inhibition of metabolism of a co-
administered drug may lead to higher plasma concentrations of the other than 
intended. Many cases of interaction of antiparasitic drugs with drug 
metabolizing enzymes via different mechanisms have been documented. 
Inhibition may be reversible, quasi irreversible or non-reversible.  
 
1.6.3.1.1. Reversible inhibition  
Reversible inhibition results when inhibitors bind to the enzyme via non-
covalent interactions such as hydrogen bonds, hydrophobic interactions and 




removed by dialysis. Reversible inhibition is further divided into competitive, 
uncompetitive, non-competitive and mixed modes. 
 
Competitive inhibition is the commonest type of interaction found among 
therapeutic drugs. In this type of inhibition, the inhibitor has an affinity for the 
substrate-binding site and therefore competes with the substrate for access to 
the binding site. However increasing the concentration of the substrate will 
out-compete the inhibitor hence minimize its effect. Examples of antiparasitic 
drugs that have been found to be competitive inhibitors include chloroquine, 
oxamniquine and primaquine (Fig 1.34), which have been shown to be 
competitive inhibitors of CYP2D6 in vitro (Masimirembwa et al., 1995). 
Chloroquine has also been demonstrated to be a significant inhibitor of 
CYP2D6 in healthy individuals (Simooya et al., 1998). 
 
Figure 1.34: Examples of antiparasitic drugs that have been shown to be 
competitive inhibitors of CYP2D6 
 
Non-competitive inhibitors bind to both the enzyme and the enzyme-substrate 
complex resulting in reduced activity. This type of inhibition is not affected by 
increasing the substrate concentration. An example of a non-competitive 
inhibitor is isoniazid inhibiting phenytoin oxidation. It has been shown to be a 
potent inhibitor of CYP2C19 and CYP3A in vitro (Zeruesenay et al., 2001). In 
vivo it has been shown to be a non-competitive inhibitor of phenytoin oxidation 






















saturable at therapeutic doses leading to accumulation of the drug if any 
minor metabolic interference occurs and the effect is felt more in slow 
acetylators of isoniazid (Kutt, 1975). 
 
Figure 1.35: Structure of phenytoin and isoniazid 
 
Uncompetitive inhibitor binds only to the substrate-enzyme complex 
preventing the formation of product. This occurs at sites other than the binding 
site causing the conformation of the enzyme to change. This type of 
interaction is rare among therapeutic drugs. The differences in the types of 
inhibition are summarized in Table 1.4. 
 
Drug-herb interactions via inhibitory mechanisms are also very common 
(Chavez et al., 2006; Fugh-Berman and Ernst, 2001; Izzo, 2005). Inhibition by 
various forms of St John’s Wort have been reported (Chaudhary and Willett, 















Table 1.4: Differences between the types of reversible inhibition 
 Competitive Non-competitive  Uncompetitive 
Binding site on enzyme  
Specifically at the catalytic site, where it 
competes with substrate for binding in a 
dynamic equilibrium- like process. Inhibition is 
reversible by substrate 
Binds E or ES complex other than at the 
catalytic site. Substrate binding unaltered, 
but ESI complex cannot form products. 
Inhibition cannot be reversed by 
substrate. 
Binds only to ES complexes at locations other 
than the catalytic site. Substrate binding 
modifies enzyme structure, making inhibitor- 
binding site available. Inhibition cannot be 
reversed by substrate. 
Kinetic effect 
Vmax is unchanged; Km, as, Defined by [S] 
required for ½, Maximal activity, is increased 
Km appears unaltered; Vmax is decreased 
proportionately to inhibitor concentration. 
Apparent Vmax decreased; Km, as defined by [S] 
required for 1/2 maximal activity, is decreased 









Reaction scheme  
   
Michaelis –Menten 
equation  
   
 
vo =         VmaxS
Km (1+1/Ki ) + S
vo =         VmaxS
Km (1+1/Ki ) + S
vo =           VmaxS




Plus competitive inhibitor 
Unhibited enzyme  





























Plus noncompetitive inhibitor 




Plus uncompetitive inhibitor 




1.6.3.1.2. Irreversible inhibition  
This type of inhibition cannot be reversed by dialysis, gel filtration or dilution 
and is more profound than reversible inhibition. Irreversible inhibition is 
characterized by time and concentration dependence, with slow onset of 
effects. Irreversible inhibitors are usually good drugs with high specificity for 
target enzyme, a characteristic that has made them very useful in elucidating 
enzyme mechanism and in mapping the active site. Irreversible inhibition is 
divided into two main groups:  quasi-irreversible and mechanism based 
inhibition. 
 
Quasi-irreversible inhibition involves the formation of metabolic intermediates 
with the heme iron by strong ligation leaving the enzyme in a non-functional 
inactive state. Binding is not covalent as in mechanism-based inhibition and in 
some cases it may be reversed. Restoration of catalytic activity may or may 
not require the synthesis of new protein. This type of reaction is common with 
drugs that undergo activation by CYPs and form inhibitory complexes e.g. 
methyldioxybenzenes, alkylamines, macrolide antibiotics e.g. troleandomycin 
and erythromycin, and hydrazines (Lin  and Lu, 1998). Some of the structures 
are shown in Fig 1.36. 
 
The activity of the enzyme can be restored depending on the compound by 
incubating the MI complexes with lipophilic compounds or potassium 
ferricyanide which can displace the MI from the active site. Although this is 
very easy to do in vitro, it is not the case in vivo where the MI complexes tend 




determinined by measuring the activity of the enzyme after incubation with 
compounds that can displace the MI from the active site. 
 
Figure 1.36: Structures thought to form metabolite intermediate (MI) 
complexes  after bioactivation with CYP. Methlenedioxyphenyl compounds  
which form carbene iron complex (left); alkylamines which form nitrosoiron 
complexes (middle); and 1.1 dialkylhydrazines which form nitrene iron 
complex (right) (Lin  and Lu, 1998). 
 
Mechanism based inhibition is defined as inactivation of cytochromes P450 
(CYPs) by metabolic products that form heme or protein adducts (Silverman, 
1988). The compounds that are transformed to reactive species and prior to 
release from the active site cause inactivation of the enzyme are known as 
mechanism based or suicide inhibitors (Fontana  et al., 2005). There are 
features that are characteristic of MBI in vitro including time-, concentration-, 
and NADPH dependency, non-prevention by glutathione and free radical 
scavengers, non reversal by dialysis and protein washing, reduction of P450 
content, 1:1 stoichiometric reaction and inactivation following pseudo first 
order kinetics. Various substructures on drugs have also been associated with 






1.6.3.1.3. Inductive drug-drug interactions 
This is when a drug accelerates the metabolism of a coadminstered drug by 
inducing corresponding metabolic pathways. This results in the reduction in 
efficacy of the affected drug due to lowered plasma levels. An example of a 
drug which has this kind of effect is rifampicin which is used as part of a 
regimen in the treatment of tuberculosis. Coadminstration of rifampicin with 
oral contraceptives has been shown to result in menstrual disturbances and 
unplanned pregnancies (Daniels et al., 1984). It has also been shown to 
increase metabolism of cyclosporin in patients resulting in transplant rejection 
due to low concentrations of the immunosupressive agent (Moddry et al., 
1985). In both cases rifampicin induces CYP3A which is responsible for 
metabolism of the cyclosporin and oral contraceptives. Quinine, primaquine 
and albendazole have also been shown to cause induction of CYP1A1/2 in 
HepG2 cells (Bapiro et al., 2002). 
 
1.6.3.1.4. Drug-herb interactions  
Herbal medicines are widely used the world over, with 80% estimated to be 
used in developing countries. Coadminstration of herbs and conventional 
medicines poses the risk of drug-herb interactions with some having clinical 
significance. The role of a number of herbs in altering the ADME process has 
been shown (Zhou et al., 2003). The inductive interaction of St John’s Wort 
with CYPs has been well studied with hyperforin being identified as the causal 






1.6.3.2. Assays for evaluating metabolism based drug toxicity   
There are many in vitro assays for predicting toxicity with subsequent 
extrapolations made to in vivo outcomes. This is because there is a clear 
understanding of the mechanisms of drug-drug/herb interactions. Common 
assays include the inhibition screen assays, pathway identification and 
induction screen assays. 
 
Inhibition has also been shown to cause clinically significant interactions 
between herbs and conventional medicines, Grapefruit juice has been shown 
to increase oral bioavailability of many conventional drugs including 
terfenadine, midazolam and verapamil and this has been linked to inhibition of 
CYP3A4 (Fuhr, 1998). Methysticin and dihydromethysticin, which are 
components of Kava have been shown to be mechanism based inhibitors of 
CYPs (Mathews et al., 2002). Other interactions with transporters and 
enzymes together with the potential adverse effects have been reviewed 
(Zhang et al., 2012). 
 
1.6.3.2.1. Inhibition assays  
Inhibition assays are performed to evaluate whether a drug has potential to 
inhibit drug metabolising enzymes. The drug metabolising enzyme marker 
substrate drug is incubated with enzymes systems e.g. human liver 
microsomes (HLM), hepatocytes or recombinant enzymes. Measurements of 
the metabolic rate in the presence and absence of drug will enable the 
estimation of the inhibitory potential of a test compound. The mechanism of 




expressed as IC50 or Ki where the IC50 is the concentration of drug required to 
cause 50% reduction in activity and Ki which is the dissociation constant for 
inhibitor binding. 
 
1.6.3.2.2. Pathway identification and reaction phenotyping 
Experiments are performed to elucidate the metabolic pathways important in 
the metabolism of candidate drugs. Metabolites and enzymes involved are 
identified. The candidate drug is incubated in HLM or hepatocytes in the 
presence of diagnostic inhibitors to identify the likely enzymes involved. 
Incubations are also performed in a panel of recombinant enzymes which are 
derived from cells engineered to express specific CYP isoforms. 
 
1.6.3.2.3. Enzyme induction assays 
Experiments are performed in enzymes that are known to be inducible for 
example CYPs 1A2, 2A6, 2B6, 2C9 and 3A4. Hepatocytes are cultured in the 
presence of the candidate drug and the messenger RNA levels or enzyme 
activity measured. Reporter cell lines such as the human hepatoma cell line 
integrated with either the CYP3A4 enhancer region and a luciferase reporter 
gene or the CYP3A4-luciferase construct and the human pregnane X receptor 




Distribution is the reversible transfer of drug from and to the site of 




the volume of distribution (Vd), fraction unbound in blood (fu), fraction unbound 
in tissue (fuT) and the blood plasma ratio (B/P).  
 
1.6.4.1. Volume of distribution 
The volume of distribution gives an indication of how widely a compound is 
distributed in the body representing the apparent volume in which the 
compound is dissolved. It is calculated using the relationship below: 
                      
        
         
  
where fu, blood is the fraction of compound unbound in blood, fu, tissue is the 
fraction of compound unbound in tissue. Vblood and Vtissue is the volume in 
blood and volume in tissue respectively. 
 
Plasma protein bound and hydrophilic compounds tend to be restricted into 
the blood stream hence their Vd is close to the Vblood (70ml/Kg). Moderately 
lipophilic and protein bound compounds distribute evenly in tissue and blood 
hence volume is close to that of body water which is the same as blood 
volume. Lipophilic drugs on the other hand bind to tissue components and 
have very low blood concentrations resulting in high Vd values which exceed 
body water volume.  An example of such as drug is the antimalarial 
chloroquine, which has a Vd of 235 L/Kg because it is highly lipid soluble 
therefore it binds outside the serum for example in  melanin containing cells 
(Krishna and White, 1996). The drug therefore is extensively distributed into 
body tissues, including the placenta  





1.6.4.2. Protein binding  
The binding of drugs to serum or plasma proteins is a saturable process, 
which occurs via various interactions including hydrogen bonding, van der 
Waals and electrostatic interactions. It is important to measure protein binding 
(PB) as it directly correlates to Vd where high plasma PB implies more drug is 
present in the central blood compartment. Low PB means more drug is free to 
partition into tissue therefore high Vd. The two plasma proteins that are mostly 
responsible for binding drug molecules are human serum albumin (HSA) and 
AGP.  
 
Protein binding has an effect on the PK and exposure to the therapeutic 
target. Bound drug cannot permeate through cell membranes and is therefore 
not available for metabolism or excretion. The distribution of the drug is also 
limited including brain permeation. Besides binding to the protein, drugs can 
also be bound to red blood cells. It is therefore important to measure the 
blood/plasma partitioning to know where the bulk of the drug will be. In many 
PK studies blood is centrifuged and red blood cells removed. This means drug 
bound to RBCs will not be quantitated. Two techniques are widely used to 





2 AIMS AND OBJECTIVES 
2.1 Aim 
To determine ADME/PK properties of new synthetic chemical entities and 
herb/natural products to guide the molecular design of better analogues and 
to evaluate the ADMET/PK of anti-parasitic drugs on the market to optimize 
their safe use. 
 
2.2 Objectives 
I. To setup the first pharmaceutical industry standard in silico and in vitro 
ADMET platform to support drug discovery and development in Africa 
 
II. To use molecular and kinetics data obtained from biochemical assays 
and in silico computational methods in the identification of ADME/PK 
liabilities of novel artemisinins and quinoline hybrid new chemical entities 
with antimalarial activities 
 
III. To determine the molecular mechanism of CYP1A2 inhibition by 
thiabendazole towards understanding the nature and extent of drug-drug 
interactions between thiabendazole and CYP1A2 substrate drugs.  
 
IV. To explore the risk of drug-herb interaction by evaluating the ADMET/PK 
of the natural product, Frutinone A, which is found in herbal extracts 





3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1. Chemicals and Biologics 
Bactosomes from E. coli co-expressing human NADPH-P450 reductase and 
the individual CYPs (CYPs 1A2, 2C9, 2C19, 2D6 and 3A4) were obtained 
from CYPEX (CYPEX, Dundee, UK). Human Liver microsomes (HLM) were 
obtained from BD GenTest (Ellisville, MO). Cryopreserved hepatocytes were 
obtained from In vitro Technologies (Baltimore, MD, USA). Substrates for the 
fluorescence-based plate assays including 3-Cyano-7-ethoxycoumarin 
(CEC), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-methoxy-4-
trifluoromethylcoumarin (MFC), and MAMC were obtained from BD GenTest 
Corporation (Ellisville, MO). 
 
Inhibitors for the CYP assays including sulfaphenazole, ketoconazole, 
quinidine, α-naphthoflavone, troleandomycin, ticlopidine, erythromycin and 
paroxetin were obtained from Sigma Chemical Co. (St. Louis, MO). 
Furafylline, tienilic acid, 1’hydroxybufuralol and bufuralol, were obtained from 
BD GENETEST Corporation (Ellisville, MO). Fluvoxamine was obtained from 
Tocris Bioscience (Ellisville, MO).Frutinone A was a generous gift from the 
Department of Clinical Pharmacology, University of Cape Town. 
 
Reagents and consumables for the fluorescence-based assays including Tris, 
ACN, β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium 
salt (NADPH), potassium phosphate monobasic, potassium phosphate 




Co. (St. Louis, MO).Thiabendazole, artemisinin, artesunate, 
dihydroartemisinin, ivermectin, praziquantel, pyrimethamine, quinine, 
tinidazole, albendazole, cycloguanil, primaquine, proguanil, amodiaquine, 
monodesethylamodiaquine, chloroquine, dethylcarbamazine, pyrantel, 
suramin, 4-chlorophemybiguanide, metoprolol, propanolol, testosterone and 
niclosamide were obtained from Sigma Chemical Co. (St. Louis, MO). 
 
L-glutathione reduced, potassium ferricyanide, 1640 RPMI media, HEPES, 
chloroquine, Cremophor, Amar Blue, Eagles Minimum Essential Medium, 
Bovine foetal calf serum (FCS), Phosphate buffered saline and ethanol were 
obtained from Sigma Chemical Co. (St. Louis, MO). All other reagents were 
of reagent grade. All other reagents were of the highest obtainable grade. 
 
3.1.2. Equipment and Software 
For in silico predictions, Metasite, Moka, and Volsurf academic licenses were 
obtained from Molecular Discovery (Molecular discoveries Ltd, Pinner, 
Middlesex, UK, www.moldiscovery.com). Other software including Autodock 
(http://autodock.scripps.edu/resources/adt),GOLD 
(www.ccdc.cam.ac.uk)GLUE (Molecular discoveries Ltd, Pinner, Middlesex, 
UK, www.moldiscovery.com) and FlexX (www.biosolveit.de)were obtained as 
either open sources or accessed through collaborative licenses. Key 
analytical equipment used in this study include, Agilent HP1100 HPLC 
(Agilent systems, Santa Clara, CA, USA), Waters Quattro and QTof LC-
MS/MS machines (Waters, Milford, MA, USA), and the Victor2 multilabel 





3.2.1 PART I: Setting up of the ADME PK platform 
The various biochemical and analytical methods were set up in preparation for 
the screening of the various compounds in the study. A set of marker 
reactions was used to determine the activity of the enzymes. The formation of 
metabolite was used to follow enzyme activity. Some of the literature methods 
were adapted to suit our setting and validations were done to ensure 
experiments were optimal for the various studies performed.  
 
3.2.1.1 Fluorescence- based plate assays  
The assays use chromogenic substrates, which result in the formation of 
fluorescent metabolites. Measuring the formation of fluorescent metabolite at 
appropriate wavelength was used to follow the activity of the enzyme. The 
marker reactions used in this study are summarized in Table 3.1. 
 
3.2.1.1.1 Optimization of assay conditions  
Assay conditions were optimized with respect to enzyme concentration, 
incubation time and substrate concentration. Conditions reported by the 
enzyme manufacturer for the assays were used as a starting point 
(www.cypex.com) and other reported generic methods (Crespi et al., 1997; 





Table 3.1: Marker reactions and detection wavelengths for the fluorescence based plate assays 
Marker reaction  Substrate Metabolite 
Metabolite Detection Wavelength (nm) 
Excitation Emission 
CYP1A2 mediated CEC 


























CEC, 3-cyano-7-ethoxycoumarin; CHC, 3-cyano-7-hydroxycoumarin; MFC, 7-methoxy-4-(trifluoromethyl)-coumarin; HFC, 7-hydroxy-4-





















3.2.1.1.1.1 Linearity with enzyme concentration 
The assay was performed using generic conditions for fluorescent assays 
(Crespi et al., 1997) in 96 well black coaster plates (Corning Incorporation, 
Corning, NY). The substrate concentration used was a quarter of the reported 
Km in literature. Varying concentrations of enzyme (0-50pmol/ml) were 
incubated with substrate and 0.1M phosphate buffer pH 7.4. Preincubation 
was then performed to warm the incubation mixture to 370C prior to reaction 
initiation. The reaction was initiated by addition of 10μl of 20mM NADPH 
(16mM for CYP2D6). This was followed by 15min incubation in a shaking 
incubator. Termination of the reaction was by addition of an ice-cold solution 
of 80% ACN in 5mM Tris. Fluorescence of the metabolites was measured at 
appropriate wavelength (Table 3.1) using the Wallac Victor2 multilabel counter 
(Wallac, Turku, Finland). 
 
3.2.1.1.1.2 Linearity with incubation time 
The assay was performed using optimised enzyme concentrations above. 
Enzyme, substrate and 0.1M phosphate buffer pH7.4 were incubated at 
varying incubation time ranging between 0 and 1hr. All the other conditions 
and metabolite detection were as above. 
 
3.2.1.1.1.3 Km determination 
The assay was performed using the optimal incubation time and enzyme 
concentration obtained above. Varying concentrations of substrate in the 




described above. Km calculations were then performed using SIGMA PLOT 
Enzyme kinetics module (SYSTAT Software Inc, Richmond, CA). 
 
3.2.1.1.2 Setup of the inhibition assay  
The assay was performed using marker reactions and known diagnostic 
inhibitors for the various CYP isoforms (Table 3.1). The structures of the 
various inhibitors and the concentrations used in the assay are shown in 
Table 3.2. 
 
Table 3.2: Experimental conditions for the inhibition assay 














































The assay was performed using previously optimized conditions as 
summarized in Table 3.3. 
 
Table 3.3: Experimental conditions for the reversible inhibition assay 
CYP Enzyme (pmol/ml) Substrate [Substrate] (μM) 
1A2 2.5 CEC 3 
2C19 10 MFC 85 
2C9 25 MFC 85 
2D6 30 MAMC 15 
3A4 10 BFC 13 
 
The inhibitors were incubated with substrate, enzyme and 0.1M phosphate 
buffer pH7.4. The plate was preincubated for 10min to warm the mixture to 
370C. Addition of 10μl 1mM NADPH (0.8mM for CYP2D6) was used to initiate 
the reaction. This was followed by incubation for 15 min at 370C. The reaction 
was terminated by addition of ice-cold 80% ACN in 5mM Tris solution. 
Formation of fluorescent metabolite was followed at the appropriate 
wavelength (Table 3.1). The remaining activity was expressed as: 
Equation 3.1 
                      
                   
                    
         
 
3.2.1.1.3 IC50 assay  
Determining the IC50, values of the diagnostic inhibitors and comparing them 
to previously reported literature values validated the reversible inhibition 
assay. Varying concentrations of the inhibitors were incubated with substrate, 




assay. The choice of inhibitor range to use was guided by reported literature 
IC50s. The ranges were as follows: α-naphthoflavone 0-1μM, quinidine and 
ketoconazole 0-2μM, ticlopidine 0-100μM and sulfaphenazole 0-12μM. The 
amount formed at each inhibitor concentration relative to the control (% 
remaining activity) was plotted against the concentration of the inhibitor. The 
data was the analysed by non-linear regression and calculated using the IC50 
model in GraphPad Prism version 5 (GraphPad Prism; GraphPad Software, 
San Diego, CA). 
 
3.2.1.1.4 Setup of the time dependent inhibition assay  
The time-dependent inhibition assays was performed using the conditions 
optimised for the reversible assay as a starting point. The method was 
adapted to our setting from published methods (Atkinson et al., 2005; 
Polasek et al., 2006). The assay was conducted in 2 stages namely the 
inactivation and the activity assay (Fig 3.1). 
 
The reaction mixtures for both the inactivation and activity assays were 
preincubated to 370C prior to reaction initiation. In both assays the reaction 
was initiated by the addition of 10μl 20mM NADPH (16mM for CYP1A2) and 
incubation done for 15min. The experimental parameters are summarised in 
Table 3.4. The buffer was at 0.1M final concentrations and the test 
compounds were at 1 and 20μM. The reaction was terminated by addition of 
ice cold 80% ACN in 5mM Tris. Measurement of the formation of fluorescent 










Figure 3.1: Outline for time-dependent inhibition assay 
 
3.2.1.1.5 Calculation of the normalized ratio 
In the screen assay, the effect of each inhibitor on the activity of the enzyme 
was expressed as the normalized ratio calculated as shown in the equation 




                  
                      
                           
 
where R + INADPH is the rate of reaction when incubation is performed in the presence of both 
inhibitor and NADPH, R - INADPH is the rate of reaction when incubation is performed in the 
presence of NADPH but in the absence of inhibitor, R+ Ino NADPH is the rate of reaction when 
incubation is performed in the presence of inhibitor but in the absence of NADPH, and R – Ino 
NADPH is the rate of reaction when incubation is performed in the absence of both inhibitor and 
NADPH. 


















Transfer 20µl to corresponding 
wells in incubation plate after 
15min incubation 
Secondary incubation (Activity assay)  
Phosphate buffer pH 7.4, water, substrate, 20µl from 
primary incubation and NADPH 
Primary incubation (inactivation assay) KPO4 
pH7.4, water, enzyme (at x10 the concentration 
required in the secondary incubation), test 




Table 3.4: Experimental conditions for the time-dependent inhibition screen assay 
CYP a[Enzyme] (pmol/ml) Substrate b[Substrate] (µM) Positive control  Negative control 
      
1A2 25 CEC 12 Furafylline 
(0.01 and 0.1μM) 
Fluvoxamine 
(0.1 and 1μM) 
2C19 100 MFC *250 Ticlopidine 
(1 and 10μM) 
Sulfaphenazole 
(0.1 and 1μM) 
2C9 250 MFC *250 Tienilic acid 
(0.1 and 1μM) 
Sulfaphenazole 
(0.1 and 1μM) 
2D6 300 MAMC 60 Paroxetine 
 (0.1 and 1μM) 
Quinidine 
 (0.01 and 0.1μM) 
3A4 100 BFC *13 Troleandomycin 
(0.1 and 1μM) 
Ketoconazole 
(0.01 and 0.1μM) 
a the enzyme amount in the preincubation mix (10x required in second incubation) 
b substrate concentration at 4x the Km (to reduce the effect of reversible inhibition) 




Compounds with a normalized ratio below 0.7 were classified as TDI, those 
with normalized ratio above 0.9 as non-TDI, and those with a normalized ratio 
lying between 0.7 and 0.9 fell in the grey zone in which their status cannot be 
clearly defined. 
 
3.2.1.1.6 Validation of the TDI assay  
The two stage time-time dependent assay was validated using known and 
non-time dependent inhibitors from literature. The compounds chosen for the 
validation are summarised in Table 3.5. The assay and detection of the 
formation of the fluorescent substrate was as described above. Validation 
was done for CYPs 1A2, 2C9, 2C19 and 3A4. 
 
Table 3.5: Validation compounds for the TDI assay 
CYP Strong TDI  Weak TDI Non-TDI 
    






2C9 Tienilic acid, hydrastine 
and fluoxetine  
Methimazole, silibinin, 
cimetidine, fluvoxamine  
Sulfaphenazole  
2C19  Ticlopidine, cimetidine  Methimazole Omeprazole 
3A4 Troleandomycin, 
erythromycin  
- Ketoconazole  
 
3.2.1.2 CYP2D6 inhibition screen assays 
The assay was performed because signal to noise ratio for the fluorescence-
based plate assay was very low making analysis difficult. The CYP2D6 
mediated bufuralol hydroxylation to 1’hydroxy bufuralol was used as a marker 





Figure 3.2: CYP2D6 mediated bufuralol hydroxylation. 
 
3.2.1.2.1 Inhibition assay 
The assay was set up in a similar manner to the fluorescent assay except the 
substrate used was bufuralol at 5μM final concentration. The reaction was 
initiated with a 10μl solution of 20mM NADPH. Termination of the reaction 
was by one volume of ice-cold ACN. The solution was left at -200C for 1hour 
to precipitate the protein. This was followed by centrifugation at 13000rpm for 
15min at 40C. The supernatant was collected and analyzed by LC/MS. 
 
3.2.1.2.2 TDI assay 
In the inactivation assay CYP2D6 (60pmol/200µl) was incubated with 
quinidine (0.01 and 0.1µM) in 0.1M phosphate buffer pH7.4. The incubation 
mixture was warmed at 370C for 10min. This was followed by addition of 10µl 
1mM NADPH to initiate the reaction. Further incubation was performed for 
15min. An aliquot was transferred to prewarmed plate at 370C containing 
substrate (25µM bufuralol) in 0.1M phosphate buffer pH 7.4. A fresh solution 
of 10µl 20mM NADPH was added to the mix to initiate the reaction. Further 
incubation for 15min was done and the reaction was terminated with ice-cold 
ACN. The solution was left at 200C for 1hour to precipitate the protein. This 
was followed by centrifugation at 13000rpm for 15min at 40C. The 




3.2.1.3 Bioanalysis of 1’hydroxybufuralol 
The metabolite (1’hydroxybufuralol) was analysed by LC/MS. Prior to analysis 
the compound was optimised on LC-MS. A 1µM solution was prepared from 
the 1’hydroxybufuralol standard and used for the subsequent optimisations. 
MS conditions were optimised with respect to the cone voltage and the 
collision energy. The compound was then analysed using the optimised 
conditions. Bioanalysis was performed on a Waters Quattro (Waters, Milford, 
MA, USA) with ESI interface. The chromatographic system was an Agilent 
1100 HPLC system, using an C18 column (2.1 x 30 mm, 1.8μm). The mobile 
phases consisted of water and acetonitrile acidified with 0.1% formic acid at 
50:50. The flow rate was 0.2ml/min. 1’hydroxy-bufuralol was analysed in +ESI 
mode where the capillary voltage was 3.5kV, Collision energy was 16 and the 
cone voltage 25V. 
 
3.2.1.4 Determination of metabolic clearance  
The intrinsic clearance (CLint) was determined in human liver microsomes and 
cryopreserved hepatocytes. Bioanalysis was by HPLC and LC/MS/MS. 
Extrapolations were done from the determined in vitro clearance to in vivo 
using scaling factors to determine the hepatic clearance (CLH) (Barter et al., 
2007; Wilson et al., 2003). 
 
3.2.1.4.1 Metabolic stability in HLM assay for analysis by HPLC 
The assay was set up using four controls: midazolam, verapamil, diltiazem 
and tolbutamide as the rapid, fast, intermediate and slow clearance controls 




(2mg/ml) and 0.1M phosphate buffer pH 7.4. The reaction was initiated by 
addition of 1mM NADPH. At varying points (0, 5, 10,15, 20 and 30min) an 
aliquot was taken and the reaction stopped by addition of ice cold ACN. 
Extraction was done twice by a double volume of ACN followed by 
centrifugation at 10000g for 15 minutes at 40C. The supernatant was collected 
and dried under a gentle stream of nitrogen. Residue was reconstituted in 
mobile phase and analysed by HPLC. Bioanalysis was performed on an 
Agilent 1100 HPLC system using a Zorbax C18 (4.6 x 150mm ID, 5μm) for 
chromatographic separation. The mobile phase consisted of A. 10mm 
ammonium acetate acidified with 0.1% TFA and B. ACN. An isocratic run was 
the performed for 15min at a flow rate of 1ml/min. The injection volume was 
0.1ml. Detection was by DAD at 214, 254, 230, 286 and 250nm. The 
disappearance of compound from media was used as a measure of the rate 
of metabolism.  
 
3.2.1.4.2 Metabolic stability in HLM assay for analysis by LC/MS  
The assay was set up using four controls: midazolam, verapamil, diltiazem 
and tolbutamide as the rapid, fast, intermediate and slow clearance 
controls(Obach, 1999).The test compounds (1µM) were mixed with HLM 
(1 mg/ml, BD Bioscience, San José, CA, USA) and phosphate buffer (0.1 M, 
pH 7.4). After 10 min preincubation at 37C, the reaction was initiated with the 
addition of NADPH (1mM). At 0, 5, 15 and 45 min aliquots were taken and 
quenched 1:1 with a solution of 100% acetonitrile and 0.8% formic acid. The 
samples were centrifuged at 2737g for 20 min at 4C and the supernatant 




Waters TQD (Waters, Milford, MA, USA) with ESI interface. The 
chromatographic system was a Waters Acquity UPLC system (Waters, 
Milford, MA, USA) using an Acquity UPLC HSS T3 C18 column (2.1 x 30 mm, 
1.8μm). The mobile phases consisted of water and acetonitrile acidified with 
0.2% formic acid and the gradient was 4-95% acetonitrile in 1.6 min at a flow 
rate of 1 ml/min. The compounds were analysed in ES+ mode using 
conditions in Table 3.6. 
 
3.2.1.4.3 Metabolic stability assay in hepatocytes for LC/MS analysis  
The assay was performed using generic incubation conditions with respect to 
substrate concentration (1μM), incubation time (0-60min) and enzyme 
concentration (1 x 106 cells/ml) (Masimirembwa et al., 2003; Masimirembwa 
et al., 2001; Thompson, 2000). The substrate concentration was assumed to 
be much lower than the likely Km of most compounds. Bioanalytical analysis 
was performed using generic ultra pressure liquid chromatography (UPLC) 
MS/MS method with a limit of quantitation of at least 0.2μM was used. 
 
The incubations were performed in duplicate in 96-well plates at 370C and 5% 
CO2/95% O2 in a Cytomat 2C15 incubator. Test compounds (1μM) were 
mixed with hepatocytes at a concentration of 1million cells/ml (In Vitro 
Technologies, Baltimore, MD, USA) and HEPES (25 mM)/l-glutamine (2mM) 
supplemented William’s E medium (Sigma-Aldrich, St Louis, MO, USA). After 
0, 15, 30, 45 and 60 min, the incubations were quenched with three volumes 
of stop solution containing acetonitrile and 0.8% formic acid. In order to 




before centrifuged at 40C at 3220g for 20 min. Prior analysis the supernatant was diluted 1:1 in water. 
 
Table 3.6: Tuning parameters and MRM transitions for metabolic stability control compounds 
Compound  Ionization Mode MRM transitions Capillary Voltage (kV) Cone Voltage (CV) Collision Energy (CE) 
Midazolam +ESI 326.35 > 291.35 3.5 35 25 
Verapamil +ESI 455.71 > 165.23 3.5 30 25 
Diltiazem +ESI 415.52 > 178.09 3.5 35 18 






3.2.1.4.4 Data analysis  
The disappearance of compound from media was used as a measure of the 
metabolism of the compound. The response was log transformed and plotted 
against the incubation time. The slope of the resulting line (k) was used to 
determine the in vitro half-life (T1/2) using the relationship: 
Equation 3.3 
  
   
    
 
 
The in vitro apparent intrinsic clearance (CLint) was then calculated using the 
following relationship for HLM 
 
Equation 3.4 
      
                                
                           
 
and the following relationship in hepatocytes  
 
Equation 3.5 
      
                                
                                   
        
 
 
The CLint was scaled to the whole liver using various scaling factors. The body 
weight of an average man was taken to be 70 kg, liver weight as 1680g and 
number of hepatocytes in 1g liver to be 117.5 million cells or microsomes 
(38.2 mg) per gram live(Barter et al., 2007; Wilson et al., 2003). Using these 
factors the apparent clearance (CLint, app) was calculated using:  
 
Equation 3.6 
          
                         





where CLint = in vitro clearance and HPGL = hepatocytes per gram liver. In 
the case of HLM the relationship is as follows:  
 
Equation 3.7 
          
                         
          
 
To estimate the hepatic clearance (CLH) due to metabolism, the well-stirred 
model was used. The well-stirred model was chosen against other models 
such as the parallel tube and the dispersion models because of its simplicity 
and the fact that very small differences in predicted values by the three 
models have been observed (Houston and Carlile, 1997). The hepatic 
clearance was expressed as: 
Equation 3.8 
    
       
       
 
where QH is the hepatic blood flow and the CLint is clearance scaled to the 
whole liver, and reflects the actual metabolic capacity of the enzyme system. 
The fraction bound in hepatocytes and in blood was not taken into account. 
 
3.2.1.5 Metabolite identification  
The assay was performed using the same conditions, as the intrinsic 
clearance in hepatocytes except the substrate concentration was 4μM and 
incubation time was120 min. The metabolite profile was obtained from MSE 
data generated on a Waters Synapt HDMS mass spectrometer (Waters, 
Milford, MA, USA) operating under positive electrospray ionization (ESI) 
conditions in V-mode. A generic method with two scan functions was used as 




energy (CE) in function 1 was 6V and in function 2 an energy ramp of 15–45V 
was used, the transfer cell CE was 12V. Dynamic range enhancement (DRE) 
were utilized and data was collected in centroid. Leucine-Enkephaline was 
used as a lock mass (m/z 556.2771) for internal calibration at a concentration 
of 250 pmol/μl and a flow rate of 40 μl/min. 
 
Chromatographic separation of metabolites was performed on a Waters 
Acquity UPLC system (Waters, Milford, MA, USA) using an Acquity UPLC 
BEH C18 column (2.1 x 50 mm, 1.7μm). The mobile phases consisted of A. 
H2O/0.1% formic acid and B: acetonitrile and the gradient was as 5–65% B in 
6 min at a flow rate of 750 μl/min. The Metabolynx™ software (Waters, 





3.2.2 PART II: Identification of ADME/PK liabilities of 3,4-HPO-4-AMINO-
7-chloroquinolinyl hybrid compounds with antimalarial activity 
 
3.2.2.1 Structures of the 3,4-HPO-4-amino-7-chloroquinolinyl hybrids 
The structures of the synthesized 3,4-HPO-4-amino-7-chloroquinolinyl hybrids 
are summarized in Table 3.7. 
 
Table 3.7:  Structures of 3,4-HPO-4-amino-7-chloroquinolinyl hybrids 
with antimalarial activity 
 
 
Compound  R2 R3 n 
3-Benzylated analogues    
3.1a Me Bn 1 
3.2a Et Bn 1 
3.1b Me Bn 2 
3.2b Et Bn 2 
3.1c Me Bn 3 
3.2c Et Bn 3 
3.1d Me Bn 5 
3.2d Et Bn 5 
3.2d.2HCl Et Bn 5 
    
Deprotected analogues    
3.1e Me H 1 
3.2e Et H 1 
3.1f Me H 2 
3.2f Et H 2 
3.1g Me H 3 
3.2g Et H 3 
3.1h Me H 5 
3.2h Et H 5 
    
3-Methoxy analogues    
3.3a Me Me 3 
3.3b Et Me 3 
3.4a Me Me 5 




3.2.2.2 Biological assays 
3.2.2.2.1 Antiplasmodial screening in vitro 
Efficacy screening was done using the sensitive (D10 and 3D7) and resistant 
(W2 and K1) P. falciparum strains. The strains were maintained in continuous 
culture according to the method of Trager and Jensen (Trager and Jensen, 
1976). In brief the cultures were maintained in 1640 RPMI media 
supplemented with 25mM HEPES, 0.23% sodium bicarbonate and albumax II. 
Synchronization was achieved by sorbitol treatment to leave only the ring 
stage parasitized cells.  
 
Efficacy screening was done with an initial ring stage parasitemia of 0.8-1.5% 
at 3% hematocrit. Parasite viability was determined using the parasite lactate 
dehydrogenase assay according to published methods with chloroquine as 
the reference drug. The IC50 was determined using non-linear regression 
model in GraphPad (GraphPad Software, San Diego, CA). The phiβ-
Haematin inhibition assay was done as described by Ncozaki and Egan 
(Ncokazi and Egan, 2005). 
 
3.2.2.2.2 Cytotoxicity studies in the KB cell line  
The KB cell line, which is derived from human carcinoma of the nasopharynx, 
was used. The cultures were maintained as monolayers in RPMI 1640 
supplemented with 10% HIF at 370C under an atmosphere of 5%CO2/ 95% air 
mixture. The assay was conducted under the same conditions. On day 1 the 
cells were harvested, counted, washed in serum free media (2000rpm for 10 




104 ml-1. A 100µl was added to wells in a 96 well plate and incubated 
overnight to allow cells to adhere. A 10-fold serial dilution of the test 
compounds starting at 600µg/ml in media was performed across the plate on 
day 2. Plate was incubated for 72hrs and on day 5 microscopic assessments 
were made. Alamar blue was then added to each well and the plate incubated 
for 4hrs after which fluorescence was measure at Ex/Em 530/580. IC50 values 
were then calculated using non-linear regression analysis. 
 
3.2.2.3 Physicochemical screens  
3.2.2.3.1 Rule based predictions  
The likelihood of the compounds to be drugs and to have good oral absorption 
was predicted using Lipinski’s rule of 5 (Lipinski et al., 2001) and Veber rules 
(Veber et al., 2002). Potential of the newly synthesized compounds to be lead 
like was predicted following a set of rules by Oprea ((Hann and Oprea, 2004; 
Oprea, 2002a; Oprea, 2002b; Oprea et al., 2001). The potential for the drugs 
to cross the BBB and act CNS drugs was predicted using rules suggested by 
Pardridge (Pardridge, 1995) and multivariate analysis in VolSurf (Crivori et al., 
2000). The various physicochemical properties (clogP, hydrogen bond donors 
and acceptors) were calculated using the chemaxon property calculator in 
Marvin Sketch (www.chemaxon.com). 
 
3.2.2.3.2 Purity determination   
Compounds were tested for purity using reverse phase HPLC method 
adapted from literature (de Aquino Ribeiro et al., 2007; Patel et al., 2004; Xie 




USA) consisting of a G1311A Quaternary Pumps, a G1322A degasser and 
G1315A diode array detector was used. Chromatographic separation was 
achieved on a Zorbax (C18, 4.6 x 150mm I.D, particle size, 5µm). The mobile 
phase consisted of 5% ACN in 0.1% trifluoroacetic acid (A) and 95% ACN in 
trifluoroacetic acid (B). The conditions for gradient solvent elution were 10-
25% B in 0-0.5min, 25-90% B in 0.5-5.5min, 90% B in 7-10min and 10% B in 
10-15min at a flow rate of 1ml/min. Detection was at 214nm at room 
temperature. Injection volume was 100µl. Run time was 15min at ambient 
temperature. Testosterone was run as a control compound. The purity was 
determined using the relationship: 
Equation 3.9 
        
                      
                                 
 
The total area of detected peaks excluded the solvent front  
 
3.2.2.3.3 Lipophilicity determination  
Lipophilicity was determined using reverse phase method, which utilizes the 
capacity factor as a predictor for lipophilicity. The same HPLC system used 
for determining purity above was used in this assay. Samples were dissolved 
in 50% ACN. Chromatographic separation was achieved on a Zorbax (C18, 
4.6 x 150mm I.D, particle size, 5µm).The mobile phase consisted of 5% ACN 
in 10mM ammonium acetate (A) and 95% ACN in 10mM ammonium acetate 
(B). The conditions for gradient solvent elution were 0% B in 0-2 min, 0-100% 
B in 2-17min, 100% B in 17-20min and 0% B in 20-22min at a flow rate of 
1ml/min. Detection was at 214nm at room temperature. Injection volume was 




compounds with accurately determined k´ values and known literature LogD7.4 
ranging from -0.15 and 5.22 were used for calibration. 
 
3.2.2.3.4 Determination of aqueous solubility  
Aqueous solubility was determined using the turbidimetric method. Stock 
concentrations were prepared in DMSO and diluted in buffer (0.01M 
phosphate buffered saline pH 7.4) prior to analysis. This was followed by a 
2hr incubation at 370C. Precipitate formation was followed at 595nm. To avoid 
false positives, compounds were diluted in solvent (100%) DMSO treated in 
the same way as the test compounds. Compounds were assayed at 
concentrations ranging between 0 and 100μM. Paracetamol and niclosamide 
were used as the soluble and non-soluble controls respectively. In silico 
predictions were done in Volsurf (Cruciani et al., 2000) and AlogPs 
(www.vcclab.org). 
 
3.2.2.4 In vitro ADME experiments  
3.2.2.4.1 Determination of CLint and metabolite identification  
The CLint was determined in HLM and hepatocytes. The assay was performed 
as described for the relevant metabolic stability assays in section 3.2.1.4. 
Data analysis was performed as described in the same section. LC-MS 
conditions for the hybrids were as summarized in Table 3.8. Midazolam, 
verapamil, diltiazem and tolbutamide were used as the rapid, fast, 
intermediate and slow control compounds. Metabolites were identified as 





Table 3.8: LC/MS parameters for 3,4-HPO-4-amino-7-chloroquinolinyl 






Voltage (kV) m/z CV 
**Mobile phase 
(A:B) 
3.1a +ESI 3.5 420.14 30 50:50 
3.2a +ESI 3.5 434.16 30 60:40 
3.1b +ESI 3.5 434.16 30 60:40 
3.2b +ESI 3.5 478.17 30 60:40 
3.1c +ESI 3.5 448.17 35 60:40 
3.2c +ESI 3.5 462.19 35 60:40 
3.1d +ESI 3.5 476.20 35 60:40 
3.2d +ESI 3.5 414.19 35 60:40 
3.1h +ESI 3.5 293.10 28 50:50 
3.4a +ESI 3.5 372.63 30 50:50 
3.4b +ESI 3.5 414.30 30 50:50 
* CV – Cone Voltage  
** A - ACN acidified with 0.1% formic acid and B - water acidified with 0.1% ACN  
 
3.2.2.4.2 Inhibition screen assay and IC50 determination  
Inhibition screen assay was performed in recombinant CYPs 1A2, 2C9, 2C19 
and 3A4 in 96 well black microtiter plates (Corning Incorporated, Corning, NY) 
using the inhibition assay previously described (3.2.1.1.2). For the compounds 
that significantly inhibited (greater than 20% inhibition), the IC50 was 
determined using the reversible IC50 assay (3.2.1.1.3). All test compounds 
were tested at 3 and 20μM for the inhibition screen assay. For the IC50 
determination the ranges used for all the test compounds was 0-50μM. For 
CYP2D6 the bufuralol to hydroxybufuralol marker reaction was used to follow 
enzyme activity. The inhibition and the IC50 assays were performed as 





3.2.2.4.3 TDI fluorescence-based screen assay 
The assay was only performed in CYP3A4. The experiment was conducted 
using the two-stage TDI screen assay as earlier described. Ketoconazole and 
troleandomycin were used as negative and positive controls respectively. 
Conditions for the assay were as in Table 3.4. All the test compounds were 
assayed at 1 and 20μM. Data was analyzed as described for TDI above. 
 
3.2.2.4.4 Mechanism of inhibition  
The assay was an adaptation of the reversible inhibition assay. CYP3A4 was 
chosen for this study as it showed the greatest susceptibility to inhibition. The 
difference was in the variation of the inhibitor concentration as well as the 
substrate concentrations. The substrate concentration was at 0.25, 0.5, 1, 2, 
5, and 10x the Km value, and the inhibitor concentration at 0, 0.5, 1 and 2x 
the IC50 value. The activity at varying substrate concentration was plotted 
against the activity expressed relative to the control. Plots were made for each 
inhibitor concentration. The data was fitted using non-linear regression 
analysis in Sigma Plot software (SYSTAT Software Inc., Richmond, CA) into 
each of the equation for the different modes of inhibition i.e. competitive, non-
competitive, uncompetitive and mixed inhibition models. The model with the 






3.2.3 PART III: Identification of ADME/PK liabilities in artemisinin-
chloroquinoline hybrids 
 
3.2.3.1 Structures of the artemisinin-chloroquinoline hybrids 
The artemisinin-chloroquinoline hybrids had already been shown to 
demonstrate potent antiplasmodial activity in both CSR and CQS strains of P. 
falciparum (Feng et al., 2011).Two compounds, 3.9 and 3.10 were chosen for 
this study together with intermediates and building blocks arising from their 
synthesis. Artemisinin, dihydroartemisinin and chloroquine were used as 
controls. The structures are shown in Fig 3.3.  Activity for the compounds is 
summarized in Table 3.9. 
 
 
Figure 3.3: Structure of artemisinin-chloroquinoline hybrids, their 





Table 3.9: In vitro efficacy screening of artemisinin-chloroquinoline hybrids and their intermediates 
Adapted from Feng (Feng et al., 2011) 
 
Compound  n D10 IC50 (μM) K1 IC50 (μM) 
aRI HeLa IC50 (μM) 
cTI dβHIA IC50 (equiv) 
Artemisinin - 0.023 ± 0.0014 0.014 ± 0.0037 0.61 bND - 0.66 ± 0.1 
Dihydroartemisinin - 0.004 0.003 0.75 bND - bND 
Chloroquine  - 0.020 ± 0.0033 0.219 ± 0.0023 11 8.54 39 1.91 ± 0.3 
3.2 - 0.006 0.006 1 bND - bND 
3.3 - 1.37 2.56 1.87 bND - bND 
3.4 - 2.15 2.74 1.27 bND - bND 
3.5 1 0.026 ± 0.014 0.023 ± 0.0014 0.88 0.286 12 0.045 ± 0.04 
3.6 3 0.035 ± 0.014 0.021 ± 0.0014 0.60 0.169 8 0.031 ± 0.01 




3.2.3.2 Metabolic stability in human liver microsomes and hepatocytes  
The assay was performed in both human liver microsomes and hepatocytes. 
Assay conditions, bioanalysis and data analysis were as described for 
metabolic stability assays in previous sections. The LS/MS conditions used for 
the artemisinin-chloroquinoline hybrids, artemisinin, chloroquine and 
dihydroartemisinin are summarized in Table 3.10. Metabolites were identified 
as described earlier. 
 
3.2.3.3 Reaction phenotyping  
All incubations were conducted in duplicate in a final volume of 200μl. 
Screening was done using recombinant CYPs 1A1, 1A2, 1B1, 2B6, 2C8, 2C9, 
2C19, 2D6,2E1, 3A5, 3A4 and human liver microsomes (HLM).Compounds 
were incubated with appropriate concentrations of recombinant enzyme or 
HLM and potassium phosphate buffer pH 7.4. All the CYPs were at 10 pmol 
per 200μl and HLM were at 1mg/ml. Reactions were initiated by addition of 
10μl 1mM NADPH. The mixture was incubated for 30 min at 370C. All 
reactions were terminated by addition of ice-cold acetonitrile. Another sample 
where the reaction was terminated at 0 min was used as a control. The 
samples were vortexed and centrifuged at 13400 rpm at 40C. The supernatant 
was then collected for LC-MS analysis. Metabolism was signified by loss of 
compound from the reaction media. The loss of the compound from media 
was determined using the relationship: 
Equation 3.10 
                    
              
             




Table 3.10: Tuning parameters and chromatographic conditions for the artemisinin-chloroquinoline hybrid drugs and 
control compounds 






Voltage (V) Mobile phase  
      
Artemisinin *300.05 +ESI  3.5 15 10mM NH4COOH: ACN acidified with 0.1% 
formic acid  (20:80)  
DHA  *285 +ESI  3.5 15 10mM NH4COOH: ACN acidified with 0.1% 
formic acid  (20:80)  
Chloroquine  320.71 +ESI  3.5 30 10mM NH4COOH: ACN acidified with 0.1% 
formic acid  (35:65)  
3.9 761.58 +ESI  3.5 30 Water acidified with formic acid: ACN 
acidified with 0.1% formic acid  (20:80)  
3.10 790.75 +ESI  3.5 35 Water acidified with formic acid: ACN 
acidified with 0.1% formic acid  (20:80)  
* NH4 adducts 
 
3.2.3.4 Inhibition assays  
The compounds were screened for inhibition using the previously described assay (section 3.2.1.1.2 and 3.2.1.1.3). IC50 




3.2.4 PART IV: Molecular Mechanism of CYP1A2 inhibition by TBZ 
 
3.2.4.1 Screening antiparasitic drugs for TDI 
Antiparasitic drugs had been previously screened for inhibition against the 
five major CYP isoforms (CYP1A2, 2C19, 2C9, 2D6 and 3A4) from our 
previous studies (Bapiro et al., 2005). To continue the work the antiparasitic 
drugs were screened for TDI as some of the compounds had already shown 
potent inhibition against some of the CYPs. Twenty-one compounds were 
screened using the 2-stage TDI assay. Screens were done for CYP1A2, 
CYP2C9 and CYP3A4. The structures of the screened compounds are 
shown in Fig 3.4. Thiabendazole (TBZ) was chosen as the compound do 
further studies on. Its metabolite 5-hydroxy-TBZ (5OH-TBZ) was also 
screened for TDI. All the subsequent assays were performed on CYP1A2, the 
enzyme TBZ significantly inhibited.  
 
3.2.4.2 IC50 determination 
The assay was conducted in a similar way to the TDI screen assay except 
that the concentration of inhibitor was varied. TBZ and its metabolite 5OH-
TBZ were preincubated at varying concentrations ranging from 0 - 40μM with 
25pmol/ml of recombinant CYP1A2 in 0.1M KPO4 pH 7.4. The assay was 
performed in the presence and absence of NADPH. The activity assay was 
then performed with high CEC concentration (12μM) to minimise the 
contribution of reversible inhibition. Reaction termination and measurement of 
CEC was conducted in the same way as the TDI screen. The data was 
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3.2.4.3 Kinetics of CYP1A2 inhibition by TBZ and 5OH-TBZ 
The two-step incubation method was used to characterise the time- and 
concentration-dependent inhibition of TBZ. In the inactivation assay varying 
concentrations of TBZ (0-20μM) and 5OH-TBZ (0 -200μM) were incubated 
with CYP1A2 (25pmol/ml) in 0.1M KPO4 pH 7.4. The reaction was initiated by 
addition of 10μl 20mM NADPH. At selected preincubation times an aliquot of 
the preincubation mix (1:10 dilution) was taken and added to the activity 
assay plate. Incubation was done for 15min at 370C. The reaction was 
terminated by addition of ice-cold 80% ACN in 5mM Tris solution. The activity 
was followed by measuring the formation of CEC. 
 
3.2.4.4 Mechanism of TDI 
Various experiments were conducted to determine if TBZ and its metabolite 
were MBI of CYP1A2. The assays conducted were the IC50 shift, electrophile 
trapping by glutathione (GSH), oxidation by potassium ferricyanide (K3FeCN6) 
and dialysis.  
 
3.2.4.4.1 IC50 shift 
Two assays were conducted to determine the IC50 shift. The first assay was 
the competitive inhibition assay where the inactivation step was omitted. TBZ 
and 5OH-TBZ were incubated with substrate at Km concentration (CEC at 
3μM) in 0.1M KPO4 pH 7.4. In the second experiment the IC50 was 
determined using the TDI IC50 assay, which was conducted in a similar way 




of 10μl 20mM NAPDH followed by 15min incubation. Analysis of fluorescent 
metabolite was as described for the fluorescent-based plate assays. 
 
 
3.2.4.4.2 Effect of glutathione on the inactivation of CYP1A2 by TBZ 
The time-dependent inactivation of CYP1A2 by TBZ was investigated in the 
presence of 5mM GSH. The GSH was added together with TBZ (1 and 20μM) 
in the inactivation assay both in the presence and absence of NADPH. The 
activity assay was then performed and the enzyme activity followed by 
measuring the formation of CHC. Control activities were determined in the 
absence of TBZ. 
 
3.2.4.4.3 Effect of K3FeCN6 on the inactivation of CYP1A2 by TBZ  
The assay was performed to determine whether the catalytic function of 
recombinant CYP1A2 could be restored after oxidation by K3FeCN6 (2mM in 
0.1M KPO4 pH 7.4). The combined effect of K3FeCN6 and GSH was also 
investigated and in this case GSH was added in the inactivation assay. The 
experiment was divided into three parts: the inactivation assay, restoration of 
activity assay and the activity assay. An aliquot (50μl) was taken from the 
inactivation assay after 10min and added to the activity restoration assay 
plate, which had 50μl K3FeCN6 (0.1M KPO4 pH 7.4 for the controls). After a 
further 10min incubation, another 10μl aliquot was taken and added to the 
activity assay plate. The activity plate consisted of fresh 0.1M KPO4 pH 7.4, 
1mM NAPDH and 12μM CEC. The reaction was then terminated by addition 
of an ice-cold 80% ACN in 5mM Tris solution. The activity was followed by 




3.2.4.4.4 Effect of dialysis  
The 2-step assay was adapted to determine the effect of dialysis. In the 
inactivation assay 25pmol/ml CYP1A2 was incubated with NADPH and either 
1μM furafylline, 20μM fluvoxamine, 20μ TBZ, 20μM 5OH-TBZ or 0.2 DMSO 
(vehicle control) 0.1M KPO4 pH 7.4. The incubation mixture was transferred to 
Slide-A-Lyser mini-dialysis units with molecular weight cut off of 10 000 
(Pierce Chemicals, Rockford, IL). Dialysis was performed at 40C for 4hrs in 
50mM KPO4 pH 7.4. The dialysis buffer was changed every hour. Parallel 
analysis was performed with incubation mixes that were stored at 40C for the 
duration of the dialysis experiment. Samples were then analysed for activity 
as above.  
 
3.2.4.5 In silico experiments  
3.2.4.5.1 Substructure search and site of metabolism prediction  
A TDI substructure search was performed before the site of metabolism 
prediction to identify chemical groups in TBZ that were likely to cause TDI. An 
in house script (Susanne Winiwater, unpublished) was used in the 
identification. TBZ was then submitted to Metasite version 2.7.5 (Molecular 
discoveries Ltd, Pinner, Middlesex, UK, www.moldiscovery.com) to predict the 
site(s) of metabolism. Metasite is fully automated and it considers structural 
complementarity between the enzyme active site and the ligand and comes 
up with the optimal orientation. Both the protein active site and the ligand are 
presented by selected distance–based descriptors using molecular interaction 
fields computed in GRID. The site of metabolism is described by a probability 




parameters were used and the top three averaged rankings with the reactivity 
component enabled were considered. Calculations were performed in a Linux 
(RedHat 8.0) operating system on a 1.8-GHz Pentium IV computer. 
 
3.2.4.5.2 Docking studies  
A crystal structure of CYP1A2 in complex with α-naphthoflavone (PDB2HI4) 
with a resolution of 1.95Å was used. The enzyme is a wild type except that 
the terminal transmembrane helical domain was removed to increase the 
solubility for crystallisation. The co-crystallised α-naphthoflavone was 
removed before docking. The structure of TBZ was drawn in SYBYL and 
converted to a 3D structure in CORINA. Two docking software were used 
namely GOLD and GLUE. 
 
3.2.4.5.2.1 Docking experiments in GLUE  
TBZ was docked into the active site of CYP1A2 with the crystallographic 
water molecules. The program maps the active site using hydrophobic, 
hydrogen bond donor/acceptor and electrostatic probes. Prior to the docking 
experiment the ligand is removed from the active site of the crystal structure. 
A dummy molecule incapable of accepting hydrogen bonds was added above 
the heme iron to inactivate the interactions between docked compound and 
the heme. The PDB file was modified in GREATER, which converted the PDB 
file format to the input required for the docking procedure (kout file). Default 





3.2.4.5.2.2 Docking experiments in GLUE  
TBZ was built and energy minimized in vacuo using the conjugated gradient 
method, which employs MMF94s force field and charges. The genetic 
algorithm implemented in GOLD was then used to optimise the orientation of 
the ligand into the active site. During the optimisation, the ligand was 
considered flexible and the enzyme active site rigid. Ten dockings were 
allowed with an early termination if the root mean square distances were 
within 1.5Å for the top three solutions. 
 
3.2.4.5.3 Prediction of drug-drug interactions  
PK simulations were performed using the Simcyp population based ADME 
simulator version 8.1 to simulate the in vivo effects of TBZ on the elimination 
of itself and other CYP1A2 substrates: caffeine and theophylline. In general 
the simulation process involved uploading enzyme kinetic data for TBZ. The 
pharmacokinetics data for CYP1A2 substrate drugs were already uploaded in 
the Symcyp software. In vivo co-administration of TBZ with CYP1A2 was only 
available for caffeine and theophylline. The modelling that was performed 
mimicked published experimental methodology (e.g. dose, interval, duration 
and sample size) when TBZ was administered alone (Tocco et al., 1966a) or 
in combination with theophylline (Schneider et al., 1990) and caffeine (Bapiro 
et al., 2005). A fasted virtual Caucasian population was used in all the 
simulations. Clinical trial sample sizes of 10 were used in all the evaluations. 
The oral route of drug administration was considered in this scenario for all 
the DDIs tested, and an additional theophylline-TBZ interaction was also 





3.2.4.5.3.1 Competitive inhibition 
In these simulations, TBZ was the competitive inhibitor, with a KI value of 
1.54μM as determined in our previous studies (Bapiro et al., 2001). The 
affected drugs were caffeine and theophylline given at doses used clinically. A 
single oral dose pharmacokinetic trial design was considered in all simulations 
that involved competitive CYP1A2 inhibition. 
 
3.2.4.5.3.2 MBI 
Clinical drug doses, frequency and duration of 3 days (TBZ is dosed twice 
daily for 3 days), were uploaded at trial design stage. The effect of TBZ on its 
own elimination was also tested after 3 days of administration. In addition, 
TBZ-theophylline interactions were simulated following published data 





3.2.5 PART V: Drug-herb interaction by evaluating the ADMET/PK of 
the active ingredient natural product, Frutinone A 
 
3.2.5.1 In vitro experiments 
3.2.5.1.1 CLint, metabolite identification and reaction phenotyping  
The assays were performed using generic incubation conditions as described 
in the previous sections. For metabolic stability assay Frutinone A was run at 
a cone voltage of 30 in positive electrospray mode. All the other conditions 
were as described in the previous sections. 
 
3.2.5.1.2 Inhibition and TDI screens 
All incubations were conducted in duplicate in a final volume of 200μl. The 
inhibition, TDI and IC50 and mechanism of inhibition assays were performed 
as previously described. For the IC50 screen Frutinone concentrations were as 
follows: 0, 0.098, 0.195, 0.391, 0.781, 1.563, 3.125, 6.25, 12.5, 25, 50 and 
100μM. Inhibition and TDI screens were performed in all the 5 major CYPs. 
The IC50 screen was only performed in CYP1A2. 
 
3.2.5.1.3 Mechanism of inhibition of CYP1A2 by Frutinone A  
The experiment was performed as previously described (Part I). Differential 
inhibition of CYP1A2 by Frutinone A was investigated in this assay. Two 
substrates were used: CEC and 7-ethoxyresorufin (ER). This was done 
because some CYP1A2 inhibitors have been shown to exhibit different modes 
of inhibition based substrates used(Shimada et al., 2010). 
 
3.2.5.2 In silico experiments 




core duo computer. Docking experiments were performed using Autodock 
Vina (Trott and Olson, 2010) and FlexX (www.biosolveit.de). The crystal 
structure of CYP1A2 in complex with α-naphthoflavone (PDB2HI4) with a 
resolution of 1.95 Å was used (Sansen et al., 2007). 
 
3.2.5.2.1 Autodock Vina 
Ligand files were prepared using Autodock tools 
(http://autodock.scripps.edu/resources/adt). Polar hydrogens were added to 
the protein and Gasteiger charges were assigned and non-polar hydrogens 
merged automatically. Charge of the heme, Fe, was corrected manually to 3+. 
Automated docking was done using Autodock Vina. A grid box centered at 
2.61, 18.23 and 20.35 defined the binding pocket. The dimensions of the grid 
were 50 Å x 50Å x 50Å and were separated by 0.375 Å. In docking all the 
rotatable bonds were allowed to rotate freely. After docking the results were 
clustered using a mean root square deviation cut-off of 2.0Å. Clusters were 
ranked according to the binding energies of their representative structure 
within each cluster. Docking results were analysed using the PyMOL 
molecular graphics system (DeLano, 2002). 
 
3.2.5.2.2 FlexX  
The active site was defined by the coordinates of α -naphthoflavone in the 
crystal structure (PDB2H14). Atoms within 6.5 Å of the complexed structures 
were included as part of the active site. Water molecules and metal atoms 
were kept in the protein description. Ligands were submitted to the program 




delocalised systems of the ligands. Energy minimizations of ring systems 
were done by CORINA_F (Molecular Networks GmbH, Erlangen, Germany 







4.1 PART I: Setting up of the ADME/PK platform 
4.1.1 Optimization of conditions for fluorescence-based plate assays 
Reaction conditions were optimized with respect to the substrate 
concentration, incubation time and the enzyme concentration. A summary of 
the conditions chosen is shown in Table 4.1. The signal to noise ration were 
all above 4 except for CYP2D6.The cut-off that is required to ensure there is 
no interference from other components of the reaction is 2.5. The CYP2D6 
was therefore set for LC/MS analysis. The linearity range for each of the 
optimised reaction in shown in brackets. 
 
Table 4.1: Summary of the optimised reaction conditions for the 
fluorescent-based plate assays 
CYP Enzyme (pmol/ml) Substrate Km (µM) Time (min) S/N 
1A2 2.5 [0-50] CEC 3.56 15 [0-20] 14.42 
2C19 10 [0-30] MFC 86.31 15 [0-40] 8.15 
2C9 25 [1-40] MFC 52.59 15 [0-40] 7.33 
2D6 30 [0-50] MAMC 14.7 15 [0-30] 3.5 
3A4 10 [0-40] BFC 12.7 15 [0-30] 9.5 
CEC, 3-cyano-7-ethoxycoumarin; MFC, 7-methoxy-4-trifluoromethylcoumarin; 
BFC, 7-benzyloxy-4-trifluoromethylcoumarin; S/N, signal to noise ratio. 
 
4.1.2 Determination of IC50 for the CYP diagnostic inhibitors 
IC50 was determined for the diagnostic inhibitors of the CYP isoforms used in 
this study (CYPs 1A2, 2C9, 2D6, 3A4 and 2C19). The resulting sigmoidal 





Figure 4.1: IC50 curves for diagnostic inhibitors of CYPs 1A2, 2C19, 2C8, 
2C9, 2D6 and 3A4 
 
The obtained values were compared to literature values as a way to validate 
the inhibition assay. The comparisons are summarised in Table 4.2. 
 
Table 4.2: Summary of the optimised reaction conditions for the 
fluorescent-based plate assays 
CYP Inhibitor  Determined IC50 (µM) Literature IC50 (µM) 
1A2 α-naphthoflavone  0.020 ± 0.007 a0.02 -0.082 
2C19 Ticlopidine  0.630 ± 0.09 b3.7 – 3.99 
2C9 Sulfaphenazole  0.280 ± 0.06 c0.26 – 1.3 
2D6 Quinidine  0.011 ± 0.009 d0.02- 0.2 
3A4 Ketoconazole  0.040 ± 0.008 e0.03 – 0.17 
a(Ghosal et al., 2003; Weaver et al., 2003; Moody et al., 1999; Sai et al., 2000; Bu et al., 2000) 
b(Donahue et al., 1997; Sudsakorn et al., 2007) 
c(Dierks et al., 2001) 
d(Dierks et al., 2001; Weaver et al., 2003; Bu et al., 2000; Yin et al., 2000; Sai et al., 2000) 

































4.1.3 Set up and validation of the TDI assay 
Known time and non-time dependent inhibitors for CYPs 1A2 2C19, 2C9, 
2D6 and 3A4 were used to determine if the assay would discriminate 
between the two. Data from the CYP1A2 validation set is shown in Fig 4.2. All 
the compounds that were reported as TDI were picked by the assay except 
for carbamazepine and tacrine. The non-TDI behaved in an expected 
manner. 
 
Figure 4.2: Time dependent-inhibition of CYP1A2 by various test 
compounds. All the compounds were at 1 and 20μM except for furafylline 
and ANF, which were at 0.01 and 0.1μM. The compounds were as follows: 
FUR, Furafylline, BER, bergamottin, RES, resveratrol, TAC, tacrine, TIC, 
ticlopidine, CAR, carbamazepine, FLU, fluvoxamine, ANF, α-naphthoflavone. 
 
Validation for CYP2C9 was performed using tienilic acid, hydrastine, 
fluoxetine, methimazole, silibinin, cimetidine and fluvoxamine. In this assay all 
the compounds behaved as expected with the exception of silibinin and 
methimazole (Fig 4.3). All the weak time dependent inhibitors (methimazole, 
silibinin, cimetidine and fluvoxamine fell in the grey area. 


































Figure 4.3: Time dependent-inhibition of CYP2C9 by various test 
compounds. The compounds were as follows: TIE, tienilic acid, HYD, 
hydrastine, FLO, Fluoxetine, MET, methimazole, SIL, silibinin, CIM, 
cimetidine, FLU, fluvoxamine, SUL, sulfaphenazole. 
 
For CYP3A4 all the compounds behaved as expected. The data is 
summarized in Fig 4.4 
 
Figure 4.4: Time dependent-inhibition of CYP3A4 by various test 
compounds. 
 





















































For the CYP2C19 validation the assay managed to pick ticlopidine and 
cimetidine as TDI, and omeprazole as non-TDI. However the assay failed to 
pick methimazole, which is a weak TDI.  
 
Figure 4.5: Time dependent-inhibition of CYP2C19 by various test 
compounds 
 
4.1.4 CYP2D6 LC/MS based plate assay 
The signal to noise ratio for CYP2D6 was poor in the fluorescence-based 
assays (Table 4.1) so an LC/MS method was set. 1’hydroxybufuralol was 
measured to follow the activity of the enzyme.  The spectra of daughter ions 
of 1’hydroxybufuralol at 1μM run using a 50:50 ACN: water mobile phase 
acidified with 0.1% formic acid. The limit of detection was 0.01μM.  
 































Figure 4.6: Mass spectra of daughter ions of 1’hydroxybufuralol and 





4.2 PART II: Identification of ADME/PK liabilities of 3,4-HPO-4-
amino-7-chloroquinolinyl hybrid compounds with antiplasmodial 
activity. 
 
4.2.1 In vitro antiplasmodial activity 
The 3,4-HPO-4-amino-7-chloroquinolinyl hybrids had efficacy in both the CQR 
and CQS P. falciparum strains (Table 4.3). Some of the compounds (3.2c, 
3.2d, 3.2d.HCl, 3.1g, 3.2g, 3.1h and 3.3a) had better activity compared to 
chloroquine, which was used as the control drug in the CQR K1 strain. 
Table 4.3: Antiplasmodial activity of 3,4-HPO-4-amino-7-chloroquinolinyl 
hybrids 
 
Comp. R2 R3 n 
Antiplasmodial Activity IC50 (μM) βHIA 
(IC50/equiv) 3D7 K1 W2 
CQ - - - 0.01 0.44 0.10 1.9 
3.1a Me Bn 1 0.49 3.15 9.93 0.93 
3.2a Et Bn 1 0.95 8.43 2.59 0.50 
3.1b Me Bn 2 0.28 3.57 2.15 0.49 
3.2b Et Bn 2 0.12 71.6 2.32 0.41 
3.1c Me Bn 3 0.05 2.2 1.12 22.4 
3.2c Et Bn 3 0.004 0.13 0.10 0.19 
3.1d Me Bn 5 35.70 4.38 0.39 0.01 
3.2d Et Bn 5 0.01 0.08 0.02 0.16 
3.2d.2HCl Et Bn 5 0.01 0.1 ND ND 
3.1e Me H 1 10.80 32.6 0.28 2.9 
3.2e Et H 1 0.40 0.89 1.24 1.1 
3.1f Me H 2 ND ND ND ND 
3.2f Et H 2 0.12 0.38 0.54 1.3 
3.1g Me H 3 0.03 0.07 0.08 2.7 
3.2g Et H 3 0.05 0.27 0.16 0.98 
3.1h Me H 5 0.390 0.16 0.07 0.18 
3.2h Et H 5 0.08 0.61 0.09 0.49 
3.3a Me Me 5 0.13 2.8 0.09 1.07 
3.3b Me Me 3 0.07 0.22 0.76 0.75 
3.4a Et Me 5 ND ND 0.22 0.47 




The compounds were potent inhibitors of β-haematin formation with all the 
compounds having better activity compared to chloroquine except for 
compound 3.1e (Table 4.3). No significant differences were observed 
between compounds with an alkyl linker of 4 or 6 chains (3.2c vs. 3.4d). All 
the compounds except 3.2b, 3.2c, 3.2d, 3.2d.HCl and 3.1h were not 
significantly cytotoxic to mammalian cells as demonstrated by their lack of 
toxicity to the KB cell line (Table 4.4).  
Table 4.4: Antiplasmodial activity of 3,4-HPO-4-amino-7-chloroquinolinyl 
hybrids 
 
Compound R2 R3 n  




K1/3D7 W2/3D7 KB/3D7 KB/K1 
CQ - - -  48.9 10.8 10.9 3811.1 77.95 
POD  - - -  - - 0.0003 0.0007 ND 
3.1a Me Bn 1  6.4 2.0 22.5 109 17 
3.2a Et Bn 1  8.9 2.7 23.3 6.3 1.0 
3.1b Me Bn 2  12.8 7.7 28.9 18.7 1.0 
3.2b Et Bn 2  596 19.3 6.6 0.21 1.0 
3.1c Me Bn 3  0.27 44.0 53.2 2331 54.7 
3.2c Et Bn 3  32.5 25 4.16 2250 69 
3.1d Me Bn 5  0.25 0.12 75.3 36 1.0 
3.2d Et Bn 5  11.4 2.1 1.86 345 1.0 
3.2d.2HCl Et Bn 5  12.5 ND 3.27 828.6 65.1 
3.1e Me H 1  3.0 0.026 ND ND ND 
3.2e Et H 1  2.2 3.1 ND ND ND 
3.1f Me H 2  ND ND ND ND ND 
3.2f Et H 2  3.2 4.5 19.5 117 1.0 
3.1g Me H 3  0.66 2.3 66.3 5136 2201 
3.2g Et H 3  5.4 3.2 28.3 1181 236 
3.1h Me H 5  0.47 0.4 1.38 18 1.0 
3.2h Et H 5  7.7 1.1 17.7 475.9 61.6 
3.3a Me Me 5  - - 18.6 358.5 166.4 
3.3b Me Me 3  - - 10.3 395 125.9 
3.4a Et Me 5  - - ND ND ND 
3.4b Et Me  3  - - ND ND ND 




For the compounds that did not demonstrate significant cytotoxicity the profile 
was comparable to that of chloroquine and was better than the 
podophyllotoxin, which was the control drug. The 3D7 strain showed better 
selectivity indices for all the compounds with the exception of compound 3.2c. 
However the selective indices were lower compared to chloroquine except for 
compounds 3.1c, 3.2c, 3.2g, and 3.2d.2HCl, which was comparable. 
Resistance indices were lower in all the compounds compared to chloroquine 
with the exception of 3.2b, 3.2c and 3.1c. 
 
4.2.2 Physicochemical profiling 
4.2.2.1 Prediction of drug likeliness and oral bioavailability  
All the 3,4-HPO-4-amino-7-chloroquinolinyl hybrids satisfied the Lipinski rule 
of 5 with the exception of 3.1c, 3.2b, 3.1c, 3.1d, 3.2a, 3.2d, and 3.2d.HCl 
(Table 4.5). The compounds that failed did so by one property (cLogP). Thus 
these compounds still had potential to have good oral bioavailability and to be 
druggable. If the Veber rules for predicting good oral bioavailability are to be 
considered in the test compounds, all the compounds except 3.1d, 3.2d and 
3.2d.HCl were in the prescribed chemical space. The compounds that failed 
did so because they had too many rotatable bonds. 
 
4.2.2.2 Prediction of lead likeliness and BBB penetration   
According to rules by Pardridge for BBB penetration, all the 3,4-HPO-4-





Table 4.5: Prediction of physicochemical properties to determine the drug likeliness, oral absorption, BBB crossing potential 
and lead likeliness for the artemisinin-chloroquinoline and 3,4-HPO-4-amino-7-chloroquinolinyl hybrid compounds 
Compound   
Predicted Physicochemical properties 
 
Violations 
Mw HBA HBD cLogP LogD Ring count Rot. bonds PSA LogSw Lipinski Veber CNS like Lead like 
3.1a  419.90 5 1 4.49 4.25 4 7 56.17 -5.24  1 0 1 1 
3.2a  433.93 5 1 5.01 4.77 4 8 56.17 -5.37  1 0 1 1 
3.1b  433.93 5 1 4.55 4.30 4 8 64.97 -5.45  0 0 1 2 
3.2b  447.96 5 1 5.07 4.83 4 9 56.17 -5.60  1 0 1 2 
3.1c  447.96 5 1 5.06 4.82 4 9 56.17 -5.78  1 0 1 2 
3.2c  461.98 5 1 5.59 5.34 4 10 56.17 -5.89  1 0 1 4 
3.1d  476.01 5 1 5.95 5.71 4 11 56.17 -6.16  1 1 1 5 
3.2d  490.04 5 1 6.47 6.23 4 12 56.17 -6.29  1 1 1 5 
3.2d.2HCl  490.04 5 1 6.47 6.23 4 12 56.17 -6.29  1 1 1 5 
3.1e  329.78 5 2 2.65 2.41 3 4 64.97 -3.77  0 0 0 0 
3.2e  343.80 5 2 3.17 2.93 3 5 56.17 -3.89  0 0 0 0 
3.1f  343.80 5 2 2.71 2.47 3 5 64.97 -3.92  0 0 0 0 
3.2f  329.78 5 2 2.51 2.26 3 5 64.97 -3.89  0 0 0 0 
3.1g  357.83 5 2 3.23 2.98 3 6 64.97 -4.04  0 0 0 0 
3.2g  371.86 5 2 3.75 3.51 3 7 64.97 -4.45  0 0 0 0 
3.1h  385.89 5 2 4.11 3.87 3 8 64.97 -4.71  0 0 0 0 
3.2h  399.91 5 2 4.64 4.39 3 9 64.97 -4.94  0 0 0 1 
3.4a  399.91 5 1 4.23 3.10 3 7 56.17 -4.94  0 0 0 1 
3.3a  371.86 5 1 3.34 3.62 3 8 56.17 -4.40  0 0 0 1 
3.4b  413.94 5 1 4.75 3.99 3 8 56.17 -5.08  0 0 0 2 
3.3b  385.89 5 1 3.86 4.51 3 10 56.17 -4.53  0 0 1 0 
Mw, Molecular weight; HBA, Hydrogen bond acceptors; HBD, hydrogen bond donors; cLogP, calculated LogP; RB, rotatable bonds; 





The exception were the benzylated analogues which were either too lipophilic 
(3.1a, 3.2a, 3.1b, 3.2b, 3.1c, 3.2c, 3.1d, 3.2d and 3.2d.2HCl) or had 
molecular weight falling outside the desired chemical space (Table 4.5). 
 
Predictions for 3,4-HPO-4-amino-7-chloroquinolinyl hybrid compounds in 
VolSurf also showed the compounds to have potential to cross the BBB. The 
compounds (highlighted in yellow) were projected on the plot of training 
compounds (black circles) (Fig 4.7). The compounds were known BBB 
crossing and non-crossing compounds from literature in-built in the software. 
In terms of lead likeliness all the other compounds were within the desired 
ranges with the exception of the benzylated analogues (Table 4.5), which had 
violations ranging from 1 to 5. The number of violations increases with 
increasing lipophilicity for the analogues.  
 
Figure 4.7: Volsurf predictions for blood brain barrier penetration by 3,4-




4.2.2.3 Lipophilicity and purity determination 
The purity for all the compounds was above 95%. From integrity studies there 
was no indication the compounds were degrading in the media even after a 
week. Further studies on the compounds were therefore continued with 
confidence. For lipophilicity determination, reference compounds with 
accurately determined k’ and known literature LogD7.4 were used to perform 
calibrations. The LogD7.4 values ranged between -0.15 and 5.22. 
Representative chromatograms for the blank and reference compounds are 











The retention times were used to correct the reported k’. Corrected k’ values 
and literature LogD7.4 values are shown in Table 4.6.  
 
Table 4.6: Calculated k´ and log D values for reference compounds 
 Literature  Experiment 
Compound k´ logD7.4  Tr (min) k´ Estimated logD7.4 
Metoprolol 7.8 0.02  9.48 7.64 -0.18 
Propanolol 9.3 1.15  11.62 9.47 1.56 
Testosterone 10.9 3.19  13.41 11.00 3.01 
Felodipine 13.4 5.2  16.07 13.28 5.17 
 
The k’ was plotted against the retention time of the reference compounds and 
the resulting curve was used to calculate the k’ for the test compounds. 
Another standard curve was made by plotting the retention times of the test 
compounds against the literature LogD7.4 to determine the LogD7.4 of the test 
compounds. A summary of the determined LogD7.4 values is given in Table 
4.7. 
 
4.2.2.4 Solubility determination  
Two compounds from the series had low solubility with the exception of 3.2g 
and 3.4a. According to cutoffs set for the turbidimetric assay all the 
compounds had high solubility except for compound 3.2c, 3.1d, 3.2d and 3.2h 
that were partially soluble (in the range 20-100µM). Compounds 3.2g and 
3.3a were poorly soluble. If the guidelines for potential solubility issues in 
humans for discovery compounds are to be followed (Kerns and Di, 2008a) all 
the compounds had moderate solubility with the exception of compound 3.2g 




below 10µg/ml are poorly soluble, between 10 and 60µg/ml moderate and 
above 60µg/ml highly soluble. 
 
Table 4.7: Experimentally determined LogD7.4 of 3,4-HPO-4-amino-7-
chloroquinolinyl hybrids 
 
Compound R2 R3 n LogD7.4 
3.1a Me Bn 1 1.53 
3.2a Et Bn 1 1.47 
3.1b Me Bn 2 1.63 
3.2b Et Bn 2 2.62 
3.1c Me Bn 3 2.27 
3.2c Et Bn 3 3.66 
3.1d Me Bn 5 4.77 
3.2d Et Bn 5 5.82 
3.2d.2HCl Et Bn 5 5.82 
3.1e Me H 1 0.26 
3.2e Et H 1 ND 
3.1f Me H 2 ND 
3.2f Et H 2 ND 
3.1g Me H 3 ND 
3.2g Et H 3 1.27 
3.1h Me H 5 1.30 
3.2h Et H 5 2.40 
3.3a Me Me 5 0.22 
3.3b Me Me 3 1.63 
3.4a Et Me 5 ND 
3.4b Et Me  3 ND 
 
As expected the deprotected compounds had higher solubility compared to 
the benzylated forms as the former were in salt form (Fig 4.9). The 3-
methoxylated analogues exhibited low aqueous solubility when compared to 




solubility which allowed testing in biological assays as the highest 
concentration required was 20µM. There was no correlation in solubility 
between experimental and predicted data.  
 
Figure 4.9: Solubility of 3,4-HPO-4-amino-7-chloroquinolinyl hybrids. The 
benzylated analogues are represented by filled circles, deprotected analogues 
by non-filled circles and the methoxy analogues by triangles 
 
There was an increase in the lipophilicity of the compounds with increase in 
linker carbon chain as expected. However there was no correlation between 
experimentally determined lipophilicity and solubility values.   
 
4.2.3 ADME profiling 
4.2.3.1 Metabolic clearance in human liver microsomes and 
cryopreserved hepatocytes  
 
Hepatic clearance (CLH) in human liver microsomes was intermediate for all 
compounds except for 3.1b, 3.1c, 3.1d and 3.1h, which were low (Table 4.8) 
using the well-stirred model. 













































Table 4.8: Metabolic stability in human liver microsomes and cryopreserved hepatocytes 
 
Compound 
Human liver microsomes  Cryopreserved hepatocytes 
 aT1/2 (min) bClint,app (ml/min/kg) cCLH (ml/min/kg) % of QH  aT1/2 (min) bClint,app (ml/min/kg) cCLH (ml/min/kg) % of QH 
A
 
Midazolam 5.13 257.90 19.42 92.47  21.0 91.65 17.09 81.36 
Verapamil 10.88 121.69 17.91 85.30  - - - - 
Diltiazem 33.81 39.16 13.67 65.09  - - - - 
Tolbutamide 301.37 4.39 3.63 17.30  - _ _ _ 
Propanolol - - - -  50.0 38.92 13.64 64.95 
Clozapine - - - -  99.0 19.74 10.18 48.45 
B
 
3.1a 34.48 7.24 5.38 25.63  67.3 29.05 12.19 58.04 
3.2a ND ND ND ND  44.4 43.99 14.21 67.69 
3.1b 96.27 2.59 2.31 10.99  54.7 35.81 13.24 63.04 
3.2b 33.49 7.45 5.50 26.19  43.3 45.12 14.33 68.24 
3.1c 49.51 5.04 4.06 19.35  20.7 94.47 17.18 81.81 
3.2c 31.36 7.96 5.77 27.48  53.2 150.02 18.42 87.72 
3.1d 72.20 3.46 2.97 14.13  30.2 64.58 15.85 75.46 
3.2d 17.77 14.04 8.41 40.07  15.4 127.18 18.02 85.83 
3.2d.HCl 21.46 11.63 7.48 35.64  22.7 86.29 16.89 80.43 
C
 
3.1e 12.58 19.84 10.20 48.57  - - - - 
3.2e 18.58 13.43 8.19 39.00  - - - - 
3.2g 15.97 15.62 8.96 42.66  - - - - 
3.1h 9.27 26.93 11.80 56.18  - - - - 
3.2h 36.87 6.77 5.12 24.37  - - - - 
D
 3.4a 20.82 11.99 7.63 36.34  - - - - 
3.3a 19.47 12.82 7.96 37.90  73.5 26.51 11.72 55.80 
aElimination half-life (T1/2) = time taken for compound to eliminated to half its original concentration; bApparent clearance (Clint, app) = in vivo clearance 




In hepatocytes, compounds 3.1c, 3.1d, 3.2c, 3.2d and 3.2.HCl were predicted 
to be fast with 3.1a, 3.1a, 3.1b, 3.2b, and 3.3a being predicted to be 
intermediate. Predicted clearance was higher in hepatocytes compared to 
human liver microsomes. The ranking of the compounds into fast, slow and 
intermediate CLH was based on the comparison of estimated CLH to hepatic 
blood flow (QH) where CLH>75% of QH is fast, CLH< 25% is slow and CLH 25-
75 is intermediate. 
 
4.2.3.2 Biotransformation in human cryopreserved hepatocytes  
Given that the metabolic clearance of many of the N-alkyl-3, 4-HPO hybrids 
was intermediate to fast in hepatocytes, further studies to understand their 
biotransformation were conducted. Metabolites identified in hepatocytes were 
mainly as a result of N-dealkylation of the pyridinone into M1 and a carbonyl 
intermediate (7-chloroquinolinyl-4-amino-aldehyde), which subsequently 
yields a carboxylic acid, M5 (7-chloroquinolin-4-ylamino carboxylic acid and to 
a minor extend M8 (N-alkenyl-7-chloroquinolin-4-yl-amine). 
 
The second significant metabolic route is linear chain cleavage to give M2 (7-
chloroquinolin-4-amine) and a carbonyl intermediate which subsequently 
gives a carboxylate M4 and a hydroxyl metabolite M3 (a pyridinyl alcohol) as 
a minor metabolite (Fig 4.10). From mass balance estimates most of the 
metabolites identified accounted for the biotransformation of the compound. 
All the compounds analyzed cleaved to form M1 with the exception of 3.3a, 
3.1h and 3.2d. Carboxylic acids resulting from the 4-aminoquinoline moiety 




resulted from the short chain analogues (n ≤ 2) with the exception of M7. 
Hydroxylation of the uncleaved compound was observed to a minor extent in 
3.2d and 3.3a (Fig 4.10). The full profiles for each of the tested compounds 




Figure 4.10: General scheme for the metabolism of selected 4-






4.2.3.3 Inhibition studies in the 5 major cytochrome P450s  
4.2.3.3.1 Inhibition screens  
None of the 4-aminoquinoline-3, 4-hydroxypyridinone hybrids had significant 
inhibitory effects on CYP2C9 and CYP2C9. In CYP1A2 the inhibition was 
moderate. In cases where the IC50 was determined in CYP1A2 (3.1d, 3.1e, 
3.1f, 3.1h and 3.2h) the value was greater than 10µM predictive of low risk 
DDI. No further analysis was therefore performed in these isoforms. Potent 
inhibition was shown on CYP3A4 and CYP2D6 with all the compounds (Table 
4.9) having IC50 values ranging between 1-10μM. This put the risk of DDI with 
substrates of the two isoforms at intermediate level. The only exception was 
compound 3.2b with CYP2D6. Inhibition against CYP3A4 was driven by 
lipophilicity with the greatest inhibition being shown by the most lipophilic 
compounds. The greatest inhibition was shown by the benzylated analogues 
in both CYP3A4 and CYP2D6. TDI was investigated in CYP3A4 and all the 
compounds were negative for TDI (Fig 4.11). 
 
4.2.3.3.2 Kinetic and mechanisms of CYP3A4 inhibition  
Further analysis into the kinetics and mechanism of inhibition of the 
compounds by CYP3A4 indicated the compounds inhibited via a non-
competitive mechanism (Table 4.9), with the exception of 3.2e, 3.2h and 3.4a, 
which demonstrated mixed type inhibition and compound 3.1f, which 
demonstrated the competitive mode. The Ki values for the compounds also 
















































































Table 4.9: Inhibition of the 4-aminoquinoline-3, 4-hydroxypyridinone hybrids by the five major drug metabolizing enzymes 
 
Compound 
Cytochrome P450 inhibition: % inhibition (IC50)  Kinetics of CYP3A4 inhibition 
 CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4  Ki  (µM) Mode of inhibition 
A
 
*Controls  95 (0.01) 40 65 96 (0.02) 70 (0.08)    
B
 
3.1a 13 4 12 98 (2.58) 68 (7.73)  9.66 non-competitive 
3.2a 31 17 25 98 (3.08) 84 (3.07)  70.99 non-competitive 
3.1b 17 32 43 89 (3.88) 75 (1.77)  0.36 non-competitive 
3.2b 8 43 62 4 90 (1.18)  1.14 non-competitive 
3.1c 15 31 37 85 (2.05) 87 (1.00)  1.19 non-competitive 
3.2c 15 58 5 81 (5.18) 91 (4.33)  27.59 non-competitive 
3.1d 88 (22.64) 49 36 100 (6.38) 93 (2.25)  3.73 non-competitive 
3.2d 10 61 48 89 (2.17) 92 (1.36)  0.79 non-competitive 
3.2d.2HCl 31 54 30 90 (3.44) 94 (0.29)  0.34 non-competitive 
C
 
3.1e 68 (17.26) 11 8 90 (2.76) 43 (5.87)  39.60 non-competitive 
3.2e 0 0 2 97 (2.31) 32 (12.34)  0.97 mixed 
3.1f 57 (36.46) 23 26 100 (6.33) 52 (14.86)  5.42 competitive 
3.2g 33 0 24 97 (3.22) 65 (6.53)  6.70 non-competitive 
3.1h 64 (14.56) 2 1 94 (ND) 75 (4.29)  5.81 non-competitive 
3.2h 63 (38.67)  18 49 98 (8.07) 89 (4.40)  3.39 mixed 
D
 
3.4a 20 3 21 92 (4.58) 46 (6.13)  3.69 mixed 
3.3a 9 0 13 84 (5.08) 64 (2.52)  4.38 non-competitive 
3.4b 9 1 20 93 (ND) 63 (12.80)  3.95 non-competitive 
3.3b 6 0 18 84 (2.32) 54 (2.15)  3.58 non-competitive 
ND; not determined; IC50 is the concentration of inhibitor resulting 50% inhibition (in brackets);  % inhibition was as determined at 
20µM. *Controls for each respective CYP were as follows: CYP1A2, α-naphthoflavone at 0.1μM, CYP2C19, ticlopidine at 10μM, 




4.3 PART III: Identification of ADME/PK liabilities in artemisinin-
chloroquinoline hybrids 
 
4.3.1 Determination of metabolic clearance in HLM and hepatocytes 
Hepatic clearance was intermediate for the two hybrids in hepatocytes and 
HLM except for compound 3.9 in HLM (Table 4.10). The clearance of the 
compounds was higher than that for both artemisinin and chloroquine. None 
of the hybrids behaved the same as chloroquine. The clearance in 
hepatocytes was rapid in the first 15 min and then slowed down thereafter. 
 
Table 4.10: Metabolic stability of artemisinin-chloroquinoline hybrids in 
HLM and hepatocytes 





% of QH 
 
Human liver microsomes  
artemisinin 25.96 25.60 11.52 54.84  
chloroquine 346.57 1.91 1.75 8.34  
3.9 9.47 269.03 19.48 92.76  
3.10 19.31 34.29 13.02 62.02  
      
Cryopreserved hepatocytes  
artemisinin - - - -  
chloroquine - - - -  
3.9 26.46 25.03 11.42 54.37  
3.10 31.90 12.66 20.75 60.31  
 
4.3.2 Metabolite identification 
Metabolites were identified in hepatocytes. The bulk of the compound 
remained unchanged after the 60 minutes incubation with 76% and 77% 








Figure 4.12: Biotransformation of compound 3.9 in hepatocytes 
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Two metabolites were identified for compound 3.10 (Fig 4.13). The fragment 
that was identified suggested the cleavage that was holding the two major 
building blocks on the compound that is the artemisinin and the 4-
aminoquinoline core. However the data suggest most of the compound 
remained intact as indicated by the high percentage of the parent compound 
identified.  
 





4.3.3 Reaction phenotyping 
The enzymes responsible for metabolizing the two artemisinin-chloroquinoline 
hybrids were determined (Fig 4.14). There was no contribution from CYPs 
2B6, 2C8 and 2E1 for both compounds. The highest contribution came from 
CYPs CYP2C9 and 2C19 for both compounds. Less than 20% of the 
compound was metabolized by the contributing enzymes except for 
compound 3.10 in CYPs 2C9 and 2C19.  
 
Figure 4.14: Reaction phenotyping for the artemisinin-chloroquinoline 
hybrids. Data for compound 3.9 is represented by the solid columns and that 
for compound 3.10 by checked columns. 
 
4.3.4 Inhibition studies 
The artemisinin-chloroquinoline hybrids and their intermediates showed 
significant inhibition against CYP3A4 (Fig 4.15). Inhibition in the hybrids was 
potent with more than 80% inhibition. The inhibition was characterized by an 
IC50 of 0.059 and 0.214μM for compounds 3.9 and 3.10 respectively (Fig 
4.16) 
 






























Figure 4.15: Inhibition of CYP3A4 by the artemisinin-chloroquinoline 
hybrids. 
 
The inhibition of intermediates was characterized by an IC50 of 0.7192, 1.014 
and 0.6333μM for 3.6, 3.7 and 3.8 respectively. Inhibition for ketoconazole, 
which is a known potent CYP3A4 inhibitor, was 0.0023μM. 
 
Figure 4.16: Inhibition of CYP3A4 mediated BFC metabolism by the 
artemisinin-chloroquinoline hybrids 
 























































The hybrids (3.9 and 3.10) and intermediate 3.6 also demonstrated potent 
inhibition against CYP2C9 and CYP2C19 (Fig 4.17). The other intermediates 
had moderate effects. Chloroquine, artemisinin and dihydroartemisinin (DHA) 
were comparable to intermediate 3.7 and 3.8.  
 
Figure 4.17: Inhibition of CYP2C9 and 2C19 by the artemisinin-
chloroquinoline hybrids. 
 























































Inhibition was not significant in CYP2D6 with artemisinin and 
dihydroartemisinin showing no inhibition (Fig 4.18). The inhibition was 
moderate for the hybrids with the compounds 3.7 and 3.8 being potent against 
CYP1A2. 
 
Figure 4.18: Inhibition of CYP1A2 and 2D6 by the artemisinin-
chloroquinoline hybrids.  






















































4.4 PART IV: Molecular Mechanism of CYP1A2 inhibition by TBZ 
 
4.4.1 TDI screen of antiparasitic drugs 
Parasitic drugs were screened for TDI in CYPs 1A2, 2C9 and 3A4. None of 
the compounds showed TDI against CYP2C9 and CYP3A4. The same was 
observed in CYP1A2 except for TBZ and its metabolite 5OH-TBZ which 
demonstrated potent inhibition and mild TDI respectively. The inhibition was 
potent at both low (3μM) and high concentration (20μM). The data for 
CYP1A2 is summarized in Fig 4.19. Compounds that were in the grey zone 
did not show any concentration dependence making them very unlikely to be 
TDI for the CYP isoforms. The negative control (α-naphthoflavone) and the 
positive control (furafylline) were clearly non-TDI and TDI respectively as 
expected. No significant loss of activity was observed in the control 
experiments where there was no inhibitor.  
 




























































































































































4.4.2 IC50 determination 
Inhibition of CYP1A2 by TBZ and 5OH-TBZwas evaluated using the activity 
assay to show the effects of TBZ and 5OH-TBZ via competitive inhibition. 
Both compounds were potent inhibitors of CYP1A2 with the inhibition 
characterized by an IC50 of 0.83 and 13.05μM respectively. The IC50 curves 
are shown in Fig 4.20. 
 
Figure 4.20: Inhibition of CYP1A2-mediated CEC metabolism by TBZ and 
5OH-TBZ 
 
4.4.3 Kinetics of CYP1A2 Inactivation by TBZ and 5OH-TBZ 
Kinetics of CYP1A2 inactivation by TBZ and 5OH-TBZ were followed by 
measuring loss of CEC dealkylation activity. Inactivation of CYP1A2 was in a 
time- and concentration-dependent manner and followed pseudo-first order 
kinetics. The time course for the inactivation is shown in Fig. 4.21a. Nonlinear 
regression analysis of the time course data was then used to determine the 
initial rate constants for the inactivation at various concentrations of the two 






























determined to be 0.08 min-1 and 1.4μM, respectively, for TBZ and 0.02min-1 
and 63.03μM for 5OH-TBZ respectively. At higher concentrations of TBZ, 
some loss of activity was observed at the zero point because of the carryover 
of TBZ into the inactivation assay mixture. Because 5OH-TBZ is a weak 
inhibitor, there were no significant changes in the activity of the enzyme at the 
varying time points for the lower concentrations (1.6, 3.1, and 6.3μM). 
However, the changes were much clearer at the higher concentrations, giving 
clearer slopes (Fig. 4.21a). 
 
 
Figure 4.21: Time- and concentration-dependent inactivation of CEC 





4.4.4 Mechanism of TDI 
4.4.4.1 IC50 shift  
The two-step assay was performed for TBZ based on the fact that TDI causes 
a decrease in the IC50 value when preincubated with NADPH. Because TBZ 
had been shown to be a potent TDI, the assay was used to further confirm the 
observed result. TBZ inhibited CYP1A2 activity, with an IC50 value of 84.5μM 
when preincubation was done in the absence of NADPH. Preincubation with 
NADPH increased the inhibition of CYP1A2 considerably (Fig. 4.21), giving a 
further strong indication that TBZ is a time-dependent inhibitor of CYP1A2. 
The IC50 value was lowered to 2.8μM. 
 
Figure 4.22: Inhibition of CYP1A2-mediated CEC metabolism by TBZ in 
the presence and absence of NADPH in the preincubation step. 
 
4.4.4.2 Effect of GSH and K3FeCN6 on the Inactivation of CYP1A2 
Protection of the enzyme inactivation by GSH and restoration of activity by 
oxidation by K3FeCN6 was investigated both in the presence and absence of 




an indication that it failed to protect the enzyme from inactivation (Fig 4.23). 
K3FeCN6 was not able to restore enzyme activity, giving an indication that the 
inhibitor was not displaced from the enzyme. Inactivation was not significant 
when NADPH was absent in the preincubation step. There was no significant 
change when the compounds were used in combination. 
 
Figure 4.23: Effect of GSH and KFe6CN3 on the inactivation ofCYP1A2 by 
TBZ. 
 
4.4.4.3 Effect of Dialysis 
To determine whether the inactivation effects by TBZ and 5OH-TBZ were 
reversible, compounds were incubated with CYP1A2. For comparison, the 
experiment was also conducted with samples that were not dialyzed. As 
indicated in Fig 4.24, the dialysis did not affect the magnitude of inactivation 
by furafylline, which is a known MBI of CYP1A2. The effects of fluvoxamine 
were greatly reduced by dialysis, and activity was restored to 100%. It was 
clear that TBZ was an irreversible inhibitor, because there was no significant 





Figure 4.24: Effect of dialysis on inactivation of CYP1A2 CEC dealkylase 
activity by TBZ and 5OH-TBZ. 
 
4.4.5 Substructure Search and Site of Metabolism Prediction 
Based on substructures associated with TDI (Fontana  et al., 2005), two 
substructures were identified: a conjugated system and the thiazole ring (Fig. 
4.25).  
 
Figure 4.25: Site of metabolism prediction and substructure search in 
thiabendazole. Two fragments associated with TDI, the thiazole moiety and a 
conjugated system, were identified (a). The structure and numbering of 
thiabendazole are also shown, and the known hydroxylation site (from 
literature) is circled. The site of metabolism was then predicted using MetaSite 
(b). The top three sites of metabolism predicted by the program are indicated 
by arrows, with the position ranked first circled 
 
These substructures have been associated with mechanism-based inhibition 




irreversibly to the enzyme (Fontana  et al., 2005). The compound was then 
submitted to MetaSite, which is a program that predicts the likely site of 
metabolism. The program has been proven to be able to predict the likely site 
metabolism within the top three predictions in 80% of the cases in structurally 
diverse compounds (Cruciani et al., 2005). MetaSite predicted the 5C on the 
benzyl group of thiabendazole as the top ranked site of metabolism (Fig. 
4.25b). 
 
4.4.6 Docking studies 
The results obtained from the docking experiments were in agreement with 
the site of metabolism predictions. There was one preferred orientation in all 
the three GOLD solutions in which the benzene ring of the compound was the 
closest to the heme catalytic center at an average distance of 4.5 Å in all the 
three solutions. One of the three docking poses is shown (Fig. 4.26). 
 
In GLUE, eight of the 10 docking solutions were in agreement with the site of 
metabolism prediction. In five of the 10 solutions, the thiazole ring was toward 
the heme and in three the benzene was the one closest to the heme catalytic 
center. In two of the solutions, both predicted groups were too far away from 
the catalytic center for any metabolism to occur. Examples of the possible 
docking poses are shown (Fig 4.27). Interactions of the benzene ring or the 
thiazole ring of thiabendazole with phenylalanine 226 of CYP1A2 seem to be 






Figure 4.26: Binding of thiabendazole into the active site of CYP1A2 
(PDB 2HI4). The heme prosthetic group, amino acid residues constituting the 
active site and thiabendazole are all depicted in sticks. Carbon atoms are 
colored orange in thiabendazole and green in the heme and amino acid 
residues. Oxygen, nitrogen, and heme iron are colored red, blue, and purple, 







Figure 4.27: Examples of different orientations in which thiabendazole 
docks into the active site of CYP1A2. The color-coding is the same as 
described for legend Fig 4.26. In five of the top 10 ranked solutions, the 
thiazole group was the group closest to the heme (b); in three solutions, the 
benzene ring in which hydroxylation occurs was closest (a); and in two 
solutions, both groups were further away (c). Interactions of the benzene or 
thiazole moiety of thiabendazole with phenylalanine 226 ofCYP1A2 seems to 
be important in determining the orientation of thiabendazole in the enzyme 
active site. 
 
4.4.7 DDI Pharmacokinetic Simulations 
The simulated DDI interactions involving TBZ as a competitive and as an 
irreversible inhibitor of CYP1A2 are summarized in Table 4.11. The MBI 




effects for the CYP1A2substrate tested. 
 
Table 4.11: Prediction of DDI between TBZ and other CYP1A2 substrates 
Combination  Mechanism  Predicted Mean 
AUC -Fold Increase 
Observed Clinical DDI 
-Fold Increase in AUC 
 
TBZ/TBZ  MBI  22.51 1.0  
TBZ/caffeine  Competitive  1.23 1.60  
 MBI 11.40 -  
TBZ/ theophylline Competitive  1.56 2.91  






4.5 PART V: Drug-herb interaction by evaluating the ADMET/PK of the 
active ingredient natural product, Frutinone A 
 
4.5.1 Determination of intrinsic clearance and metabolite identification 
The hepatic clearance (CLH) of the compound was predicted to be low (Figure 
4.28) with a calculated in vitro T1/2 of 179.55 min and in vitro clearance 3.86 
μl/min/million cells at 1μM of Frutinone A.  
 
 
Figure 4.28: Rate of metabolism of Frutinone A in cryopreserved 
hepatocytes. Metabolism was measured by the disappearance of Frutinone 
A from media containing human cryopreserved hepatocytes. The data was 
linearized to enable calculation of the half-life using the slope of the line 
 
Calculations were means of two replicates. Estimated whole liver clearance 
was 10.89ml/min/kg. Hepatic clearance was estimated using the well-stirred 




plasma protein and hepatocytes was not taken into account when the 
calculations were done. The value predicted for hepatic clearance was 
calculated to be about 30% of the blood flow (QH = 21 ml/min/kg). One minor 
by product (4%) postulated to have resulted from lactone ring opening and 
enzymatic or non-enzymatic aqueous hydrolysis was identified (Figures 4.29). 
 
 
Figure 4.29: Proposed hydrolysis pathway for Frutinone A in 
cryopreserved human hepatocytes. The hydrolysis byproduct was identified 
using LC-MS and Metabolynx™ software and was postulated to be a result of 
enzymatic- or non-enzymatic-mediated lactone ring opening via hydrolysis. 
 
 
Up to 96% of the parent compound remained in the incubation. The parent 
had a mass of 264.04 and retention time 2.80min. The by-product on the 
other hand had a mass of 282.05 and retention time of 2.63min.Spectra for 







Figure 4.30: MS spectra of protonated ions of Frutinone A (m/z 265.0496) 
and its minor by-product M1 (m/z 283.0534). Frutinone A was incubated in 
cryopreserved hepatocytes for 0 and 120 min. Spectra were obtained from 
scans made on the sample at 0 min where no reaction was expected to have 





4.5.2 Reaction phenotyping 
The compound was tested for metabolism by any of the 11 CYPs and HLM. 
There was slight metabolism observed with CYP1A1, 1B1, 2C8, 2C9 and 
HLM (Table 4.12). No metabolism was observed with the rest of the CYPs 
including CYP1A2. 
 
Table 4.12: Disappearance of Frutinone A from media in incubations 
with various enzymes 
 
Enzyme  % lost compound  
CYP1A1 28.53 ± 0.56 
CYP1A2 0.00 ± 0.02 
CYP1B1 15.68± 0.41 
CYP2B6 0.95± 0.63 
CYP2C19 0.00 ± 0.04 
CYP2C8 26.41± 0.53 
CYP2C9 25.93± 0.56 
CYP2D6 0.00 ± 0.00 
CYP2E1 0. 00 ± 0.01 
CYP3A4 0.00 ± 0.01 
CYP3A5 0.00 ± 0.02 
HLM 6.76 ± 0.37 
 
The amount of compound lost in the media relative to the control was determined 
and used to estimate the metabolism of the compound as described under materials 
and methods. The results are an average of two replicates  
 
4.5.3 Reversible and time-dependent inhibition screens on the effect of 
Frutinone A on the major CYPs 
 
The effect of Frutinone A on the five major CYP isoforms (CYP1A2, 2C9, 
2C19, 2D6 and 3A4) was investigated. The compound inhibited all the five 
isoforms. Potent inhibition was shown with CYP1A2 with moderate effects on 
CYPs 2C9, 2C19, 2D6 and 3A4 (Table 4.13). TDI screening was conducted 




Table 4.13: Effect of Frutinone A on the activity of the five major CYP 
isoforms 
 
Enzyme  Compound  
% Remaining 
activity (low conc)  
% remaining activity 
(high conc) 
CYP1A2 α-naphthoflavone  53.87 ± 6.56 16.29 ± 4.05 
 Frutinone A 11.77 ± 1.90 7.45 ± 1.78 
CYP2C19 Ticlopidine  53.29 ± 0.03 16.84 ± 0.15 
 Frutinone A 79.17 ± 0.34 51.52 ± 1.05 
CYP2C9 Sulfaphenazole 71.24 ± 5.12 30.28 ± 2.25 
 Frutinone A 73.79 ± 12.98 62.04 ± 12.13 
CYP2D6 Quinidine  42.00 ± 6.46 9.57 ± 0.90 
 Frutinone A 100.76 ± 8.71 64.36 ± 1.41 
CYP3A4 Ketoconazole  83.27 ± 7.10 20.13 ± 0.77 
 Frutinone A 81.97 ± 1.65 41.16 ± 4.58 
 
There was no TDI observed when Frutinone A was preincubated with NADPH 
(Figure 4.31). There was also no concentration dependence making it unlikely 
that this compound would be a time-dependent inhibitor of CYP1A2. 
 
Figure 4.31: Time-dependent inhibition (TDI) effects of Frutinone A on 
CYP1A2 activity. Frutinone A was incubated in human liver microsomes both 
in the presence and absence of NADPH. Furafylline and thiabendazole were 
used as positive control TDI inhibitors and α-naphthoflavone CYP1A2 was 
used as a negative control non-TDI inhibitor. Frutinone A and thiabendazole 
were evaluated at 1 and 20μM, and furafylline and α-naphthoflavone at 0.01 





4.5.4 Effect of Frutinone A on CYP1A2 mediated CEC O–deethylation 
and ethoxyresorufin O -deethylation 
Further investigations were carried out on CYP1A2 as the greatest inhibition 
had been seen with this enzyme. Frutinone A inhibited CYP1A2 with an IC50 
value of 0.56μM (Figure 4.32). 
 
Figure 4.32: Inhibition of CYP1A2 mediated 3-cyano-7-ethoxycoumarin 
metabolism by Frutinone A. -Naphthoflavone was used as a positive 
control inhibitor. The IC50 for -naphthoflavone and Frutinone A were 
0.008µM and 0.56µM respectively. 
 
The mode of inhibition by Frutinone A was determined to be mixed with CEC 
and competitive with ER (Figure 4.33). The α -naphthoflavone inhibited via 
mixed-type inhibition. The inhibition kinetic parameters for Frutinone A and α -







Figure 4.33: Enzyme kinetics for the inhibition of CYP1A2 by Frutinone A and -naphthoflavone. Frutinone A inhibited 
CYP1A2 mediated 3-cyano-7-ethoxycoumarin metabolism via a competitive mechanism and 7-ethoxyresorufin via a mixed 
mechanism. The control compound, α-naphthoflavone inhibited via a mixed mechanism in both substrates. Incubations were made 
at varying concentrations of substrates and inhibitor. 
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Table 4.14: Disappearance of Frutinone A from media in incubations 
with various enzymes 
 
 CEC ER 
-naphthoflavone   
Km 2.3µM 0.72 
Ki 0.005µM 0.003 
Mode of inhibition Mixed Mixed 
R2 0.94 0.98 
   
Frutinone A   
Km 1.9 0.97 
Ki 0.48 0.31 
Mode of inhibition Mixed Competitive 
R2 0.95 0.93 
The parameters were determined as described in the experimental section. The data 
was derived from fitted curves using non-linear regression (Fig 4.32) and were 
results of duplicate experiments   
 
4.5.5 Docking studies for Frutinone A 
To validate the accuracy of the docking software, the docking orientation of 
the docked α-naphthoflavone was compared to that of co-crystallized α -
naphthoflavone. There was a clear overlay of the two structures when they 
were superimposed on top of each other as indicated in Figure 4.34. Also as 
previously described, α–naphthoflavone had a single preferred binding 
orientation. Frutinone A interacted with the amino acids in the active site in the 







Figure 4.34: Validation of docking protocol. Orientations of the co-
crystallised and docked α-naphthoflavone that were computed in Autodock 
Vina were superimposed and compared. The co-crystallised α-
naphthoflavone (ANF 2 = purple), docked α-naphthoflavone (ANF 1 = yellow) 
and heme (grey) are depicted as sticks. The main amino in the active site 
(cyan) are depicted as wireframe. Other amino acids in the binding pocket 
have been left out for ease of visualization. 
 
 
Figure 4.35: Comparison between binding orientation of α-
naphthoflavone and Frutinone A Frutinone A and α-naphthoflavone were 
docked into the CYP1A2 active site. Frutinone A (green) and α-
naphthoflavone (yellow) are depicted as sticks. The main amino acids in the 
binding pocket (cyan) are depicted as wireframe. Heme is shown as grey 





4.5.6 Binding orientations of Frutinone A compared to that of 
substrates 
In an effort to explain the mixed inhibition we observed in the experiments, 
two software packages were used to dock Frutinone A, CEC and ER. Docking 
was also performed for α-naphthoflavone to control the experiment. Distances 
for the atoms nearest to the heme were measured to determine how likely 
metabolism could occur in those compounds. Distances measured with 
Autodock for CEC, ER, Frutinone A and α-naphthoflavone were 4.4, 4.0, 4.8 
and 4.6 Å, respectively, with binding free energies of −7.0, −8.6, −13.3 and 
−14.5 kcal/mol. With this software, all the compounds were docking in the 
same binding orientation (Fig 4.36). 
 
Figure 4.36: Binding of the various docked compounds in the active site 
of CYP1A2. The dockings were performed using the Autodock Vina software. 
The broken lines show hydrogen bonds between the docked concentrations of 
the compounds and the amino acids. Distances of the nearest atom to the 




However using FlexX, additional alternative binding orientations for substrates 
(Fig 4.37) were observed. The substrates bind below the hydrophobic pocket 
characterized by phenylalanines 226, 260 and 256. Distance of the 
metabolized sites for CEC and ER were 4.3 and 4.2 Å, respectively. 
 
Figure 4.37: Binding orientations of CEC and ER in the active site of 
CYP1A2. The dockings were performed using the FlexX software. The active 







5.1 PART I: Setting up of the ADME/PK platform 
Prior to the screening of the compounds for ADME/PK liabilities the various 
biochemical assays were setup and validated. Although the assays are used 
routinely in many drug discovery settings in developed countries, this is the 
first time to our knowledge an attempt has been made in Africa to come up 
with a facility that supports ADME studies for newly synthesized compounds 
in medicinal chemistry. 
 
Most drug discovery efforts in Africa have traditionally been driven by both 
synthetic chemistry and natural products coupled to in vitro and in vivo 
pharmacological screens for potency. In vivo PK studies have also been done 
in a few cases in support of these drug discovery initiatives. The integration of 
ADME/PK in the drug discovery value chain from hit identification through to 
candidate selection has been shown to reduce attrition rates of NCEs due to 
PK liabilities from 40 to 10% (Kola and Landis, 2004). Successfully setting up 
the ADME/PK assays in our laboratory will therefore provide support to our 
projects and other drug discovery scientists in Africa. This will help in 
integrating this science in the drug discovery value chain, thus promote 
productive collaboration among medicinal chemists, ADME and 
pharmacology. In this project the approach was implemented in the lead 






In this project, we applied the ADME/PK platform in the characterization of 
existing and newly synthesized compounds with potential to be used as 
antiparasitic drugs. We also used the platform to screen for potential 
interactions between herbal/traditional medicines and drug metabolizing 
enzymes and the implications of their use with substrates of those 
compounds. Given that herbal/traditional medicines are widely used in Africa 
for treating various ailments including parasitic infections such as malaria and 
TB, it is important to explore the risk of concomitant administration of 
conventional medicines and herbal remedies. Drug-herb interactions have 
been studied with common examples being induction of CYP3A by St John’s 
Wort (Moore et al., 2000; Madabushi et al., 2006) and inhibition of CYP3A by 
constituents of grapefruit juice (Bailey et al., 1995; Bailey et al., 1998; Fuhr, 
1998; Kiani and Imam, 2007). 
 
The setting up of this ADMET platform is also consistent with the increasing 
efforts to promote drug discovery and development initiatives in Africa through 
organizations such as the African Network for Drug and Diagnostics 
Innovation (ANDi), WHO-TDR, MMV, and others organizations. The platform 
we have setup is already supporting projects from some R&D based 
pharmaceutical companies in Africa, some university drug discovery research 
groups and other related biomedical and pharmaceutical R&D institutions. 
 
As an example of validation, known time- and non-time dependent inhibitors 
of CYP2C9 were used to validate the time dependent assay.  The validation 




hydrastine, silibinin, fluvoxamine, fluoxetine and sulfaphenazole (control). 
Fluvoxamine and sulfaphenazole, which were non-TDI compounds (Atkinson 
et al., 2005), were not picked by the assay. Silibinin and methimazole were 
not picked because they require very high concentration to show the inhibitory 
effects and this is consistent with literature (Zuber et al., 2002; Guo et al., 
1997). Cimetidine has previously been reported as a weak inhibitor (Furuta et 
al., 2001) and our observations were consistent with this. Parameters were 
also within range for the other isoforms. 
 
Assays for metabolic stability, reaction phenotyping, metabolite identification, 
inhibition screening and for physicochemical profiling were successfully set up 
and used to screen the various compounds in the study. It was clearly 
demonstrated that the platform can be utilized to screen for liabilities in newly 
synthesized compounds as well as in drugs that are currently in use. The Km 
values for CYP marker reactions were within the range of reported literature 
values (Ghosal et al., 2003; Naritomi et al., 2004; Crespi et al., 1997) hence 









5.2 PART II: Identification of ADME/PK liabilities of 3,4-HPO-4-amino-7-
chloroquinolinyl hybrid compounds with antiplasmodial activity 
Malaria still relies on chemotherapy for treatment. However there have been 
challenges associated with chemotherapy. Resistance and toxicity are some 
of the major challenges. There is continuous need to develop drugs that have 
efficacy and good safety profiles. Towards this aim, compounds with potential 
to have efficacy against resistant strains of P. falciparum were synthesized. 
Although the aim of this project was to evaluate ADME/PK liabilities in the 
compounds, the work was run in parallel with pharmacology screens as well 
as modifications of the potential compounds in medicinal chemistry.  
 
The compounds were shown to have good activity against the CQR and CQS 
P. falciparum strains. The mechanism of action was unexpectedly shown to 
be β-haematin inhibition especially in the sensitive strain. The strong β-
haematin inhibition activity was shown to translate into strong antiplasmodial 
activity more in the sensitive 3D7 than in the resistant K1 strain. This could 
have been as a result of the mutant PfCRT in the resistant strain exporting 
test compounds out of the food vacuole resulting in the lowering of drug 
concentrations at the target site. However, it should be noted that the β-
haematin inhibition and antiplasmodial activities were determined in cell free 
and cell based media respectively. Therefore good β-haematin inhibition 
activity may not necessarily translate into good antiplasmodial activity 






The disease and the expected route of delivery, which was oral for this study, 
determined the choice of physicochemical properties to be studied. Properties 
allowing absorption by the human host as well as the parasite were preferred. 
The compounds were predicted to be drug like and all the other properties 
were within acceptable ranges; clogP (2.6 - 4.5), experimental logD (3 -5) and 
solubility (>20 µg/ml) with the exception of a few compounds (Table 4.5). 
Benzylated analogues had higher solubility besides them being the most 
lipophilic. 
 
Lipophilicity was the main physicochemical property driving the antiplasmodial 
activity, β-haematin inhibition activity and CYP inhibition. The lipophilicity 
seemed to be driven by the N-1 alkyl group, which is the same group thought 
to affect antiplasmodial activity. Significant correlations between lipophilicity 
and antiplasmodial activity were observed for the W2 strain in the deprotected 
analogues (R2 = 0.41) and benzylated analogues (R2 = 0.88). Correlations 
were also strong for β-haematin inhibition with the benzylated analogues 
having an R2 of 0.59 and the deprotected analogues with R2 of 0.76. 
Lipophilicity also played a significant role in cytotoxicity From the CYP 
inhibition screens, it was observed that CYP3A4 inhibition was driven by 
lipophilicity, with the greatest inhibition being observed in the benzylated 
analogues (Table 4.9). 
 
However there were instances where it was observed that lipophilicity was not 
the only factor driving biological activity. There was no correlation between 




group replaced the benzyl group. This led to the postulation that other 
mechanisms were at play. The 3,4-HPO-chelator moiety may be enhancing 
the selectivity for the resistant strains possibly via some favourable 
interactions with the unprotected 3-OH group. The benzyl group may also be 
participating in π-π interactions with the heme porphyrin. This coupled with 
high lipophilicity could explain better β-haematin and antiplasmodial activity of 
the benzylated analogues compared to the methoxylated ones. Blocking the 
chelator group by benzylation or methoxylation (Table 4.3 and 4.4) led to a 
decrease in activity. However, data from the N-alkyl-3 HPOs indicate the 
chelator by itself is not enough to cause significant antiplasmodial activity as 
shown by the poor activity in these compounds (Table 4.3). 
 
Prediction studies for intestinal absorption indicated that the synthesized 
analogues will be well absorbed (Table 4.5). Predictions for CNS penetration 
were indicative of good permeation. This property, if not optimal, could be a 
limiting factor in the capacity of the drug to access malaria parasites in the 
brain in the case of cerebral malaria. ADME studies were performed to access 
the safety of the compounds if they were to be used in humans.  
 
From the CYP inhibition studies the compounds were shown to be potent 
inhibitors of CYP3A4 and CYP2D6. The mode of inhibition in CYP3A4 was 
mainly non-competitive in most of the compounds. This is very difficult to 
model, as the site of interaction between the ligand and the enzyme is 
relatively unknown.  The IC50 and Ki for both CYP2D6 and CYP3A4 suggested 




enzymes. Since CYP3A4 and CYP2D6 metabolize about 70% of drugs 
currently on the market, the interactions may be a cause of concern. There 
was, however, no trend between lipophilicity and CYP2D6 inhibition. 
 
Hepatocytes cleared the compounds faster than the microsomes. This could 
be due to the fact that hepatocytes have the full complement of drug 
metabolizing enzymes compared to microsomes. The mainly fast and 
intermediate clearance observed could be an indication that the compounds 
would need to be dosed more than once a day in the prophylaxis /treatment of 
malaria. Should these compounds be pursued as leads, a strategy for 
designing more metabolically stable compounds should be developed. 
 
Biotransformation studies in hepatocytes indicated that the synthesised 
analogues were extensively metabolised to various primary and secondary 
metabolites (Appendix A).The primary metabolism mainly involved the 
formation of the M1 metabolite and an intermediate metabolite which 
proceeds to form mainly metabolite M5 (Fig 4.10). The analogues also 
undergo metabolism to M2 metabolite through N-dealkylation and to an 
aldehydic intermediate metabolite that mainly proceeds to form the M3 and/or 
M4 metabolites. Given this metabolic stability status, efforts to stabilise the 
compounds with respect to metabolic clearance, should involve changes to 
substituents on the carbon adjacent to the aromatic ring of M1 such that 
hydrogen abstraction at this site is difficult or impossible. Similarly, to block 
the formation of the second most common metabolite, M3, substitutions on 




substitutions at the carbons can be with halogens such as Cl or Br whose 
electron withdrawing effects inhibit CYP-mediated metabolism 
 
Hot spots on the molecules were revealed to be N-dealkylation to M1 and 
formation of a carbonyl intermediate, which subsequently gives rise to 
metabolites M8 and M5. A strategy to stabilize these analogues could involve 
the substitutions of hydrogen on C-1’carbon next the pyridinone N, with 
halogens such as chloro or bromo groups. These electron-withdrawing atoms 
could reduce the reactivity of this molecule. The second major metabolite 
involves the cleavage of the molecule at a site adjacent to the quinoline 
moiety. A strategy to stabilize the molecule at this site could also include 
substitution of hydrogens with halogen. The resulting analogues should be 
retested for metabolic stability since instability could be introduced at other 
parts of the molecule. It is also necessary to retest for antiplasmodial activity, 







5.3 PART III: Identification of ADME/PK liabilities in artemisinin-
chloroquinoline hybrids 
 
The artemisinin hybrid compounds were synthesized with the aim of creating 
a conjugate, which borrows good characteristics from both chloroquine and 
artemisinin. Artemisinin has a very short half life of 1 hour (World Health 
Organisation, 2010a) but is very effective against both sexual and asexual 
stages of P. falciparum.  Chloroquine has a long half-life and has been the 
drug of choice for treating malaria before the parasite developed resistance to 
the drug. The hypothesis is that the hybrid compound will have both features, 
therefore effective against all stages of the parasite and the resistant strains. 
 
From previous studies the artemisinin-chloroquinoline hybrids were shown to 
have good antiplasmodial activity in both the CQR and CQS(Feng et al., 
2011). One of the liabilities that was noted was cytotoxicity. In this work the 
compounds were characterized to determine if they possessed any further 
ADME liabilities. From metabolic stability studies the compounds were found 
to have intermediate stability in both hepatocytes and HLM with greater than 
70% of the compound being detected intact.  
 
The hybrids of chloroquine and artemisinin were hypothesized to result  in 
pharmacokinetic properties influenced by those of the individual components 
where chloroquine is known to have a long half-life and artemisinin to have a 
very short half life. In the study, we observed the in vitro metabolic clearance 
of artemisinin-chloroquine hybrids to be predictive of moderate in vivo hepatic 




derivatives is however confounded by the fact that the in vivo half-life of 
chloroquine is affected by volume of distribution (t1/2 = (In2.Vd)/CL) which is 
very high as chloroquine binds to various tissues including melanin containing 
tissues. Recent studies on the metabolic stability of many chloroquine 
analogues also showed variable metabolic stabilities that did not correlated 
with in vivo half-lives (Ray et al., 2010) that make it difficult to make simplicity 
prediction of likely in vivo half-life properties of chloroquine-artemisinin based 
on the in vitro metabolic stability data.   
 
The compounds however were shown to be potent inhibitors of CYP3A4, 
CYP2C9 and CYP2C19. Given the inhibition by CYP3A4 and the good 
antiplasmodial activity, it could be postulated that lipophilicity is playing a role 
as the two are mainly driven by lipophilicity. The same is true for the 
cytotoxicity. Lipophilicity has been demonstrated to be associated with good 
interaction with biological membranes and enzymes. However there may be a 
challenge as if activity and liabilities are both being driven by the same 
properties. Changing groups associated with liabilities may lead to loss of 
activity.  
 
For CYP3A4 both the hybrids and the intermediates demonstrated potent 
inhibition. Intermediate 3.6 showed potent inhibition in all the isoforms tested 
except CYP2D6. It can be assumed that if any changes are to be made on the 





5.4 PART IV: Molecular Mechanism of CYP1A2 inhibition by TBZ 
This study was performed using TBZ, a broad spectrum anthelminthic used to 
treat parasitic infections in humans (Brown et al., 1961; Hennekeuser et al., 
1969; Walton et al., 1999). It has also been used as an agricultural fungicide 
for pre and post harvest treatment of fruit and vegetables and as a 
preservative in many consumer food products (Szeto et al., 1993; Arenas and 
Johnson, 1994; Groten et al., 2000; Walton et al., 1999). From earlier studies 
TBZ had been shown to be extensively metabolized in humans (Tocco et al., 
1966b). It has also been shown to inhibit CYP1A2 (Bapiro et al., 2005)and to 
induce members of the CYP1A and CYP2B family in rats (Price et al., 2004; 
Aix et al., 1994). 
 
In this study we investigated the potential for TBZ and its metabolite to be a 
TDI of CYP1A2. TBZ was picked as a potent TDI for CYP1A2 from a screen 
of antiparasitic drugs against CYP1A2, 2C9 and 3A4. Its metabolite 5OH-TBZ 
was also picked as a weak TDI of the enzyme. TDI has been linked to some 
clinically important toxicity which has resulted in some drugs being withdrawn 
(tienilic acid) from the market and some having restrictions in their usage 
(ticlopidine) (Riley et al., 2007). The inactivation of CYP1A2 by TBZ and 5OH-
TBZ was concentration-, time- and NADPH dependent (Fig 4.21), an 







Figure 5.1: Proposed biotransformation of thiabendazole (its elimination 
and bioactivation) (Coulet et al., 2000; Fujitani et al., 1991; Dalvie et al., 





















r'~ I r-\ 
" . .. 






, ", , 
h " , , ... -
" " 
~(TBZ) 
, , , -" 
" " 
r ' ) " , i(">--'- r , " " " , 
 
S lUII
/ t  ~ " " / 
'" lOXIF





The KI determined for TBZ (1.4μM) was lower than the total plasma 
concentrations the drug is capable of reaching (19μM) (Bapiro et al., 2005). 
The kinact of 0.08min-1 is relatively high such that the resulting kinact/KI of 
0.05μM/min is predictive of likely significant enzyme inactivation. In the 
treatment of strongyloidiasis in humans, the drug is given over 3 days at 
25mg/kg/day (Satoh and Kokaze, 2004; Merck, 1999) thus providing the time 
component during which CYP1A2 will progressively be inactivated. In a 
chronic exposure study to TBZ (50mg/kg/day), the pharmacokinetic studies 
did not, however, show accumulation of TBZ (Bauer et al., 1982) 
 
TBZ showed much lower potency when preincubated in the absence (IC50 = 
84.5μM) compared to the presence of NADPH (IC50 = 2.8μM) (Fig 4.22). This 
shift in the IC50 further suggests that TBZ is a likely TDI. It should be noted, 
however, that the high value (84.5μM) cannot be compared to the low IC50s 
(1.2 and 0.83μM) obtained in the reversible inhibition assay (Bapiro et al., 
2001) since the inhibitor is diluted ten-fold before the inhibition is allowed to 
occur. A high substrate concentration was used to minimize competitive 
inhibition, hence the high IC50 value in our study.  
 
There was no protection of CYP1A2 from inactivation by TBZ in the presence 
of the nucleophilic trapping agent, glutathione, an indication that reactive 
intermediates were not escaping the active site prior to inactivation. This is 
one of the characteristics that differentiate irreversible inhibitors from the 
reversible ones. In the case of irreversible inhibitors glutathione will have no 




enzymatic reaction react rapidly with amino acids in the active site rather than 
diffuse out. 
 
Dialysis experiments were conducted to further confirm the mechanism of 
CYP1A2 TDI by TBZ and 5-OH TBZ. Approximately 20% of CYP1A2 activity 
was restored after dialysis following inactivation by TBZ (Fig 4.23) suggesting 
the mixed mode of inhibition. There was no restoration of activity when 
furafylline, a positive control MBI was used to inhibit CYP1A2. Activity was 
restored for the reversible inhibitor, fluvoxamine. Significant recovery was 
demonstrated for 5OH TBZ suggesting the generation of reversible inhibitory 
metabolite(s) in vitro. The results also confirm that 5OH-TBZ is a weak TDI 
and TBZ a true MBI. This has important implications for the proposed 
bioactivation path (Fig 5.1) where the route of TDI associated metabolism 
might not go through 5-OH TBZ but directly from TBZ as proposed in Fig 5.2. 
 
Figure 5.2: Proposed routes by which thiabendazole is metabolized in 
vitro (a) and in vivo (b). 
 




literature. The first ranked site of metabolism was on the 5C of the benzene 
ring, a site where metabolism has been shown to take place (Coulet et al., 
1998). All three docking poses in GOLD and three of 10 docking poses in 
GLUE showed the site at a favorable distance to the heme catalytic center. 
The thiazole group was predicted as the likely site of metabolism by both 
MetaSite, and five of 10 docking poses in GLUE had the group close to the 
heme. In the other two docking poses, both predicted sites of metabolism 
were too far away from the catalytic center.TBZ has been reported to be a 
potent and mixed inhibitor of CYP1A2 both in vitro and in vivo (Bapiro et al., 
2005; Bapiro et al., 2001). 
 
The docking results could explain the observed results. When the compound 
is docked with the benzyl moiety oriented toward the heme (Fig 4.27a), 
hydroxylation to 5-hydroxythiabendazole, which is the main route of 
metabolism, is favored. The docking solution could explain the competitive 
inhibitory effects of thiabendazole on CYP1A2. When the thiazole moiety 
docks close to the heme (Fig 4.27b), bioactivation of thiabendazole could 
likely result in TDI. When TBZ docks in the active site cavity but far away from 
the reactive center (Fig. 4.27c), noncompetitive inhibition could result from 
allosteric binding. Therefore, it can be assumed that depending on the 
conditions in vivo and conformation of the active site, any of these types of 
inhibition can occur, giving a possible explanation to the observed mixed type 
inhibition in vitro (Bapiro et al., 2001). The docking results also indicate that 
the observed TDI could arise from various mechanisms involving epoxidation 




to explore these potential biotransformations, results of which could result in 
modification of the metabolism scheme proposed in Fig 5.1. 
 
Assuming competitive inhibitory effects of TBZ on CYP1A2, Simcyp version 
8.1 was used in the prediction of -fold increase in exposure of theophylline 
and caffeine (Table 4.11). Our result of 1.82-fold decrease in steady-state 
clearance of theophylline after TBZ therapy assuming competitive enzyme 
inhibition is in agreement with previously published clinical trial data 
(Schneider et al., 1990). Theophylline infusion was started 37h after TBZ oral 
therapy, and a 2.91-fold decrease in theophylline clearance was observed. 
From pharmacokinetic principles (Lin and Pearson, 2002), the same 
magnitude in increase in drug exposure is anticipated.  
 
These findings are particularly important in the use of theophylline, a narrow 
therapeutic index drug, in which a small change in plasma concentrations can 
result in serious side effects (Schneider et al., 1990). In light of this published 
data and our findings, a dose reduction that is dependent on the route of 
administration and time of initiating the affected drug is recommended. The 
results for the effect of thiabendazole on caffeine are comparable with what 
has been found clinically for single doses of these two co-ingested drugs 
(Bapiro et al., 2005) for which an increase in AUC of 1.6 was observed. 
 
Results from simulations of TDI effects on itself and those of theophylline and 
caffeine indicated that TBZ would inhibit its own clearance, resulting in >20-




TBZ effects on theophylline and caffeine were predicted to result in 5.65 and 
11.4 increases in exposure. These simulation results imply accumulation of 
TBZ with possible MBI activity on CYP1A2. The great impact of TBZ on its 
own elimination could partly be explained by it potentially being solely 
metabolized by CYP1A2 (fm1A2=1.0), whereas the drugs theophylline (fm1A2 
=0.85) (Monks et al., 1979)and caffeine (fm1A2=0.98) (Karjalainen et al., 2006) 
could be eliminated by other pathways. 
 
Our MBI simulation results (Table 4.11) are contrary to some clinical reports 
that indicate that TBZ does not accumulate upon chronic administration 
(Schneider et al., 1990). Our in vitro results might offer an explanation for this 
poor in vitro to in vivo prediction of MBI-based DDI. In vitro studies using 
recombinant CYP1A2 clearly shows that TBZ is an MBI and that 5-OH TBZ is 
a weak inhibitor. The proposed pathway in vivo indicates the involvement of 
conjugation reactions that clear the 5OH-TBZ. We propose that in the in vitro 
system, in which there are no phase 2 reactions, 5OH-TBZ accumulates and 
feedback inhibits this route. This leaves more TBZ available and increases the 
probability of the substrate docking (Fig. 4.27) mode associated with 
bioactivation to metabolites, which are MBI (Fig. 5.2). This could explain why 
no MBI is observed in vivo because the MBI we observe is an in vitro artifact 
because of the simplicity of the system devoid of other enzymes involved in 
TBZ metabolism and disposition. This could also be explained by the inherent 
differences between recombinant enzymes and human liver microsomes 




5.5 PART V: Drug-herb interaction by evaluating the ADMET/PK of the 
active ingredient natural product, Frutinone A 
 
Herbal/traditional medicines have been widely used in the treatment of many 
illnesses including inflammation, pain, colds and as immune boosters. Many 
of the remedies have been widely used together with conventional medicines 
posing the risk of drug-drug interactions. This is particularly of concern 
especially with drugs with narrow therapeutic indices such as warfarin and 
digoxin. The study of the level of drug-herb interaction therefore is of great 
importance. Effects of herbal/traditional medicines on drug metabolizing 
enzymes including their role in causing interaction have been studied and 
reviewed (Zhou et al., 2003; Chavez et al., 2006; Saxena et al., 2003; Izzo 
and Ernst, 2009; Tarirai et al., 2010).  
 
Extracts from the polygala fruticosa herb have been widely used in different 
parts of Africa. In South Africa P. fruticosa has been widely used to dropsy, 
scrofula and as a part of a decoction for tuberculosis treatment (Watt Jm, 
1962). In Zimbabwe the herb is used to treat abdominal pains and venereal 
diseases (Gelfand M, 1985). Experiments have also shown the extract to 
have antifungal activity (Bergeron C, 1997; Paolo et al., 1989; Hostettmann et 
al., 2000). Among the extracts isolated Frutinone A was the most active, with 
the other 2 chromonocoumarins (Frutinone B and C) being inactive 
(Hostettmann et al., 2000). The Frutinones are differentiated from each other 
by hydroxyl and methoxy substitutions (Fig 5.1), and it is these substitutions 
that have been linked to lack of activity in Frutinone B and C. In this study the 
interaction of Frutinone A, a purified compound from a herbal extract with 





Figure 5.3: Chemical structures of Frutinone A, B, and C. The three 
chromonocoumarins were isolated from polygala fruticosa Berg (Paolo, 1989). 
 
Frutinone A is a chromonocoumarin isolated from polygala fruticosa Berg, a 
herb growing in the Cape and Natal provinces of South Africa. The natural 
product was isolated from the lipophilic extract of the shrub (Paolo et al., 
1989) and from the roots and aerial parts of two other African species , P. 
gazensis Bak and P. teretofolia L. (Bergeron C, 1997). From our investigation 
of metabolic properties of the pure compound, the data suggest that Frutinone 
A is metabolically stable and only minute amounts of a by-product presumably 
resulting from enzymatic or non-enzymatic hydrolysis-mediated lactone ring 
opening were identified after incubation with human hepatocytes. From the 
reaction phenotyping studies Frutinone A was not metabolized by CYP1A2. 
 
In vitro screening for metabolic interactions across 5 major human drug 
metabolizing enzymes, CYP1A2, 2C9, 2C19, 2D6 and 3A4 showed Frutinone 
A to be a very potent inhibitor of CYP1A2. Molecular modeling investigations 




predictive of metabolic stability and potent competitive enzyme inhibition. 
These findings could have implications in the safe use of herbal remedies 
containing Frutinone A and the potential development of Frutinone A and/or 
related structures as conventional drugs.  
 
To our knowledge no studies on potential interactions of various extracts with 
drug metabolising enzymes have been reported. Although toxicity studies 
using crude extract of the plant in rats have shown the extracts to be safe 
(Mukinda et al. 2010), there is need to conduct further studies with human 
drug metabolising enzymes for insights into possible safety issues when used 
in humans and in combination with other drugs. Although there have also 
been no reports of Frutinone A being used in its pure form, we speculate that 
its presence in the extract may cause interactions with drug metabolising 
enzymes.  
 
Metabolism of the compound in hepatocytes is very minor, with only one 
minor by-product (4% of the parent compound) being identified in our study 
(Fig 4.28 and 4.29) which could not be attributed to any CYP reaction as 
indicated by the reaction phenotyping assay. The compound was also 
predicted to have low clearance. We therefore predict that Frutinone A has 
the potential to be circulated unchanged in the system for long periods. 
 
Frutinone A inhibited all the 5 major drug metabolising CYPs tested (1A2, 
2C9, 2C19, 2D6 and 3A4) with the most potent inhibition observed for 




of metabolic drug-drug interactions (DDI) where Frutinone A could inhibit the 
elimination of CYP1A2 substrate drugs. The actual extent of DDI is, however, 
difficult to establish since there is no data on in vivo Frutinone A exposure 
levels.  Nevertheless the metabolic stability of the compound also alludes to 
likely extended DDI should Frutinone A attain systemic exposure levels 
associated with a risk for DDI. 
 
As already mentioned in vivo studies in rats have shown no toxic effects of 
Frutinone A containing herbal extracts (Mukinda et al. 2010). Further studies 
on the potential risk of direct toxicity of Frutinone A or extracts that contain 
this compound need to be done in in vitro human systems since animal 
studies cannot always easily be extrapolated to humans. At this juncture it is 
noteworthy that the safety studies in literature (Mukinda et al. 2010) were also 
not evaluating safety issues related to DDI.   
 
Given the inhibitory potency of Frutinone A on CYP1A2, an enzyme produced 
from an orthologus gene CYP1A2 found in both humans and rats, our studies 
lend support to the possibility of conducting in vivo DDI studies in rats which 
could be extrapolated to humans. Such studies could be conducted using 
both Frutinone A and Frutinone A-containing extracts in formulations used in a 
treatment setting. Although no further studies were done on CYP2D6, 
CYP2C9, 2C19 and CYP3A4, the possibility of interactions with these 





The potency of Frutinone A on CYP1A2 could be explained by its 
pharmacophoric similarity with compounds known to be substrates/inhibitors 
of CYP1A2. In silico experiments were conducted to explain the low metabolic 
stability of Frutinone A, the lack of time dependent inhibition (Fig 4.31) and the 
observed potent reversible inhibition of CYP1A2 (Table 4.13). From our 
docking studies, many similarities in the way Frutinone A and α-
naphthoflavone, which is a known reversible inhibitor of CYP1A2, interact with 
the CYP1A2 active site space and chemistry were observed. 
 
The compounds both show a good fit into the active site of CYP1A2 driven by 
direct hydrophobic interactions with side chains of phenylalanines 226, 260 
and 125. These interactions and close fit have been associated with tight 
binding of α-naphthoflavone in the CYP1A2 active site (Mukinda et al. 2010). 
The distance of the nearest atom of Frutinone A to the heme was 4.6Å with 
Autodock and 5.04Å with FlexX. This distance has been earlier described to 
be too long for productive formation of metabolites via direct π-attack (Sansen 
et al. 2007). This may also help to explain why there was no significant 
formation of oxidative metabolites from the metabolism of Frutinone A by 
human hepatocytes. 
  
Our docking studies may also help to explain the mechanism by which 
Frutinone A and α-naphthoflavone inhibit CYP1A2. Our control compound α-
naphthoflavone inhibited via a mixed-type mechanism with both CEC and ER. 
Earlier studies have demonstrated α-naphthoflavone to be a competitive 




A study by another group has also shown α-naphthoflavone to be a mixed 
mode inhibitor (Cho et al. 2003). In our study the best fit favored the mixed-
type inhibition with competitive inhibition having a greater contribution in the 
mixed type inhibition when compared to the non-competitive inhibition. 
 
Frutinone A demonstrated mixed inhibition with CEC and competitive 
inhibition with ER. On the inhibition of CEC the greater contribution was from 
non-competitive inhibition, substrate-dependent mode (competitive versus 
non-competitive) and potency of inhibition of CYP1A2 by alpha 
naphthoflavone was previously postulated to be due to the nature of substrate 
and inhibitor binding modes in the CYP1A2 active site where those for the α-
naphthoflavone/ER pair favoured competitive inhibition and that of alpha-
naphthoflavone/EC favoured non-competitive inhibition (Shimada et al. 1998). 
They postulated that the structures of the substrates, ER and EC influenced 
these outcomes.  
  
Docking simulations from the two software used in this study showed two 
binding modes for substrates. Docking simulations in Autodock Vina (Fig 
4.36) show the substrates CEC (4.36c) and ER (4.36d) binding in the same 
pocket as the inhibitors Frutinone A (4.36b) and α-naphthoflavone (4.36a) 
which could explain the competitive inhibition. Docking simulations in FlexX 
(Fig 4.37) show an alternative binding mode where the substrates bind just 
below the hydrophobic pocket created by side chains of phenylalanines 226, 
260 and 259.  We propose that this binding orientation allows both the 




competitive inhibition. The existence of several binding modes in the active 
sites of CYPs has been observed for CYP2C9 and CYP3A4 and could explain 
both regio-selective metabolism of compounds and mode of inhibition as 
postulated in this study. 
 
In this study we have therefore shown the potential for Frutinone A, a natural 
product extracted from a plant to interact with CYPs especially CYP1A2.  The 
compound has also demonstrated behaviour very similar to α-naphthoflavone, 
which is a known potent inhibitor of CYP1A2. We have also suggested that 
there might be an alternative binding site in the active site of CYP1A2, which 







 An ADME/PK platform was successfully setup in this study. The tool 
can be used in an integrated manner with medicinal chemistry and 
pharmacology in support of drug discovery projects in Africa. In this 
study, this has been demonstrated by applying it in the identification of 
ADMET/PK liabilities of new chemical entities with antimalarial activity 
and drugs on the market used for the treatment of parasitic diseases. 
 
 The 3,4-HPO-4-amino-7-chloroquinolinyl hybrids were predicted to 
pose drug-drug interaction risks if given together with other drugs, 
which depend on CYP2D6 and CYP3A4 for elimination. Whilst the 
efficacy of the compounds is promising and have good 
physicochemical profiles, they carry potentially limiting liability of CYP 
inhibition especially against CYP3A4. 
 
 The artemisinin-chloroquinoline hybrids were metabolically stable and 
remained intact in the presence of drug-metabolizing enzymes. They 
therefore have potential to reach the target site. However they still 
need to be optimized to remove the liability of cytotoxicity and CYP 
inhibition. More work needs to be done to determine structure activity 
relationships. This is to further investigate if the liabilities are affected 
by the same properties that are responsible for the efficacy.   
 
 The thiabendazole study was able to show that TBZ is a potent MBI 




tools for likelihood of TDI still needs to be validated, the study 
demonstrated they could be useful in both predicting and explaining 
observed characteristics in both in vivo and in vitro experiments. Future 
MBI studies will therefore be done using hepatocytes with proven UDP-
glucuronosyl transferase and sulfanotransferase activity to verify our 
current hypothesis in explaining why no clinical MBI-based DDI have 
been observed. 
 
 The study on the interactions of Frutinone A with CYP1A2 study offers 
mechanistic insights into CYP1A2-substrate/inhibitor active site 
interactions. Inhibitory effects of Frutinone A may be attributed to its 
pharmacophoric similarity with CYP1A2 substrates/inhibitors. The 
potent CYP1A2 inhibition by Frutinone A could be predictive of the 
potential drug-herb interaction risk if the compound is co-administered 
with low therapeutic index CYP1A2 substrate drugs such as 
theophylline. 
 
 Future work on the compounds will therefore need to take into account 
the role of absorption and transporters in predicting the fate of these 
compounds. There is also need to do detailed structure activity 
relationships which include multivariate analysis to determine if desired 
and non-desired properties fall in the same chemical space. Detailed 
metabolite profiling studies will also need to be done as some side 
effects observed for some compounds such as  amodiaquine are as a 






Appendix A: Proposed biotransformation routes in hepatocytes for 
,4-HPO-4-amino-7-chloroquinolinyl hybrids 
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